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ABSTRACT 
 
The aim of this thesis was to assess several aspects of platelet function, especially in 
response to drugs.  
Peripheral arterial disease (PAD) is associated with hyperactive platelets that may be 
resistant to aspirin. Therefore, the effect of the administration of clopidogrel, aspirin or both 
anti-platelet agents was investigated in patients with PAD. Platelet function was assessed by 
different techniques including platelet shape change (PSC), an early phase of platelet 
activation that precedes aggregation. PSC was measured using a high-resolution channelyzer 
and expressed as median platelet volume (MPV). There was an increased inhibitory effect of 
clopidogrel plus aspirin on platelet activation. Clopidogrel was a more potent inhibitor of 
ADP-induced platelet activation than aspirin.  
The ADP receptors, P2Y1, P2Y12 and P2X1 influence platelet activation. The P2Y1 
receptor antagonist MRS 2179 blocked ADP-and ADP plus serotonin-induced PSC in vitro. 
The P2Y12 receptor antagonist AR-C69931MX significantly inhibited ADP-induced PSC. 
We demonstrated for the first time that the IC50 of a P2Y1 receptor-blocker can be derived 
using PSC.  
Tirofiban is a glycoprotein IIb/IIIa receptor antagonist and therefore a powerful 
inhibitor of platelet aggregation. Tirofiban did not affect fibrinogen/agonist-induced PSC but 
inhibited platelet aggregation in vitro. A lack of inhibition of PSC may limit the use of 
tirofiban in clinical practice. 
Current methods to measure platelet cholesterol (PC) involve complex extraction 
processes. A faster and simpler technique to measure PC was developed. There was a 
significant correlation between PC and some circulating lipid levels. This method may be 
useful for multiple sampling. PC may represent ‘tissue’ cholesterol levels. Furthermore, 
because high PC is associated with increased platelet activity, statins may decrease both PC 
and risk of thrombosis.  
The findings in this thesis may provide a better understanding of platelet function 
and how to assess it. Furthermore, potential therapeutic targets are discussed. 
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OVERALL AIMS AND HYPOTHESIS 
 
Aims: To gain a better understanding of the effect of antithrombotic drugs on platelet 
function and receptors particularly in relation to peripheral arterial disease (PAD). I also 
aimed to develop a rapid and simple method for the measurement of platelet cholesterol 
(PC), a variable known to influence platelet function.  
Hypothesis: PAD patients tend to have hyperactive platelets. The usual drug prescribed is 
aspirin. However, some of these patients may be aspirin resistant. Thus, it is important to 
consider other antiplatelet drugs like clopidogrel which acts on P2Y12 purinergic receptors. I 
investigated the effect of clopidogrel, aspirin and both drugs on platelet function in PAD 
patients. Platelet function was assessed by different techniques, including platelet shape 
change (PSC), an early phase of platelet activation. A channelyzer method was developed in 
this laboratory to measure PSC. This technique is sensitive, reproducible and has high 
resolution. The hypothesis was that clopidogrel was superior to aspirin and that both drugs 
together were superior to monotherapy.  
It is known that clopidogrel acts via the P2Y12 purinergic receptors. However, I also 
wanted to investigate the involvement of other platelet purinergic receptors (namely P2Y1 
and P2X1) on PSC. Others have implicated the P2Y1 purinergic receptor in PSC, but used a 
less sensitive method (optical transmission aggregometry). It has since come to light that 
these measurements actually represent the formation of platelet microaggregates rather than 
PSC. Thus, I quantitatively assessed PSC using MRS2179, a P2Y1 purinergic receptor 
blocker. Because clopidogrel is a prodrug, I used the P2Y12 purinergic receptor blocker ARC 
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69932IMX to assess the effect of this purinergic receptor on PSC. To my knowledge, this is 
the first study that actually quantifies PSC inhibition by this or any other P2Y12 receptor 
blocker. I also investigated whether the P2X1 purinergic receptor is/is not involved in PSC. 
PAD patients may be resistant to aspirin and/or clopidogrel. It is therefore important to 
consider antiplatelet drugs that work via other receptors. Hence, I investigated the effect of a 
GPIIb/IIIa receptor antagonist, tirofiban, on fibrinogen- and agonist-induced PSC and 
aggregation. There is evidence linking raised plasma fibrinogen levels and platelet 
hyperactivity with vascular events. I also assessed if fibrinogen affects PSC in human 
platelets. The hypothesis would be that GPIIb/IIIa antagonists like tirofiban do not affect 
PSC and that this may be a reason for their diminished efficacy.  
It is well documented that increased platelet activity is linked to raised circulating 
cholesterol levels. Also, high platelet cholesterol (PC) levels affect platelet membrane 
fluidity which may also modulate the conformational state of platelet receptors, thereby 
indirectly affecting the effectiveness of antiplatelet drugs. Moreover, PC can be used as a 
marker of ‘tissue’ cholesterol. The present methods to assess PC are cumbersome. They 
involve time consuming and complex processes with toxic and potentially harmful 
chemicals. I set out to develop a simplified, reproducible, rapid and safe method to measure 
PC. I also investigated if there was a correlation between PC and circulating lipid levels. The 
hypothesis was that such a correlation would be present since others had reported a fall in 
PC after treatment with a statin. A rapid PC method would make it possible for me to 
evaluate all the receptor experiments described above in relation to PC levels. The 
hypothesis would be that PC levels will influence platelet receptor responses.  
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General Introduction 
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1.1 A Brief History about Platelets 
The mechanisms by which platelets are produced have been studied for over 100 
years (Born, 1967a,1967b). Platelets were initially termed “the dust of the blood”. It was 
James Homer Wright in 1906 who first recognized how giant bone marrow megakaryocytes 
(MKs) ‘gave birth’ to platelets (Kuter, 1996). Claims have been made by different scientists 
as to who was the first to identify platelets. From as early as 1873 Osler described their disc-
like structure (Osler W, 1874). Seven years later Bizzozero (Coller, 1984) identified the 
platelet anatomically and related them to haemostasis and experimental thrombosis. He went 
on to demonstrate that platelets adhere to the blood vessel wall at the site of injury to form 
aggregates. In fact, Bizzozero was the first to identify bone marrow megakaryocytes but he 
never recognised them as precursors of platelets. Hence, James Homer Wright in 1906 used 
his new polychrome staining solution (Wright’s stain) to show the similarities in shape and 
colour of the red-to-violet granules in platelets and megakaryocytes and is credited as the 
first to demonstrate the formation of platelets. Moreover, since the intervening 125 years 
since Bizzozero’s pioneering work, we have seen a considerable increase in our 
understanding of the platelet with regard to its structure, formation and role in haemostasis 
and thrombosis (Born 1965, Coller, 1984).  
 
1.2 Platelet Formation  
Megakaryocytes (MKs) are highly specialised precursor cells that function solely to 
produce and release platelets into the circulation. Platelets sometimes known as 
thrombocytes along with erythrocytes (red blood cells, RBC) and leucocytes (White et al., 
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1976) circulate in the blood. Erythrocytes account for 96% of the total number of blood cells 
and are responsible for carrying oxygen to cells, while leucocytes are involved in immune 
and inflammatory responses. An average person has approximately 5.5 litres of blood. The 
different cell types circulating in the blood along with their count and diameter are shown 
below: 
 
 Platelets  150-450 x 109/L  0.5-3 µm 
 
 Erythrocytes  M 4.4 – 5.8 x 1012/L  7 µm  
    F 3.9 – 5.2 x 1012/L  7 µm   
 
  Leucocytes  4.5 – 11.0 x 109/L  12 µm  
  
 
 Although it is accepted that platelets are derive from megakaryocytes (MKs), the 
mechanisms involved remain controversial and complex. Throughout the years, several 
models of platelet production have been proposed. These include: (a) platelet budding, (b) 
cytoplasmic fragmentation via the demarcation membrane system (DMS), and, (c) pro-
platelet formation. However, the mainstream understanding is that MKs are descended from 
pluripotent stem cells and undergo multiple DNA replications without cell divisions, a 
process called endomitosis (May et al., 1998). During endomitosis, polypoid MKs initiate a 
rapid cytoplasmic expansion phase which is characterised by the development of a highly 
developed DMS and the accumulation of cytoplasmic proteins and granules essential for 
platelet function (Hartwig et al., 1991). In the final stages of development, the MKs 
cytoplasm undergoes a re-organisation into beaded cytoplasmic extensions called pro-
platelets. Finally, the pro-platelets yield individual platelets. 
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1.3 Platelet Structure 
 The platelet has a life span of 7-10 days. The platelet plays a double role of being 
‘good’ and ‘evil’. They may be called upon to aid in host survival, but unfortunately, 
functions important in host preservation can also contribute to host destruction by being 
involved in thrombosis. Thus, an understanding of the platelet structure (see figure 1.1), 
pathology and physiology may prove useful in the treatment of vascular disease and 
bleeding disorders.  
 
Figure 1.1 Platelet Structure 
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1.3.1 The Resting Platelet 
 A distinguishing feature of the platelet is that it lacks a nucleus normally found in 
most cells. Human platelets circulate in the blood as discs and are heterogenous in size with 
dimensions of 0.5 x 3.0 µm (Hartwig et al., 1991). The average mean cell volume is 6 to 10 
femtoliters (fl) (Matsuoka et al., 2000). It is thought that the disc shape of the platelet (see 
figure 1.4) may aid in some aspect of their ability to flow close to the endothelium in the 
blood stream. The platelet plasma membrane is relatively smooth however high-resolution 
scanning electron microscopy (ScEM) (Hartwig et al., 1991) suggested a folded appearance. 
It is thought that these tiny folds may provide additional membrane needed when platelets 
spread on surfaces (Stossel et al., 2001).  
 There are periodic small openings of the surface connecting the open canalicular 
system (OCS), a complex network of inter-winding membranes that permeate the platelet’s 
cytoplasm (Kovacsovics et al., 1996). The OCS has two major functions, firstly to serve as a 
passageway to the blood stream in which the contents can be released, and secondly to 
function as reservoir of plasma membrane and membrane receptors. In the resting platelet at 
least one third of the thrombin receptors located on the OCS is awaiting transport to the 
surface of activated platelet. Another membrane system of the platelet is the dense tubular 
system (DTS) and serves mainly the calcium storage system. In the resting platelet, the DTS 
maintains the cytosolic calcium concentrations in the nanomolar range (see figure 1.2) 
(Yoshida, 1989; Ebbeling, 1992). 
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Figure1.2 Representative TEM showing resting platelets. 
A transmission electro micrograph (TEM) of a representative population  
of normal resting platelets (see Methods, 2.6) showing various dense bodies 
and other structures and granules. 
GC-glycocalax; Mit- mitochondria; DB-dense body  
 
 The platelet plasma membrane has a thick exterior coat called the glycocalyx. The 
lipid bilayer on which the glycocalyx rests serves an extremely important role in the 
acceleration of clotting, a function not shared by other cells in the circulating blood. When 
resting, the lipid bilayer of the platelet contains large concentrations of transmembrane 
receptors (Moake et al., 1988). The most important receptors found on the surface of the 
resting platelet include the glycoprotein receptor for von Willebrand factor (vWF) (Moake et 
al., 1988), receptors for adenosine diphosphate (ADP), thrombin, epinephrine and 
thromboxane A2 (TXA2); the Fc receptor Fcγ RIIA; and the β3 and β1 integrin receptors for 
fibrinogen and collagen (Born 1965, 1967a, 1967b, Berridge, 1984). These receptors are 
known to play a key role in adhesion of platelets to damaged surfaces, and also may trigger 
GC 
MT 
DB 
Mit 
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full activation of the platelet to promote platelet aggregation Born 1976a, 1967b) and 
interaction with other cellular elements, and to accelerate the process of clot formation 
(Matzdorff, 2005).  
 An interesting characteristic of the platelet is that it contains granules within which 
biologically active molecules are stored. In resting platelets, granules are situated close to 
the OCS membranes. Platelets have three major recognised types of storage granules: 
‘dense’ granules (calcium rich and therefore opaque on electron micrography), α-granules 
and lysosomes (table1.1). The granules contain substances with platelet pro-aggregatory, 
vasoconstrictory, mitogenic and vascular permeability enhancing effects (Mininkova, 2010; 
Hattori, 1974). 
 
Table 1.1: Intra-platelet Granules 
α-granules                                Dense Granules                           Lysosomes  
 
PDGF                                         Ca2+ Mg2+                                      Acid hydrolases 
PF-4                                           ADP, ATP                                    β-hexosaminidase                                     
β-TG                                          Serotonin  
Fibrinogen                                  Histamine 
Fibronectin                                 Noradrenaline 
vWF                                           Adrenaline 
 
(See list of abbreviations)  
  
 Platelet α-granules can uptake and package plasma proteins via receptor-mediated 
endocytosis and pinocytosis. There are also other membrane proteins critical to platelet 
function that are packaged into α-granules; these include αIIbβ3, CD62P, CD36 as well as 
the majority of cellular P-selectin. The contents of the dense granules (sometimes called 
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dense bodies), 250 nm in size, function primarily to recruit additional platelets to sites of 
vascular injury. These contents are released upon platelet activation initiating PSC and 
aggregation (both of which will be considered further in this thesis) as well as the granule 
release reaction. The third major storage granule type, the lysosomes, functions primarily in 
the break down of material ingested by phagocytosis or pinocytosis. 
 The technique of detergent-permeabilization followed by rapid freezing, freeze 
drying, and metal shadowing has been previously used to obtain high resolution images of 
cytoskeleton of the resting platelet (Rand et al., 2003). As previously mentioned the resting 
platelet is disc shaped. This shape is maintained by a highly specialised cytoskeleton (Rand 
et al., 2003). When the platelet is resting there are three major components of the 
cytoskeleton. Starting from the plasma membrane inward they include (1) a spectrin based 
skeleton, adherent to the cytoplasmic side of the plasma membrane, (2) a microtubule coil 
running along the perimeter of the disc, and (3) the actin filaments, a rigid cross linked 
network that fills the cytoplasmic space of the cell.  
 
1.3.2 The Activated Platelet 
 An important function of the platelet is to detect damage on vessel walls and respond 
rapidly. Thus, in response to vascular damage platelets undergo dramatic changes by 
attaching themselves to the damaged area, changing shape and spreading over that injured 
site.  
Initiation of activation entails (a) aggregation, (b) secretion, (c) activation of the biochemical 
synthetic pathway to produce and release TXA2 and other potent platelet agonists, and, (d) 
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then activation of a major platelet integrin, αIIbβ3, the receptor for vWF (Harrison et al., 
1999). A major component of this thesis involves PSC thus, this process is explained in 
some detail, below. 
 When activated, platelets follow a sequence of complex events instigated by a rise in 
cytoplasmic calcium levels.  
 
 
Figure 1.3 Representative TEM showing activated platelets 
A transmission electro micrograph (TEM) of a representative population  
of activated (ET-1 and 5HT) platelets showing the spike-like surface extensions 
(pseudopodia), which is accompanied by surface enlargement. There is a  
rearrangemets of the microtubules which are translocated centripetally.  
 
  
 Initially, when the platelet contacts an injured surface it looses its disc shape and 
adapts a more rounded one. Secondly, finger-like projections (pseudopodia) grow from the 
cells periphery as the platelet flattens over surfaces and broad lamellae are extended 
(Jagroop et al., 2000). On flattening the platelet granules and organelles become 
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concentrated into the centre of the cell, resulting in a ‘fried egg’ appearance. Finally, a 
dynamic phase of membrane motility begins along various points along the lamellae 
(membrane ruffles form and retract inward) (see figure 1.3). During the platelet activation, 
the actin filaments contents doubles from resting platelet concentration of 0.22 to 0.44 mM. 
As mentioned earlier, the first change to occur upon activation is when the normal disk 
shape platelet converts into a compact sphere with long dendritic extensions to facilitate 
adhesion (Grundmann et al., 2003).  
 The conversion of resting disc shaped platelet into a rounded shape occurs if the 
cytoplasmic calcium levels rise into the micromolar range (Hayward et al., 2006). The 
resting platelet maintains a cytosolic calcium of 10 to 20 nM (Harrison et al., 1999). 
Intracellular calcium may increase to near 10 µM when calcium channels open after 
activation of the phospholipase C pathway. That is when the enzyme hydrolyses 
polyphosphoinositide (PI4,5P2) forming a second messenger diacylglycerol and 
inositoltriphosphate (IP3) (Knofler et al., 1998). IP3 is soluble, thus it diffuses into the 
cytoplasm moving to the receptors on the dense membrane of the platelet, where it binds and 
releases the stored calcium (Escolar et al., 1999). Phospholipase C is activated by the βγ-
subunit of trimeric G-proteins that couples it to serpentine receptors. These include protease-
activated receptors, the ADP receptors (P2Y1 and P2Y12) and the 5HT receptor. 
 PSC is driven by rapid remodeling of the platelet cytoskeleton that is dependent on 
the new assembly of actin filaments (Jilma, 2001). This process is a complex one that is 
outlined below. The protein activated by calcium to remodel the cytoskeleton is gelsolin, an 
80-kDa protein. Gelsolin contains two main actin-binding sites that are activated by 
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increased calcium levels. In the initial stage of cytoskeletal remodeling, the long filaments 
that exist in the resting cell are converted to many short filaments when platelets change 
from a disk shape to rounded. This process is mediated by the actin-severing property of 
gelsolin as calcium levels increase. In order to allow platelet spreading the rounded platelet 
must assemble new filaments and does this at the cell cortex by elongating the barbed end of 
the short filament fragments and by generating new barbed ends for monomer addition.  
  
 
Figure 1.4 Representative ScEM showing resting platelets 
Scanning electron microspy (ScEM) showing a representative population of 
normal resting platelets. Platelets appear to be disc shaped, and are ‘separated’  
from each other. 
 
 
 The resting platelet stores actin in a monomeric complex with β4-thymosin and 
profiling. The ends of the actin filament have different affinities for actin monomers, with 
barbed ends having a 10-fold affinity for the monomer. Thus, the polymerisation reaction of 
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the barbed end of the growing filament provides a force to push out the finger-like filopodia 
and lamellipodia. A complex protein called Arp 2/3 is activated to generate new barbed ends 
when gelsolin and other proteins that cap the barbed ends of the actin filaments are removed 
(Cohen, 1979; Zucker et al., 1985).  The arrangement of the actin filament establishes the 
shape of the protrusion and polymerisation of actin filaments. Filopodia are tight bundles of 
actin filaments that originate near the centre of the platelet (Cohen, 1979; Cohen et al., 
1982). Figure 1.3 of resting platelets as seen with ScEM is shown above. 
 The next stage as mentioned above is when the platelet flattens over surfaces and 
broad lamellae extend (Boyles et al., 1985; Zucker-Franklin, 1970). The lamellipodia of the 
spread platelet are organised into a three dimensional network of cross-linked actin 
filaments (see figure 1.5). The considerable re-organisation of the actin cytoskeleton is also 
accompanied by the exocytosis of the platelet storage granules (Boyles et al., 1985; Zucker-
Franklin, 1970). The stage of platelet activation that follows PSC is platelet aggregation 
(described below in section 1.4.3) 
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Figure 1.5 Representative ScEM showing activated platelets 
Scanning electron microscopy (ScEM) showing a representative population  
of activated (with ET-1 and 5HT) platelets. There is a more rounded shape  
with finger-like projections (pseudopodia) which grow out from the cells periphery.  
  
1.3.3 Platelet Receptors 
 Since platelets lack a nucleus, they cannot adapt to different situations by de novo 
protein synthesis. Thus, in order to compensate and deal with physiological functions, 
platelets possess several mediators in their storage granules (Cramer, 1999; Italiano, Jr. et 
al., 2003). Because of the relatively small size of platelets, their membrane and membrane 
proteins represent a larger proportion of cellular mass compared with other cells. Moreover, 
since the main function of platelets is haemostasis, it is not surprising that their major 
receptors have a direct role in this process, either in platelet activation, or as adhesive 
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receptors interacting with damaged cell walls or with other platelets that contribute to a 
thrombus formation (Ishii, 2011)  
 As well as being involved in haemostasis platelets are involved in a range of less 
well understood functions like inflammation, anti-microbial host defense, tumour metastasis 
and angiogenesis. Thus, platelets express a range or receptors with no obvious direct role in 
hemostasis, but they could be implicated in other activities like immunological defense 
against viruses, bacteria, and parasites among other pathogens. Many of the receptors are 
present in low copy numbers, however they act synergistically with major agonists and have 
critical roles in regulating overall platelet responsiveness, thus they are physiologically 
important. With present technology, we have identified a number of platelet receptors and 
their demonstrable physiological function detected on platelets (see table 1.2).   
 
Table 1.2: Platelet Plasma Membrane Receptors 
Name             Category Ligand Effect 
GPIIb/IIIa 
 
Integrin 
 
Fibrinogen              
vWF                  
PLT aggregation 
 
GPIb/IX/V 
 
LLR 
 
vWF 
Thrombin 
PLT adhesion 
 
PAR 1 
PAR 2 
 
P2Y1 
P2Y12 
7-TMR 
 
 
 
 
Thrombin 
ADP 
 
 
 
PLT activation: 
Aggregation 
& 
PSC (Jagroop et al.,   
2003a) 
GP VI 
 
Ig Gene 
 
Collagen 
 
PLT activation: 
 
P-selectin 
 
Lectin 
 
PSGL 
 
WBC tethering 
& binding 
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1.4 Laboratory Investigation of Platelets  
Several laboratory techniques have been used to assess platelet function. In this 
thesis only some of the many techniques currently available are mentioned. Each test has its 
advantages and disadvantages and the therefore, results should be interpreted in the context 
of patient history and examination. The ideal test should be quick, simple, inexpensive, 
reproduceable and non-invasive (Harrison, 2000). Currently available tests can measure 
platelet number, size, their capacity to aggregate, and the concentration of release substances 
or the expressed receptors of activated platelets. However, accurate assessment of platelet 
count and function is highly dependent on sample collection and preparation (Barradas et 
al., 1993). Selection of subject/patient is the first factor to be considered. Blood donors 
should be relaxed and not have taken any anti-platelet agents for at least 1 week (preferably 
2 weeks) preceding blood sampling (Harrison, 2005). In order to reduce stasis, it is 
recommended that the blood is collected using 19-21 gauge needle, and with plastic 
syringes, and which also prevents platelets from sticking to the sides (Harrison, 2005). In 
addition, the first aliquot of the sample should be discarded.  
 
1.4.1 Choice of Anti-coagulant 
An important factor to consider when collecting blood is which anti-coagulant to use 
as this affects both platelet count and functionality. The most recommended (depending on 
the test) is trisodium citrate (0.102 or 0.129 M, buffered or non-buffered) at a concentration 
of 9 parts blood to 1 part trisodium citrate solution. This anti-coagulant causes a lowering of 
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ionised calcium thus preventing coagulation (see Appendix A, PSC & Appendix B, platelet 
aggregation references authored by Jagroop et al.) 
Heparin inhibits the generation and activity of thrombin via its complex with anti-
thrombin III. Heparin may be considered unsatisfactory if a centrifugation step is required 
(Mikhailidis et al., 2002). This is because of platelet sedimentation with red cells. Thus, in 
platelet rich plasma (PRP) the platelet count may be significantly lower when collected in 
heparin as compared with citrate (Jagroop et al., 1996; Jagroop et al., 1999; Mikhailidis et 
al., 1996;Mikhailidis et al., 1986; Mikhailidis et al., 1987). In addition, platelets may 
aggregate or adhere to the sides of the containers giving a false low platelet count in PRP.  
The use of ethylene-diamine-tetra-acetic-acid (EDTA), (Dastjerdi et al., 2006) can 
lead to calcium chelation, and thus a lower platelet count as cells aggregate. Since platelet 
aggregation is dependent on the presence of calcium, EDTA is not suitable for use in platelet 
aggregation studies. Furthermore, EDTA expands platelet volume (Jagroop et al., 2003b).  
Hirudin, may be used as it preserves the concentration of ionised calcium necessary 
for certain tests, but this anti-coagulant is considered too expensive for routine tests 
(Danchin et al., 2010; Rao et al., 2010).  
D-phenylalanine-proline-arginine chloromethyl ketone (PPACK) is an anti-thrombin 
that does not cause calcium chelation and therefore does not exert an effect on platelet 
function based on available calcium. This anti-coagulant may be useful when assessing the 
platelet inhibition by GPIIb-IIIa antagonists like eptifibatide, abciximab and tirofiban 
(Hobbach et al., 2003; Proimos, 2001; Verstraete, 1995). However, PPACK is relatively 
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expensive and requires higher concentration in relation to other anti-coagulants to prevent 
platelet clotting (Verstraete, 1995).  
Acid-citrate-dextrose (ACD) (Mackenzie et al., 2010), an anti-coagulant, is useful 
for washing or gel-filtering platelets. It prevents platelet aggregate formation in the 
centrifugation process (Groh et al., 1993). ACD alters the pH of PRP to 6.5 and is thus 
unsuitable for platelet aggregation experiments. However, ACD-A, a formulation of ACD is 
acceptable for platelet aggregation testing since it maintains the PRP at a pH of 7.2 
(Cazenave et al., 1983; Groh et al., 1993).  
 
1.4.2 Bleeding Time  
One of the oldest methods (developed in the early 1900s) to assess platelet function 
is bleeding time (BT). Various methods have been used to assess BT. The Duke technique is 
where a small incision is made on the ear-lobe, and the Ratnoff technique is when an 
incision is made on the ball of the finger (Harrison, 2005). The bleeding time as designed by 
Duke was thereafter modified and known as the Ivy test (Harrison, 2005), which is a 
combined bleeding time-tourniquet test (Bock et al., 1999). In fact, by 1984 a survey of 
current practice in the BT test was undertaken by the National External Quality Assessment 
Scheme (NEQAS), UK in blood coagulation. Most centers (88.5%) performed BT and of 
these, the Ivy test was the most commonly performed. Only 13.6% performed the Duke 
method. The use of a commercial template method, known as 'the Simplate', provided a 
measure of agreement among the hospitals using this instrument (Hayward et al., 2006). In 
one study the authors compared the sensitivity and the reproducibility of the BT techniques 
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according to Ivy and Simplate II (Hayward et al., 2006). They concluded that the Simplate II 
method is not superior in sensitivity or reproducibility to the Ivy method, which is cheaper, 
takes less time, and does not leave scars (Moake et al., 1988). There was however, some 
contradiction regarding the BT test. In a study, Bowie et al. (Shenkman, 2003) concluded 
that BT when properly standardized, is an important test in the evaluation of haemostatic 
disorders. Moreover, the positive aspects of this test is that it does not require expensive 
equipment or even a laboratory and is not affected by the variables associated with blood 
sampling and anti-coagulation (Morrison, 2007). 
However, it is now widely regarded that there are only four clinical reasons for using 
the BT test: (1) as a screening test for patients before invasive procedures, (2) to determine 
the cause of ongoing bleeding, (3) to explain previous episodes of bleeding, and, (4) to 
diagnose hereditary bleeding disorders e.g. vWD (Gobbi et al., 2006). Nowadays assessing 
BT even for these reasons is considered not be as accurate as once thought. This was 
demonstrated when a MEDLINE search was done to assess the accuracy of BT as a 
screening test for patients; BT often failed to provide sufficient data for calculation of 
sensitivity and specificity of this test (Gibbs, 2009; Michelson, 2009). One study showed 
that 14 % patients who underwent cardiac surgery had excessive bleeding, but their BTs 
were not different from those of the remaining 86 % who did not bleed (Michelson, 2009). 
Furthermore, studies of the predictive value of BT in cardiac surgery and non-cardiac 
surgery demonstrated that BT does not provide conclusive evidence (Michelson, 2009; van 
Werkum et al., 2008).   
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To date the disadvantages of BT far outweigh the advantages with the main one 
being the reproducibility of the method; it also appears to be a non-specific and insensitive 
test (van Werkum et al., 2008). The skill of the technician greatly affects the results, thus 
there is a high interoperator variability (Barradas et al., 1988). A lack of consistency can 
even be due to skin thickness and temperature (Accumetrics Inc., 2007). Frequent scarring 
of the subjects have also been reported (van Werkum et al., 2008). Thus, BT is no longer 
recommended as a clinical test for platelet function, and has been discontinued in most 
centres. 
 
1.4.3 Platelet Shape Change and Platelet Aggregation 
The initial reaction of platelet adhesion to vessel endothelium is PSC, which is 
followed by platelet aggregation. PSC is an early phase of platelet activation that precedes 
platelet aggregation. Many techniques have been developed to assess platelet activation. The 
measurement of PSC is one such method. Turbidometric aggregometry (using PRP) is one 
of the several techniques used to assess PSC (Barradas et al., 1992; Frojmovic et al., 1982; 
O'Brien et al., 1966). However, this is at best a semi-quanti-tative method; it is an estimation 
of the increase in the optical density in the phase preceding aggregation (Barradas et al., 
1992; Frojmovic et al., 1982; O'Brien et al., 1966). In this thesis, a high-resolution (0.07 fl) 
channelyzer (ZM34 coupled to a Coulter counter) was used to determine the apparent size of 
platelets. The sensitivity of this method can be attributed to the fact that this channelyzer 
uses 256 channels in comparison to those previously used by others, that had only 128 and 
therefore was a lower resolution (Frojmovic et al., 1982; Gear, 1981; O'Brien et al., 1966; 
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Sanderson et al., 1996). Moreover, this technique is suited to assessing small increments in 
median platelet volume (MPV) that are associated with PSC induced by low doses of 
agonists (Jagroop et al., 2000a; Jagroop et al., 2001; Jagroop et al., 2003a; Jagroop et al., 
2004; Jagroop et al., 2008) (see Appendix A: PSC reference list with IA Jagroop). It has 
previously been shown that PSC, which is accompanied by an increase in MPV, occurs 
concomitantly with morphological changes in human platelets (Jagroop et al., 2000a).  
 Our previous studies support others who suggest that inducing an increase in median 
platelet volume (MPV) requires lower concentrations of agonists than those required to 
initiate aggregation (Sanderson et al., 1996). The PSC phenomenon is essentially aspirin-
resistant because arachadonic acid (AA) metabolism is not involved in this phenomenon 
except when this fatty acid is used to activate platelets (Barradas et al., 1992; Siess et al., 
1984).  
 With the use of the channelyzer method, PSC in several situations of potential 
clinical relevance have been demonstrated, as described below. For example, thrombin-
induced PSC is inhibited in vivo by the addition of either UH or low molecular weight 
heparin (LMWH, nadroparin) (Jagroop et al., 1996; Siess et al., 1984). In addition, 
doxazosin, an alpha 1-adrenoceptor antagonist, used in the treatment of essential 
hypertension and/or benign prostatic hyperplasia inhibited serotonin (5HT)-induced shape 
change in human platelets (Jagroop et al., 2001; Siess et al., 1984). In another study, we 
showed that naftidrofuryl (Praxiline) which is used to improve claudication in (peripheral 
arterial disease) PAD was able to reverse the PSC induced by endothelin-1 (Jagroop et al., 
2000d; Siess et al., 1984). The effect of endothelin-A (ET-A), BQ123 and ET-B, BQ788 
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receptor antagonists on PSC induced by ET-1 was investigated. We hypothesized that both 
ET(A) and ET(B) receptors might contribute to the ET-1-induced PSC (Jagroop et al., 
2000d; Siess et al., 1984). Losartan, a selective angiotensin II antagonist, is used in the 
treatment of hypertension (Chang et al., 2010; Russell et al., 2011). Using the PSC 
methodology, it was shown that losartan at concentrations similar to those achieved in the 
circulation during treatment, significantly inhibited angiotensin II- as well as U46619 (a 
thromboxane A2 (TXA2) analogue)-induced PSC. Thus, suggesting that losartan, in addition 
to its blood pressure lowering action, also appears to have anti-platelet activity (Jagroop et 
al., 2000c; Siess et al., 1984).  Indeed, we demonstrated for the first time using human 
platelets as a neuronal model with our PSC method, that an appetite suppressant, 
dexfenfluramine (previously used to treat obesity) showed serotonergic action (Jagroop et 
al., 2000b; Siess et al., 1984). These drugs (dexfenfluramine and fenfluramine) were 
voluntarily withdrawn due to reports of adverse effects on heart valves (1997c; McCann et 
al., 2007; Wee et al., 1998).  
 The MPV (a measure of PSC) was also assessed in patients with PAD, where platelet 
hyperactivity has been reported (Barradas et al., 1993; Barradas et al., 1994b; Siess et al., 
1984). Patients with PAD have elevated plasma levels of 5HT and reduced intra-platelet 
levels of this bioamine (Barradas et al., 1994a;Cheshire et al., 1996; Fawcett et al., 1998). 
Other bioactive compounds (e.g. ADP, and TXA2) are also released upon platelet activation. 
It is therefore of potential clinical relevance that various platelet agonists induce PSC 
(Barradas et al., 1994a; Cheshire et al., 1996; Fawcett et al., 1998). Thus, from some of our 
previous studies (outlined above), we have documented that selective antagonists block the 
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increase in MPV as induced by these various agonists. These observations can be considered 
as evidence that MPV measurements represent, specific, receptor-mediated, phenomenon. 
 This PSC method usually only requires low concentrations agonists, which is 
sufficient in PRP to induce a response in that allows antagonist inhibition. High agonist 
levels would not allow us to see these responses at pharmacological levels of antagonists. 
Also, it should be noted that when measuring PSC we are assessing inhibition in the early 
phase of platelet activation. With this in mind, in this thesis we showed that it was possible 
to establish that both ADP receptors P2Y1 and P2Y12 were involved in the PCS phenomenon 
in human platelets (Jagroop et al. 2003a).  
Platelets interact with each other to form aggregates. Platelet aggregation can be 
quanti-fied by aggregometry. The original aggregometer which consisted of an 
absorbptiometer was first described by Born in 1962 followed by O’Brien, which became 
the de facto “gold standard”. The most commonly used method nowadays is a 
spectrophotometer attached to a chart recorder. This requires the preparation of PRP, which 
is set in the spectrophotometer as the most opaque setting possible (0% aggregation) and the 
platelet poor plasma (PPP) is set as the most transparent situation possible (100% 
aggregation). In response to an agonist platelets aggregate and the sample becomes “more 
clear” and the increased light transmission (or infrared signal) through the test sample is 
recorded. Platelet aggregation is calculated by dividing the distance from baseline to 
aggregation achieved, by the distance from the baseline to the theoretical 100% aggregation 
(PPP). Platelet aggregation has obvious disadvantages, the main one being the absence of 
red cells and an obligatory centrifugation step for PRP preparation. For these reasons, in the 
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early 1980’s new methodological methods for the study of platelet aggregation were 
developed.  
 The most common whole blood method for platelet aggregation is electrical 
impedance that measures the amount of activated platelets accumulating across electrodes. 
The electrical impedance method may also be used with PRP. Single platelet counting 
methods became popular among researchers (Fox, 1982). In this thesis, platelet aggregation 
was measure in whole blood with the use of an ACT diff Analyzer (Beckman Coulter, Inc, 
Fullerton, CA) (see Appendix B, platelet aggregation reference list authored by IA 
Jagroop). An initial baseline value was obtained in anti-coagulated blood, this was regarded 
as 100%. Then platelet counts obtained after the addition of various agonists were calculated 
as a percentage of the free platelet count in reference to the 100% baseline value. The final 
calculation is considered as the percentage of platelet aggregation that occurred in the 
sample (more details of the methods for whole blood platelet aggregation are described in 
chapter 2, section 2.7).  
 This method still has some disadvantages even with the inclusion of red cells. For 
example, this method is not available at the bedside. The assay is time consuming and the 
blood sample is required to be sent promptly to an onsite laboratory for testing. Also, there 
is considerable interlaboratory variation when performing platelet aggregometry. This may 
be due to the training of the technician, selection of agonist concentration, the adjusted 
platelet concentration that is required as the standard in each assay, processing temperature, 
completion time of the assay, and the rate of stirring samples. With these limitations, there is 
difficulty in comparing the results between laboratories.  
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1.4.4 Platelet Function Analyzer-100®  
Automated whole blood platelet function screening assays like the Platelet Function 
Analyzer-100 (PFA-100®) are gaining popularity even though they do not measure the 
vascular component of the BT (Steinhubl et al., 2001). A study compared BT and PFA-100® 
as screening tests for platelet dysfunction in 113 hospital inpatients. The results 
demonstrated improved sensitivity of the PFA-100® over BT and whole blood platelet 
aggregation studies supported the PFA-100® results (Neri Serneri et al., 2004). Thus, PFA-
100® is now available as an alternative to BT (van Werkum et al., 2008), with more that 500 
publications to date (MEDLINE accessed 8th Feb 2011). This instrument provides a quanti-
tative measure of primary, platelet-related haemostasis at high shear stress. The PFA-100® 
measures the fall in flow rate as platelets within citrated blood are aspirated through a 
capillary and begin to seal an aperture (150 µm) within a membrane. The membrane is 
treated with collagen and epinephrine (CEPI) or collagen and ADP (CADP). The final 
closure time (CT; time taken to occlude the aperture) and the volume of blood that has been 
aspirated through the aperture are recorded. Closure time can be measured to a maximum of 
300s.  
The PFA-100® has been used to provide rapid results as an early indication of a 
potential bleeding problem. Also, PFA-100® Closure time (CT) represents a fast, simple and 
sensitive method of assessing glycoprotein IIb/IIIa antagonism in vivo; it is comparable to 
optical aggregometry, and suitable for testing larger numbers of glycoprotein IIb/IIIa 
antagonists (Hayashi et al., 1989; Kumlin et al., 1986; Lawson et al., 1986; Murphy et al., 
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1994). However, PFA-100® may not be sensitive enough for monitoring clopidogrel therapy 
(Kumlin et al., 1986).  
PFA-100® has both good intra-assay and inter-laboratory reproducibility, with the 
sample error being reported at approximately 10% (Murphy et al., 1994). However, there are 
a number of variables that may affect PFA-100® testing, for example, anti-coagulation 
concentration. (Fitzpatrick et al., 1977). Another factor that affects PFA-100® is platelet 
number. That is to say, that when a haematocrit is 10% or less or a platelet count is 10x109/L 
the test will result in non-closure The PFA-100® has many advantages as a screening test to 
measure platelet function. Firstly, it requires whole blood eliminating the need for sample 
preparation (Sakariassen et al., 1983). In addition, the whole blood is collected in citrate, 
which therefore allows samples to be shared for other coagulation tests. The test requires 
very little blood (only 0.8 ml/cartridge). An attractive feature of the PFA-100® system is its 
simplicity and ease of use without the need for operators to have specialised knowledge or 
training. It produces remarkably rapid and reproducible results with good precision 
(Baumgartner et al., 1972; Sakariassen et al., 1983).  
There are disadvantages associated with the PFA-100® system. Currently, only two 
types of cartridges are available (Sixma et al., 1998). Also, even when a prolonged CT is 
obtained and a platelet disorder is indicated, results cannot distinguish severe platelet 
disorders from vWD and thus its specificity is limited (Sixma et al., 1998). The test can also 
sometimes give false-positive results in patients who have normal platelet function (Roald et 
al., 1994). 
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It is therefore recommended that when doing a PFA-100® test, a full blood count 
should always be performed to exclude thrombocytopenia or anaemia (Kaplan et al., 1981).  
Also PFA-100® should be used as a screening tool and alongside already existing platelet 
function tests (Wohl, 1981).  
 
1.4.5 Impact Cone and Plate(let) Analyzer  
The Impact (DiaMed, Cressier, Switzerland) was designed to test platelets under 
close to physiological conditions. Circulating platelets interact with and adhere to the 
exposed sub-endothelial extracellular matrix under flow, thereby forming platelet aggregates 
leading to bleeding arrest. It is therefore essential to study platelet function under the 
conditions that contribute to the physiological parameters that play a role in platelet 
adhesion and aggregation. The physiological milieu of platelets, includes flow, red blood 
cells and other blood components. This currently available technique uses a polystyrene 
surface on which plasma proteins, namely fibrinogen and vWF (Reikvam et al., 2009), are 
immobilised and form a thrombogenic surface. One of the advantages of the method is that 
it only requires a small volume of whole blood (130 -200 µL) anti-coagulated with tri-
sodium citrate (3.8%) this is placed on the plastic and a defined shear rate of 1800 sec-1 is 
applied using a cone and plate device. The next stage involves staining and measuring the 
percentage of surface covered (SC) by the stained objects and measuring the average size of 
the adherent particles using and image analyser. Results show that under these conditions 
only platelets and not other blood cells will adhere to the surface and forms elongated 
aggregates that align with the laminar flow lines. With normal blood, platelet deposition is a 
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shear- and time- dependent process that reaches a maximum level within 2 min at high shear 
rate (1800 sec-1).  
 CPA has been useful in the assessment of platelet function in a variety of normal and 
clinical situations. For example, in full-term and pre-term babies (Luddington, 2005), in 
patients with diabetes (Luddington, 2005), thrombocytopenia (Luddington, 2005; Reikvam 
et al., 2009),  vWD (White, 1998), thrombotic thrombocytopenic purpura (Clauser et al., 
2009), phospholipid syndrome (White, 1998) and for testing platelet function in stored 
platelet concentrates (Clauser et al., 2009; Nurden, 2005). Platelet aggregation was assessed 
by light transmission aggregometry (Dager et al., 2004) and Impact-R.  
The Impact is entirely dependent on the functional state of the GPIIb-IIIa and the 
GPIb-IX receptors and their ligands (fibrinogen and vWF) making it a useful tool for testing 
the response to GPIIb-IIIa antagonists (Jaumdally et al., 2007).  
In summary, the Impact cone and plate(let) analyser is based on the principle of 
quanti-fication of high shear  platelet adhesion/aggregation onto a surface (Threatte, 1993). 
It has been used in the detection of inherited and acquired defects in primary hemostasis 
(Blann et al., 2003; Lim et al., 2004), detection of platelet hyperfunction and monitoring 
anti-platelet therapy (Leung et al., 1993; Treasure et al., 1995). To date, the main 
disadvantage of this technique is that there is little widespread experience. However, the use 
of the Impact cone and plate analyser may gain popularity because of its advantages which 
include: (a) the use of a small volume of blood, (b) the technique is rapid and simple, and, 
(c) this unique method gives both visual and numeric evaluation of both platelet adhesion 
and aggregation properties under close to physiological conditions. 
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1.4.6 The VerifyNow System 
 The VerifyNow system has the advantage over platelet aggregation because it is one 
of the most user-friendly point-of-care platelet function tests and it produces rapid results. 
However, although this device is simple and rapidly performed, it is not as sensitive as the 
laboratory platelet aggregometry (Patrono et al., 2004b). The machine has the same 
fundamental advantages as platelet aggregometry in that it measures the most important 
function of platelets, which is their ability to aggregate in a GPIIb/IIIa-dependent manner 
(Maron et al., 2000). The VerifyNow system measures light absorbance. Citrated blood is 
inserted into the single-use cartridge that contains biochemical reagents, agonists and 
fibrinogen coated beads. Depending on the inhibitory level of the anti-platelet drug, specific 
agonists activate the platelets. As a result, the activated platelets cause agglutination and fall 
out of solution. It is this rate and extent of platelet-induced agglutination that is measured 
(1996 no authors listed). Verify Now previously known as the Ultegra Rapid Platelet 
Function Analyzer currently measures three types assays; the IIb/IIIa assay (sensitive to 
GPIIb/IIIa antagonists, like abciximab), the aspirin assay (sensitive to aspirin), and the 
P2Y12 receptor assay (sensitive to thienopyridines) (Farhan et al., 2010; Pfisterer et al., 
2010).  
 The first type of assay using the GPIIb/IIIa cartridge contains fibrinogen coated 
polystyrene beads and thrombin receptor activating peptide (1999 no authors listed; 
Lagerqvist et al., 2005) as agonist (1996 no authors listed). The second VerifyNow assay 
specifically monitors the inhibitory effect of aspirin therapy. The agonist in this cartridge is 
AA in a final concentration of 1mmol/l. AA is converted by the COX enzyme to TXA2 (Neri 
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Serneri et al., 2004; 1996 no authors listed; 1997b no authors listed ). This assay can be 
used to detect aspirin responders from non-responders (Casella et al., 2003). The third 
VerifyNow assay is to monitor the inhibitory effects of thienopyridine therapy, the P2Y12 
receptor assay. The cartridges for this assay contain two different chambers for agonists. 
Chamber 1 contains thrombin receptor activation peptide (TRAP) which determines a 
maximal baseline of platelet function measure and chamber two contains ADP (20 µmol/l) 
and PGE1 22 nmol/l.  
 The VerifyNow P2Y12 receptor assay is more sensitive for the specific ADP-P2Y12 
receptor pathway since PGE1 is added to suppress platelet activation, which contributes from 
ADP-binding to the P2Y1-receptor (1997b; Diehm et al., 2004). Results from this assay are 
reported as P2Y12 receptor reaction units percentage inhibition and base. The VerifyNow 
P2Y12 receptor assay has been used to evaluate the anti-platelet effects of clopidogrel (Ahn 
et al., 2011; Malinin et al., 2006).  
 Although this technique had the advantage over other techniques for its use in point-
of-care testing, the disadvantage remains that it is one of the most expensive platelet 
function assays (Michelson et al., 2006; Michelson, 2004).  
 
1.4.7 Flow Cytometry 
 Flow cytometry has been used to identify activated platelets in patients with unstable 
angina, stable CHD, pre-eclampsia, cerebrovascular ischemia, acute MI, and coronary 
angioplasty (1997b no authors listed; Patrono, 1994). Since platelets undergo changes 
during storage, flow cytometry is useful to monitor the quality of blood bank platelet 
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concentrates (Ehrman et al., 1980). Platelet membrane GP deficiencies are also evident with 
flow cytometry. Thus, major platelet disorders like Glanzmann thrombasthenia or Bernard 
Soulier syndrome can be diagnosed with the appropriate monoclonal anti-bodies (Mylotte et 
al., 2011). Other uses of flow cytometry include monitoring anti-platelet agents (e.g. 
thienopyridines, GPIIb/IIIa antagonists and aspirin), and to evaluate patients with immune 
thrombocytopenia and alloimmunisation (Scharf et al., 2011).  
 Platelets are labeled with a specific anti-body conjugated to a fluorescent probe such 
as fluorescein isothiocyanate, peridinin chlorophyllprotein or phycoerythrin. In the flow 
cytometer the cell suspension which includes labeled platelets passes through a flow 
chamber and across a focused laser beam (Gurney et al., 2002; Lacroix et al., 2010). The 
laser beam has a wavelength similar to that needed to excite the fluorescent molecule. The 
light emitted by each type of fluorescent molecule has a characteristic wavelength and is 
detected by the flow cytometer (Lacroix et al., 2010; Siljander, 2011).  
 The obvious advantage of flow cytometry is that it can be used for a variety of tests. 
A small volume of whole blood is used, thus platelets can be directly analyzed in their 
physiological milieu including red and white blood cells (Mylotte et al., 2011; Tarrant, 
2005). Moreover, since whole blood is used minimum sample manipulation is required thus 
preventing the artifactual in vivo activation and potential loss of platelet sub-population. 
With flow cytometry both the activation state and the reactivity state of circulating platelets 
can be observed. Also, this method does not involve the use of any radioactive materials 
(Shafi, 1986).  
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 Among the disadvantages of flow cytometry, are the high running cost of the 
equipment and reagents. Also, the preparation of the sample is complex and must be 
processed quickly. Analysis using this technique requires a highly trained technician. Flow 
cytometry allows us to analyze only the markers on circulating platelets. Thus, if the 
platelets are activated and rapidly cleared they may not be detected (Gurney et al., 2002). 
 
1.4.8. Thromboxane A2 Generation 
 Thromboxane A2 (TXA2) is synthesised by activated platelets and its release signals 
that further stimulate platelet activation at the site of injury where additional platelet 
recruitment forms a clot. TXA2 a potent vasoconstrictor can stimulate mitogenesis and 
accelerates haemostasis and proliferation at vascular injury (Bhavaraju et al., 2010; 
Moliterno, 2008). The biosynthesis of TXA2 is increased in clinical syndromes where 
platelet activation is prevalent, for example, myocardial infarction, severe PAD, 
preeclampasia, scleroderma, sickle cell anaemia, pulmonary hypertension and stroke, to 
name a few (Drouet et al., 2010). 
 TXA2 is rapidly converted to the more stable and inert compound TXB2. This is 
further metabolised to 11-dehydro TXB2. It is TXB2 that is assessed to give an indirect 
measure of TXA2 (Miura et al., 1999; Seidel et al., 2011). TXB2 can be measured from 
clotted blood (at 370C) or from supernatants derived from PRP or purified platelets where 
cyclooxygenase COX-1 activity has been stimulated by agonists (FitzGerald et al., 1987; 
Patrono et al., 1990). The metabolite 11-dehydro TXB2 can also be measured in urine by a 
commercially available assay (AspirinWorks®). The advantage of measuring serum TXB2 is 
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that it is directly dependent on aspirin’s target COX-1. The disadvantage of measuring 
serum TXB2 is that it is an indirect measure in the sense that platelets are not directly 
assayed, and it may not be entirely platelet specific (Roth et al., 1975a). Also, the 
measurement of serum TXB2 or urinary 11-dehydro TXB2 are not rapidly available to 
clinicians as point-of-care tests (Miura et al., 1999; Seidel et al., 2011).   
 Both quantitative immunoassays and standardised stable isotope dilution mass 
spectrometry have been the development to measure the two major metabolites of TXB2 
(Ehrman et al., 1980). Kumlin and Granstrom developed a radioimmunoassay (RIA) for 11-
dehydro TXB2. They initially examined the chemical stability as well as its chromatographic 
properties in order to reliably assay 11-dehydro TXB2. Two different anti-plasmas were 
raised in rabbits against conjugates of 11-dehydro TXB2 with bovine serum albumin. These 
displayed somewhat different properties in their recognition of the two forms of 11-dehydro 
TXB2. Thus, a radioimmunoassay employing these anti-bodies was developed (Roth et al., 
1975b). Recent instrumentation has become sufficiently sensitive to assay the TXB2 
metabolites by liquid chromatography electrospray ionization tandem mass spectrometry 
(LC-ESI-MS/MS), reducing sample preparation to solid phase extraction (1997b;Patrono, 
1994).  
 The quantitation of TXB2 by immunoassays or mass spectrometry (Loll et al., 1995) 
have been useful in defining aspirin’s dose-dependent inhibition of the capacity of platelets 
to form TXA2 (1997b  no authors listed; Patrono, 1994) as well as to validate the use of low 
doses of aspirin in cardiovascular prophylaxis (1997b no authors listed; Patrono, 1994). 
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1.4.9 Perfusion Chambers 
 In the early 1970’s Baumgartner and Haudenschild introduced the first annular 
perfusion chamber (Aster et al., 2004). It was then possible to study the influence of plasma 
components, platelet membrane glycoproteins, red blood cells and the shear rate of the blood 
on the platelet adhesion to the sub-endothelium of blood vessels (Weil et al., 1995). Thus, 
for the past 35 years it has been recognised that shear forces generated by flowing blood 
have a significant impact on platelet adhesion and thrombus formation. Moreover, it became 
clear that studies on platelet adhesion and thrombus formation were only relevant when 
performed under conditions of flow (Liberopoulos et al., 2006). This lead to the 
development of other types of flow chambers, including the flat perfusion chamber, where 
Sakariassen et al also made it possible to study isolated purified subendothelial proteins and 
isolated cultured vessel wall cells (Patrono et al., 2004a).  
 Perfusion studies with human blood were traditionally performed in relatively large 
chambers requiring large volumes of blood, 55 ml circulated per min to achieve a typical 
shear rate of 1600 sec-1 (Farrell et al., 1991). To address the problem of the need for large 
blood volumes, a newer perfusion chamber was developed with smaller dimensions. In 
comparison this used only 0.3 ml blood circulated per min for a shear rate of 1600/sec 
(Peters et al., 2003). Having a smaller chamber has the advantage of a reduction in platelet 
activation occurring during perfusion. Also, less volumes of anti-bodies or inhibitors are 
required and it is possible to perform several perfusions with native blood from the same 
patient (Patrono et al., 2004a). However, there are still some problems that need to be 
addressed, namely if a surface of laminin or thrombosponding is used, an uneven 
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distribution of adhered platelets is obtained. In addition, there appears to be sedimentation of 
red blood cells in the tubing when the flow rate is slow. Further research into the 
development of this type flow chamber was required.  
 Another problem faced by flow chambers was the presence of anti-coagulant when 
thrombus formation was studied. To overcome this problem an ex vivo perfusion system was 
developed which can be used with non-anti-coagulated blood (Diener et al., 2004). The 
blood can be directly drawn from the antecubital vein through the perfusion chamber to 
better study the role of anti-thrombotic drugs (2002 no authors listed).  
  
1.4.10 Additional Methods for Platelet Testing 
 In addition to the methods listed above, a few other tests can be used to assess 
platelet function. A summary of these platelet function tests is outlined below. The 
advantages, limitations and suitability for clinical applications are also mentioned.  
The measurement of soluble platelet markers that are specific to platelet release are a means 
for detecting increased platelet activation in vivo. Platelet factor-4 (PF-4) and beta-
thromboglobulin (β-TG) are stored in platelet α-granules and are secreted upon platelet 
activation (1990). These two proteins are specific to platelets that can be detected in both the 
MK and the platelet with the use of immunofluorescence and immunoperoxide methods 
(Juul-Moller et al., 1992). Other soluble platelet release markers like sCD40L, sCD62P and 
GPV are usually detected by ELISA (1991 no authors listed). However, the disadvantage of 
these methods is that they are prone to artefactual activation during blood collection and 
processing (Taylor et al., 1999).  
 
 
 
 
 
 
 56 
 Thromboelastography (TEG) was originally developed more than 50 years ago 
(Farrell et al., 1991). TEG records the continuous profiles of whole blood coagulation by 
measurement of the viscoelastic changes associated with fibrin polymerisation, and thereby 
provides a global assessment of haemostatic function (Yusuf et al., 2001). The rate of fibrin 
polymerisation as well as the overall clot strength is assessed. The TEG or 
thromboelastometry (ROTEM) works on the principle where blood is incubated 370C in a 
heated cup where a pin is suspended and connected to a detector system. In the case of TEG 
it is a torsion wire and in the case of ROTEM it is an optical detector. The cup and pin 
oscillate relative to each other. As fibrin forms between the cup and the pin the transmitted 
rotation is detected and a trace is generated (Mehta et al., 2001). TEG is a registered 
trademark of the Haemoscope Corporation. However, an alternative instrument marketed by 
Pentapharm GmbH uses an adaptation of the TEG, the rotational TEG or ROTEM 
(ROTEG).  Thus, the term TEG/ROTEM is sometimes used. The main uses of the 
TEG/ROTEM have been to monitor blood component therapy during surgery, in the field of 
liver transplantation and it has also been useful in cardiac surgery (Mehta et al., 2001). This 
instrumentation can also be used within surgical and anaesthesiology departments as point-
of-care testing and for determining the risk of bleeding and as a guide to transfusion 
requirements. Thus, the main advantage of the TEG/ROTEM is that it is an inexpensive 
near-patient method for the quick evaluation of the patient’s global haemostatic system 
(Steinhubl et al., 2002).   
 Another method used in the diagnosis of platelet disorders is electron microscopy 
(EM) (Sabatine et al., 2005).  Since the development of EM, there has been a tremendous 
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insight into platelet structure, function, and their relation to pathology. This technique has 
helped to understand, characterize and classify many platelet disorders (1996 no authors 
listed). There are several instances where EM has been critical for identifying and 
characterising genetic problems. For example, platelet storage pool deficiency where there is 
less of the organelles that store adenine nucleotides, 5HT and calcium, which destined to be 
secreted during the platelet release reaction. EM has made it possible to distinguish various 
types of giant platelet disorders into distinct conditions based on the nature of platelet 
structural defects (Chen et al., 2005). Thus, with the use of EM it has been possible to 
understand and classify platelet disorders that originate from platelet organelles, 
cytoskeleton and membrane defects. For example, grey platelet syndrome, Paris-Trousseau 
syndrome, MYH9-related thrombocytopenia’s as well as Wiskott-Aldrich syndrome (Diener 
et al., 2004). We have previously demonstrated that there is a relationship between ScEM 
and MPV in assessing PSC. An increase in MPV occurs concomitantly with morphological 
changes where the normally discoid circulating platelets become spherical and throw out 
from their surface, projections of varying shapes (Jagroop et al., 2000a). This then develops 
into multiple pseudopodia resulting in a increase in the surface area (Diener et al., 2004). 
The main disadvantage of ScEM however, is that it requires expensive equipment, also it is 
only available in specialised units (Markus et al., 2005).  
 Clinicians can utilize a range of tests for platelet function (some of which are 
outlined in this thesis), for the diagnosis and management of patients presenting with 
bleeding problems, atherothrombosis, to monitor the efficacy of anti-platelet drugs and to 
identify patients at risk of arterial disease. New platelet function tests are increasingly being 
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developed that aim to be simpler point-of-care instruments that can be useful pre-
surgery/peri-operatively to aid in the prediction of bleeding and for monitoring haemostasis.  
 
1.5 The Role of Platelets in Atherosclerotic Disease 
 PAD is defined as atherosclerotic occlusive disease of the extremities. PAD patients 
have are at a high risk of stroke, myocardial infarction (MI). Patients with PAD tend to have 
activated platelets (Bowbrick, 2003; Busti, 2010; Barradas, 1994; Barradas, 1993). This was 
supported by the findings of the Anti-platelet Trialists Collaboration (Drouet et al., 2010), 
which showed that anti-platelet therapy reduces the odds of graft or native arterial occlusion 
in patients with PAD undergoing bypass surgery or angioplasty. Furthermore, a meta-
analysis of anti-platelet agents in patients with PAD showed a benefit in terms of vascular 
events (Robless et al., 2001). Platelets also play a major role in atherosclerosis and its 
complications in the coronary and cerebral vascular systems. 
 Platelets play a role in the development and progression of atherosclerosis. Injury to 
the arterial endothelial cell results in the endothelial cell dysfunction, the first step in the 
process of atherosclerosis. This injury causes a platelet response (see figure 1.6).  
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Figure 1.6: Activation and adhesion of platelets.  Platelets adhere to the damaged 
endothelium in the presence of its components collagen and von Willebran factor (Moake et 
al., 1988). Collagen interacts with glycoprotein Ia/IIa (GPIa/IIa) and vWF with GPIb/IX 
complex on platelets which results in platelet adhesion to the subendothelial matrix. The 
binding activates GPIIb/IIIa receptor within the platelet membrane, which changes its shape 
on activation to express a high-affinity binding site for fibrinogen (FIB). This process is 
called ‘outside in’ signalling and leads to further platelet activation, aggregation and 
accumulation at the site of injury. 
 
 Platelet adhesion leads to activation and the platelet degranulation of the platelet 
dense granules and the release of its contents like PDGF, ADP, α-granule proteins and β-
TG. P-selectin which is present on the membranes of the α-granules of resting platelets will 
move to the outer membrane once activation occurs. A cascade of events involves the 
adhesion on monocytes on the luminal surface, which is then converted to activated 
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macrophages that take up lipoprotein particles to become foam cells. This leads to the 
formation of fatty streaks that contribute to the early stages of atherosclerosis.  
The pathogenesis of atherosclerosis also involves the proliferation of smooth muscle 
cells. PDGF is important in this process and is essential for the migration of smooth muscle 
cells to the intima. PDGF receptors are found on the surface of smooth muscle cells, which 
upon stimulation by exogenous PDGF, results in smooth muscle cell proliferation, and 
synthesis of a PDGF-like protein that promotes proliferation of smooth muscle cell by 
stimulation of mitosis. 
Studies have shown that the platelets of diabetic patients, tend to be hypersensitive to 
aggregating agents (Winocour, 1994). It was also observed that  the release of α-granule 
content in vivo; activity of the AA pathway and prostaglandin and TXA2 formation. 
Increased were increased (Winocour, 1994). 
 The increased platelet activity from diabetic patients parallels the enhanced vascular 
disease in diabetics (Winocour, 1994). In type 1 and 2 diabetes there is an association with 
impaired endothelial function. The decreased bioavailability of nitric oxide (NO), decreased 
production of prostacyclin and the increased production of TXA2, affects the endothelium-
dependent vasodilator function in diabetes. The decreased levels of NO associated with type 
2 diabetes leads to increased platelet activation and aggregation and a greater risk in 
developing thrombosis and atherosclerosis (Nenci, 2000)  
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That is to say, the increased platelet aggregability and adhesiveness are due to the following 
(Winocour, 1994;Sobol, 2000;Nenci, 2000): 
• A reduction in membrane fluidity 
• Altered Ca2+ and Mg2+ homeostasis (increased intra-cellular Ca+ mobilization and 
decreased intra-cellular Mg2+) 
• Increased AA metabolism 
• Increased TXA2 synthesis 
• Decreased prostacyclin production  
• Decreased NO production 
• Decreased anti-oxidant levels 
• Increased expression of activation dependent adhesion molecules (e.g. GpIIb-IIIa, P-
selectin). 
 
 In type 1 and type 2 diabetes, platelets show enhanced aggregation at an early stage 
in the disease which precedes the development of CVD (Natarajan, 2008). Platelet 
hyperactivity may be due to a range of biochemical abnormalities, which include reduced 
membrane fluidity that can reflect changes in the lipid composition of the platelet membrane 
or even the glycation of membrane proteins (Natarajan, 2008).  
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Figure 1.7: Platelet activation of the coagulation cascade via the IP3 pathway.  
Thrombin is generated after endothelial cell disruption and binds to protease-activated 
receptors 1 (PAR1) and PAR4. This activates phospholipase C and hydrolyses 
phosphatidylinositol 4,5 biphosphate (PIP2) into inositol triphosphate (IP3) and 
diacylglycerol (Markus et al., 2005). IP3 mobilises calcium stores which activates 
phospholipase A2 leading to arachidonic acid (AA) production. Cyclooxygenase-1 (COX-1) 
catalyses the synthesis of thromboxane A2 (TXA2) from AA in platelets, which leads platelet 
granule release, and further ADP-induced activation and aggregation.  
 
  
 
PAR1 PAR4 
PLC activation 
PIP
2 
IP3 DAG 
Calcium 
mobilisation
n 
MP 
AA 
Granule Release ADP- platelet 
activation 
TXA2 
COX-1 
PLA2 activation 
 Thrombin 
 
 
 
 
 
 
 63 
 The platelets from diabetic patients may also show increased AA metabolism, 
leading to enhanced TXA2 production and enhanced platelet sensitivity. Calcium 
mobilization is increased from their storage pools and results in a higher concentration of 
intra-cellular calcium levels. This has been correlated with a reduction in membrane fluidity. 
Platelet hyperaggregability and adherence in diabetics is also associated with a reduction in 
intra-cellular Mg2+ (Vinik, 2001). Decreased NO and prostacyclin production in diabetic 
patients, results in the inhibition of platelet-endothelium interactions which leads to the 
endothelium-mediated vasodilation. In diabetic patients, increased aggregability and low 
vitamin C may be associated with a reduced anti-oxidant level (Carr, 2000) 
 Diabetics tend to have a larger number of platelets that express activation-dependent 
adhesive molecules like GPIIb-IIIa, P-selectin, lysosomal Gp53 and thrombospondin. 
Patients with diabetes have been shown to have increased levels of fibrinogen, which is 
consistent with elevated of platelet GPIIb-IIIa expression.  
 Finally, in patients with diabetes, the leading cause of disability and premature death 
is CVD. A patient with diabetes has a two-fold to four-fold increased risk of CHD, stroke 
and PAD. Both atherosclerosis and thrombosis contribute significantly to the increased risk 
of CVD in diabetic patients. Many studies have shown that anti-platelet therapy can be used 
in the treatment of diabetic patients (see section 1.6).  
 Atherosclerotic plaque commonly develops at the sites where major arteries branch 
or curve. It is there that shear force is higher and thus, shear induced platelet aggregation is 
initiated by the binding of soluble vWF to platelet GPIb. Advanced atheromatous lesions 
contains high levels of tissue factor which initiates the coagulation cascade by interacting 
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with factor VII and then activating factor X. Thrombin is generated as the end result of the 
coagulation cascade which also induces platelet aggregation. Platelet aggregates are formed 
from the deposited platelets which contributes to the occlusion of vessels. PDGF which is 
released from the platelet rich thrombus may be responsible for smooth muscle cell 
migration and proliferation. Mural thrombi are later incorporated into the vessel wall, which 
results in organised thrombi and subsequent luminal stenosis (Cassar et al. 2002).  
The endothelium appears to play a pivotal role in the development of atherosclerosis 
through its effect on vasoregulation, platelet and monocyte adhesion and coagulation. There 
are an array of coronary risk factors (see Table 1.3) that may impair endothelial function 
(Jagroop et al., 2004). It is possible to predict the extent of atherosclerosis by the presence 
or absence of these established risk factors (Schleinitz et al., 2005).  
Risk factor modification has been shown to improve endothelial function. A 
significant reduction in cardiovascular events were observed when cholesterol and in 
particular LDL-C levels were reduced (Diener et al., 1996).  
To manage CHD it is important to distinguish the type of CHD. There are three 
stages of CHD, which can be characterized, as pre-clinical, stable and unstable. At the pre-
clinical stage, anti-platelet therapy (ASA or warfarin), (see section 1.6) is recommended. In 
addition, diet modification as well as a statin is recommended for patients with an elevated 
cholesterol (in particular LDL-C) (2002). The second stage of CHD, the stable stage, 
involves the development of stable coronary symptoms. Patients are recommended diet and 
exercise in order to improve their lipid profile. Again, drug therapy is in the form of statins 
e.g.  simvastatin and pravastatin (Leonardi-Bee et al., 2005).  Patients should receive low 
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dose ASA for life. In patients where ASA is contraindicated, clopidogrel can be used as a 
substitute (Quinn et al., 1999). Patients should also receive beta-blockers. The use of 
angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers can 
control blood pressure and improve survival in secondary prevention (Quinn et al., 1999). 
The third stage of CHD, unstable CHD, is characterised by its severity and treated 
accordingly (Gent et al., 1989). There are a further 3 stages of unstable CHD, unstable 
angina, acute MI and sudden ischemic cardiac death.  
 
Table 1.3: Risk Factors for Coronary Heart Disease that can  
    also Impair Endothelial Function  
• Male gender                        
• Dyslipidemia                                                   
• Obesity 
• Diabetes mellitus                                                      
• Hypercholesterolemia 
• Tobacco/cigarette smoking                             
• High-fat diet 
• Hypertension                                                    
• Sedentary lifestyle          
• Genetics (family history  of premature CHD) 
•  
•                                            
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  Following activation, platelet responses involve PSC, aggregation and the release of 
several mediators (Diener et al., 1996). Platelet activation has been associated with 
increased plasma levels of CD40 ligand (Tran et al., 2004). Platelet activation in vivo is also 
associated with the physical changes such as mean platelet count, MPV and mean platelet 
granularity. Large denser platelets are more active in haemostasis (Leon et al., 1998) 
(Sudlow, 2005). P-selectin is expressed following inflammation and mediates leukocyte 
rolling and recruitment. Moreover, increased levels of plasma P-selectin levels are 
associated with several  cardiovascular disease (De Schryver et al., 2003; Jagroop et al., 
2004; Tsiara et al., 2003).  
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1.6 Anti-platelet Therapy 
 
1.6.1 Clopidogrel 
Clopidogrel (Plavix) is a theinopyridine, a class of ADP receptor/P2Y12 inhibitors 
(Duerschmied et al., 2010) and is used as a potent anti-platelet agent. It demonstrates 
efficacy in preventing thrombotic events (MI, stroke, and vascular death) in high risk 
patients (1996, no authors listed), (Anderson et al., 2010). Clopidogrel is not active in vivo; 
biotransformation by the liver is necessary to allow the generation of an active metabolite 
that expresses anti-aggregatory activity (Savi et al., 1992). Other ADP P2Y12 receptor 
antagonists are in current clinical use or at various phases of development. These include 
prasugrel, ticagrelor cangrelor and elinogrel (these are further discussed in chapter 3). Trials 
are underway to determine if these ADP P2Y12 receptor antagonists have a faster onset of 
action, and/or greater anti-thrombotic effects than clopidogrel, without an unacceptable 
increase in hemorrhagic or other side effects (Mousa et al., 2010).  
The Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (1996, no 
authors listed) study (n = 19,185) was carried out to test the efficacy and safety of a dose of 
75 mg daily of clopidogrel vs ASA, 325 mg daily for 1 to 3 years. The majority of the 
difference in effectiveness occurred in the patients who entered the trial because of 
symptomatic PAD (1997b, no authors listed). Clopidogrel may be superior to ASA in the 
treatment of PAD (Matsagas and Jagroop et al., 2002). A strong association exists between 
PAD and other atherosclerotic disorders such as CHD and cerebrovascular disease. Platelet 
hyperactivity in PAD may play a role in the process that leads to complications and disease 
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progression. Other studies indicated, that platelets in patients with PAD are relatively ASA-
resistant (Reininger et al, 1999; 1997b no authors listed; Diehm et al., 2004). Therefore, 
clopidogrel may be a better choice than ASA in treatment of PAD (Matsagas and Jagroop et 
al., 2002). The data from the CAPRIE Trial, in patients with PAD, demonstrated that those 
randomized to clopidogrel 75 mg daily had a 24% significant (p=0.0028) reduction in 
vascular death, non-fatal MI, and non-fatal stroke than patients randomized to ASA 325 mg 
daily (1997b, no authors listed). These data favour the use of clopidogrel in patients with 
PAD. However, this interpretation is limited by the fact that this analysis was post-hoc. ASA 
alone may no longer be the optimal therapy for PAD (1997b, no authors listed; Diehm et al., 
2004).  
 
1.6.2 Aspirin 
ASA may represent the "golden balance" between yielding maximal clinical benefit 
with minimal complications. ASA is widely used as an effective inhibitor of platelet 
aggregation (1997b, no authors listed; Patrono, 1994). ASA works by preventing the 
conversion of arachidonate to TXA2, a potent vasoconstrictor and platelet agonist, by 
irreversibly inactivating the cyclooxygenase (COX) activity (also referred to as COX-1 and 
COX-2) (Ehrman et al., 1980; Roth et al., 1975a). These isoenzymes catalyze the first step 
in prostanoid biosynthesis (i.e. the conversion of arachidonic acid to PGH2). PGH2 is the 
immediate precursors of PGD2, PDE2, PGF2, PGI2 (Ehrman et al., 1980) and TXA2 (Roth et 
al., 1975b). In human platelets, TXA2 is released in response to various platelet agonists 
(e.g. collagen, ADP, PAF, and thrombin) and induces irreversible aggregation (1997b, no 
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authors listed; Patrono, 1994). The molecular mechanism of permanent inactivation of COX 
activity by ASA is a consequence of the acetylation of a serine residue that prevents access 
of the substrate to the catalytic site of the enzyme (Loll et al., 1995). Since ASA can 
inactivate COX-1 even in mature megakaryocytes  and since 10% of the platelet pool is 
replaced every day, a single dose of 160 mg or the chronic administration of daily doses of 
30-50 mg of ASA, is capable of completey inhibiting platelet TXA2 production (1997b, no 
authors listed; Patrono, 1994). In contrast, the inhibition of COX-2 requires larger doses of 
ASA (because of decreased sensitivity of COX-2 to ASA) and a much shorter dosing 
interval (1997b, no authors listed; Patrono; 1994). 
There are a few side effects associated with the use of ASA. Long-term therapy with 
ASA is associated with a modest increase in the incidence of upper gastrointestinal bleeding 
(Aster et al., 2004; Weil et al., 1995). The inhibition of platelet function, the impairment of 
PGE2-mediated cytoprotection in the gastrointestinal (GI) mucosa, as well as the ulcerogenic 
effect generated by the direct contact of this drug with the gastric mucosa, contribute to the 
increased risk of upper GI bleeding (Liberopoulos et al., 2006). Whereas the inhibition of 
TXA2-mediated platelet function is dose-independent (at least for daily doses >30 mg), the 
side effects are dose-dependent (Patrono et al., 2004a). 
 There is evidence that doses of approximately 300 mg/day of ASA produce fewer 
GI effects than those of approximately 1200 mg/day (Farrell et al., 1991). The Clopidogrel 
in Unstable Angina to Prevent Recurrent Events (CURE) investigators (Peters et al., 2003) 
retrospectively investigated the relationship between the ASA dose (75-325 mg/daily) and 
the risk of major bleeding. The administration of ≤ 100 mg/day of ASA resulted in the 
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lowest rate of major or life-threatening bleeding complications both in placebo (1.9%) and 
clopidogrel (3%) arms of the trial. Bleeding risks increased with increasing ASA dose, with 
or without clopidogrel, without any increase in efficacy. 
Although the search for the lowest effective dose of ASA for platelet inhibition was 
largely driven by the concern of concomitant inhibition of vascular PGI2 production, it is 
still uncertain whether dose-dependent suppression of the latter attenuates the anti-
thrombotic effect of ASA in the clinical setting (Patrono et al., 2004a). The Anti-thrombotic 
Trialists’ Collaboration (Diener et al., 2004) meta-analysis of 287 secondary prevention 
studies (2002, no authors listed), showed that among the trials of high daily doses of ASA 
vs no ASA, no particular range of ASA dose was preferable for the prevention of serious 
vascular events. The proportional reduction in vascular events was 19% with 500-1500 
mg/daily, 26% with 160-325 mg/daily and 32% with 75-150 mg/daily. However, daily doses 
<75 mg seemed to have a smaller effect (proportional reduction 13%). Additionally, ASA in 
a dose of 75 mg/day was effective enough to reduce the risk of MI or death in patients with 
unstable angina (1990, no authors listed) and chronic stable angina (Juul-Moller et al., 
1992), as well as to reduce the incidence of stroke or death in patients with transient 
ischaemic attacks (TIA) (1991, no authors listed). The Acetylsalicylic Acid and Carotid 
Endarectomy trial (Taylor et al., 1999) reported that the risk of the composite outcome of 
MI, stroke or death within 3 months of carotid endarterectomy was significantly lower 
among patients taking 81 or 325 mg ASA daily than in those taking 625-1300 mg. Similarly, 
in the UK-TIA study, no difference in efficacy was found between doses of 300 and 1200 
mg/day (Farrell et al., 1991) 
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1.6.3 Aspirin and Clopidogrel Combination 
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial 
(Yusuf et al., 2001) was designed to compare the efficacy and safety of the early and long-
term use of clopidogrel plus ASA with those of ASA alone, in patients (n=12,562) with 
acute coronary syndromes and NSTEMI. Patients who presented within 24 h after the onset 
of symptoms, were randomly assigned to receive either clopidogrel (300 mg immediately, 
followed by 75 mg once daily) or placebo, for 3-12 months. ASA, 75-325 mg/daily, was 
given to all patients. Death from cardiovascular causes, non-fatal MI, or stroke occurred in 
9.3% of the patients in the clopidogrel group and 11.4% in the placebo group. The second 
primary outcome (composite of the first primary outcome or refractory ischaemia) occurred 
in 16.5% of the patients in the clopidogrel group and in 18.8% of the patients in the placebo 
group (p<0.001). In the Percutaneous Coronary Intervention (Mehta et al., 2001) sub-study 
of the CURE trial (Mehta et al., 2001) 2,658 patients undergoing PCI were pretreated with 
ASA plus clopidogrel or ASA plus placebo before PCI. The primary endpoint was a 
composite of cardiovascular death, MI, or urgent target-vessel revascularization within 30 
days of PCI. The number of patients with the primary endpoint was significantly lower in 
the clopidogrel group (7.2%) compared with the placebo group (4.2%) (95% CI 0.4-0.85, p 
= 0.005). As continuity of the PCI-CURE trial, the Clopidogrel for the Reduction of Events 
During Observation (CREDO) trial (Steinhubl et al., 2002) was designed to evaluate the 
efficacy and safety of clopidogrel therapy for 1 year and the efficacy and safety of a loading 
dose of clopidogrel prior to elective PCI.  
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The Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in 
MI (TIMI) 28 study (Sabatine et al., 2005) enrolled 3,491 patients, 18 to 75 years of age, 
who presented within 12 h after the onset of STEMI. Patients were randomly assigned to 
receive either clopidogrel (300 mg loading dose followed by 75 mg once daily) or placebo. 
All patients were to be treated with a fibrinolytic agent, ASA (150-325 mg on the first day 
and 75-162 mg/day thereafter), and for those receiving a fibrin-specific lytic agent, heparin 
for 48 h. Coronary angiography was performed 48-192 h after the start of study medication. 
The primary endpoint was the composite of an occluded infarct-related artery (defined by a 
TIMI flow grade of 0 or 1), death from any cause before angiography could be performed, 
or recurrent MI before angiography. For patients who did not undergo angiography, the 
primary endpoint was death or recurrent MI by day 8 or hospital discharge, whichever came 
first. There was a 6.7% reduction in the rate and a 36% reduction in the odds of the primary 
endpoint with clopidogrel therapy (95% CI, 24-47%; p<0.001).  
Other studies that examined ASA in combination with clopidogrel, include the 
Clopidogrel and Metoprolol in MI Trial (1996, no authors listed; Chen et al., 2005), the 
Management of Atherothrombosis with Clopidogrel in High-risk patients trial (Diener et al., 
2004), and the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid 
Stenosis (Markus et al., 2005) trial (Markus et al., 2005).  
The CARESS trial (Diener et al., 2004) was designed to evaluate whether 
clopidogrel in combination with ASA is superior to ASA alone in reducing the incidence of 
asymptomatic microembolic signals (MES) as detected by transcranial Doppler ultra-sound 
(TCD). This was carried out in patients with recently diagnosed symptomatic carotic 
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stenosis. 107 patients diagnosed with MES were randomised for treatment of either ASA or 
ASA plus clopidogrel. Results indicated a significant reduction in the primary end-point of 
43.8 % of dual-therapy patients who were MES positive on day 7, as compared to 72.7 % of 
mono-therapy patients. The secondary end-point of MES frequency per hour was reduced 
(in comparison to baseline) by 64.1 % in the dual-therapy group at day 7, and by 61.6 % on 
day 2. In addition to TCD recordings, collagen-induced platelet aggregation tests were 
carried out on PRP (from 71 patients) at baseline and at day 7. Mean maximum intensity of 
platelet aggregation at day 7 was 106.7 % of baseline in the monotherapy group and 70.9 % 
in the dual-therapy arm (a relative risk reduction 36.6 %). Markus et al. concluded that in 
patients with recently symptomatic carotid stenosis, combination therapy with clopidogrel 
plus ASA is more effective than ASA alone in reducing asymptomatic embolism (Diener et 
al., 2004).  
Jagroop et al (Jagroop et al., 2004) evaluated the effect of ASA (75 mg/day), 
clopidogrel (75 mg/day) and both anti-platelet drugs on platelet function in patients with 
PAD (see chapter 3). There was a significant decrease on ADP-induced aggregation after 
clopidogrel but not after taking ASA. Dual therapy significantly decreased SPA, which was 
not significantly altered by either monotherapy. The same phenomenon was observed with 
5HT-induced aggregation. Soluble P-selectin decreased significantly with the combination 
therapy. 
A cost-effectiveness analysis of combination therapy (ASA plus clopidogrel) showed 
that in patients with high risk acute coronary syndromes, 1 year of treatment with 
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clopidogrel plus ASA results in greater life expectancy than ASA alone, at a cost within the 
traditional limits of cost-effectiveness (Schleinitz et al., 2005). 
 
1.6.4 Aspirin and Dipyridamole Combination 
The combination of ASA with dipyridamole (DP) was compared with ASA 
monotherapy for stroke prevention among patients with TIA or stroke, in several clinical 
trials. The European Stroke Prevention Study-2 (ESPS-2 study) (Diener et al., 1996) 
evaluated this anti-platelet combination therapy in 6,602 patients with TIA or stroke in the 
preceding 3 months. After 2 years of follow-up, the combination therapy produced a relative 
risk reduction by 23.1% compared with ASA alone, in both the stroke endpoint and the 
composite stroke or death end-point. The ESPS-2 trial was analyzed together with additional 
trials included in the meta-analysis by the ATC, the addition of DP to ASA was associated 
with a non-significant 6% risk reduction in serious vascular events (fatal stroke, MI, 
vascular deaths) compared with ASA monotherapy (Tran et al., 2004).  
The MATCH trial set out to determine whether the addition of aspirin to clopidogrel 
could have a greater benefit than clopidogrel alone in prevention of vascular events with 
potentially higher bleeding risk (Diener et al., 2004). A randomised, double-blind, placebo-
controlled trial to compare aspirin (75 mg/day) with placebo. This was carried out in 7599 
high-risk patients (treated for 18 months) with recent ischaemic stroke or transient ischaemic 
attack, and at least 1 additional vascular risk factor who were already receiving clopidogrel 
75 mg/day (Diener et al., 2004). The results from this study indicated that patients at high-
risk (i.e. who recently suffered ischaemic stroke or transient ischaemic attack, TIA), when 
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treated with a combination of aspirin and clopidogrel are associated with a non-significant 
difference in the reduction of major vascular events. Moreover, addition of aspirin increases 
the risk of life-threatening or major bleeding (Diener et al., 2004). 
1.6.5 Aspirin and Ticlopidine Combination 
In the STent Anti-coagulation Restenosis Study (STARS) (Leon et al., 1998) 1,965 
patients undergoing coronary artery stenting were randomized to 1 of 3 different anti-
thrombotic regimens: 325 mg/day of ASA, ASA plus ticlopidine 250 mg twice daily, or 
ASA plus warfarin daily to achieve anincidence of neutropenia or thrombocytopenia of 2-
2.5. The main endpoints of this trial consisted of clinical and angiographic cardiac outcomes 
within 30 days of coronary stenting, and included MI and a composite outcome of MI, 
vascular mortality, vessel thrombosis and need for revascularization. The combination of 
ASA with ticlopidine was more effective than ASA alone or ASA plus warfarin for the MI 
and composite outcomes, but resulted in more major haemorrhages, defined as any 
haemorrhage requiring transfusion. Ticlopidine has been linked with aplastic anemia 
(Bortolotti et al., 2002; Kao et al., 1997; Symeonidis et al., 2002) and is discussed further in 
section 1.6.7 
 
1.6.6 Dipyridamole  
Dipyridamole (DP) is a pyrimidopyridine derivative with anti-platelet and 
vasodilator properties. Several possible anti-platelet actions of DP include the inhibition of 
platelet cyclic nucleotide phosphodiesterase, the direct stimulation of PGI2 release from 
endothelial cells and the inhibition of adenosine uptake by platelets (Sudlow, 2005). All of 
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these putative mechanisms increase intra-platelet adenosine 3',5'-cyclic monophosphate 
(cAMP), which inhibits the mobilization of free calcium, central to platelet activation. DP is 
also a potent vasodilator, and its coronary dilating effect is the reason for its use in 
diagnostic stress echocardiography and thallium imaging. During rapid intra-venous 
administration in these procedures, DP tends to lower blood pressure. However, the long-
term (>15 months) oral administration of DP in patients with recent cerebral ischaemia of 
arterial origin, did not affect blood pressure (De Schryver, 2003).  
In the ESPS-2 study (Diener et al., 1996), DP compared with placebo, significantly 
reduced the incidence of stroke (p=0.04). In a post-hoc analysis of ESPS-2 data, treatment 
with DP in patients with coronary heart disease or MI at study entry, did not result in a 
higher number of fatal and non-fatal cardiac events. 
The ATC's meta-analysis (2002, no authors listed) of direct randomized comparisons 
between DP alone and ASA alone in high risk patients, found no significant difference in 
effect on serious vascular events, including stroke, MI, or vascular death. However, since 
the largest body of evidence concerns ASA, and the wide confidence interval includes the 
possibility that DP is less effective than ASA, this implies that DP alone should not 
generally be considered as an alternative to ASA. 
In a meta-analysis by the Dipyridamole in Stroke Collaboration (DISC) (Leonardi-
Bee et al., 2005) in patients with previous ischaemic stroke or TIA, DP significantly reduced 
stroke compared with controls (OR 0.82; 95% CI, 0.68-1.00). Furthermore, this meta-
analysis showed that the combination of DP with ASA significantly reduced stroke 
compared with DP alone (OR 0.74; 95%CI, 0.60-0.90). Dual therapy also significantly 
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reduced the composite outcome of non-fatal stroke, non-fatal MI, and vascular death as 
compared with DP alone (OR 0.76; 95% CI, 0.64-0.90). 
 
1.6.7 Ticlopidine 
Ticlopidine has been used as an inhibitor of platelet aggregation and was widely used 
in PAD. However, the use of this drug is limited since it has been associated with 
neutropenia and other adverse hematologic effects, such as aplastic anaemia (Bortolotti et 
al., 2002; Kao et al., 1997; Symeonidis et al., 2002). Aplastic anaemia is a rare complication 
that carries high mortality (Bortolotti et al., 2002).  A meta-analysis of the literature 
evaluated 57 patients who were on ticlopidine (Symeonidis et al., 2002). A reversible direct 
cytotoxic effect of ticlopidine on the pluripotent/bipotent hematopoietic progenitor stem cell 
was proposed with the use of ticlopidine (Symeonidis et al., 2002). It was estimated that 
ticlopidine-induced aplastic anaemia was higher than previously suspected (Symeonidis et 
al., 2002).  
To summarize, there is currently evidence regarding oral anti-platelet treatment in 
patients with CVD, CAD, and PAD. It can be stated, that aspirin, ticlopidine, or clopidogrel 
on its own, and aspirin combined with clopidogrel, or aspirin combined with dipyridamole 
are effective in preventing recurrent vascular events among various subgroups of patients 
with vascular disease (Tran et al., 2004). Moreover, current clinical trial evidence prefers the 
use of aspirin or clopidogrel as first-line agents for the majority of patients with vascular 
disease. The future practice by clinicians will be dictated by further clinical trials evaluating 
combination anti-platelet therapies.   
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1.6.8 GPIIb/IIIa Receptor Antagonists  
One of the mechanisms to inhibit platelets is to block the platelet surface membrane 
glycoprotein (GP) IIb/IIIa receptor, which binds circulating fibrinogen or vWF and 
crosslinks platelets as the final common pathway to platelet aggregation (Auer et al., 2003). 
Intravenous agents directed against this receptor include the chimeric monoclonal anti-body 
fragment abciximab, the peptide inhibitor eptifibatide, and non-peptide mimetics tirofiban 
and lamifiban (Auer et al., 2003). Clinical trials with a combined total of more than 18,000 
patients have shown the benefits of intra-venous IIb/IIIa blockade (i.e. the final common 
pathway for aggregation) (Mak et al., 1999b). Overall, at 30 days, 13 fewer deaths or MIs 
occurred for every 1000 patients treated in these trials. This favorable outcome was 
extended to 6 months, resulting in 16 fewer such events per 1000 patients treated. Over 
20,000 patients were enrolled in 9 (1994, no authors listed) major studies of abciximab, 
eptifibatide, and tirofiban (1994 no authors listed; 1997b, no authors listed). The result was 
that many countries approved the use of abciximab due to the EPIC trial (1994, no authors 
listed), eptifibatide and tirofiban showed positive trends in the IMPACT-II trial (1997b, no 
authors listed). Despite being as potent as their intra-venous counterparts, all of the oral 
inhibitors showed no benefit or even increased mortality in clinical trials (Cox, 2004b). 
There are a number of possible reasons for their failure. The target was different, chronic 
treatment to prevent thrombotic events as opposed to short-term treatment to prevent acute 
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events and as a result, different dosing regimens were used (Cox, 2004b). Many of the oral 
inhibitors had low bioavailability that led to a large peak-trough difference (Storey, 2002). 
Tirofiban is discussed further in Chapter 5.  
 
1.6.9 Picotamide 
Picotamide, a derivative of methoxy-isophtalic acid, is an antagonist of TXA2/PGH2 
receptors, which also inhibits TXA2 synthase at equivalent concentrations. This dual action 
may enhance the therapeutic efficacy in the prevention of thrombosis, including inhibition of 
platelet aggregation and accumulation of anti-aggregatory prostaglandins (Gersele et al. 
1991). In a double blind, placebo-controlled study in 2,313 patients with PAD, picotamide 
significantly reduced the relative risk of combined major and minor cardiovascular events 
by 23% compared to placebo (Balsano et al. 1993). The Drug evaluation in Atherosclerotic 
Vascular disease In Diabetics (DAVID) study included 1,209 adults, aged 40-75 years with 
type 2 diabetes and PAD (Neri Sereneri et al. 2004). Patients were randomized to receive 
picotamide (600 mg twice daily) or ASA (320 mg/day) for 24 months. The cumulative 
incidence of the 2 years overall mortality was significantly lower in the picotamide group 
(3.0%) compared with the ASA group (5.5%) (RRR 0.55 for picotamide vs ASA). 
 
1.6.10 Cilostazol 
Cilostazol is a selective inhibitor of phosphodiesterase-III (PDE-III) with anti-
platelet, anti-thrombotic and vasodilating properties (Chapman et al., 2003; Robless et al., 
2008). Cilostazol exhibits anti-proliferative effects on smooth muscle cells and has 
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beneficial effects on high-density lipoprotein-cholesterol and triglyceride levels. The 
efficacy of cilostazol was demonstrated in randomized, double blind trials, where the 
administration of the drug in over 2,000 patients with moderate to severe intermittent 
claudication (IC), resulted in a significant increase of walking distance and in an 
improvement of quality of life (Chapman et al., 2003).  
The Cochrane Peripheral Vascular Diseases Group carried out searches to determine 
the effect of cilostazol on improving walking distance and in reducing vascular mortality 
and cardiovascular events in patients with stable IC (Robless, 2008; Storey, 2002). The 
authors concluded that patients with IC should be treated with secondary prevention for 
cardiovascular disease and reported that cilostazol had a beneficial effect in improving 
walking distance in people with IC (Robless, 2008; Storey, 2002). Moreover, cilostazol is 
generally well tolerated, but common adverse events are headache, diarrhoea, abnormal 
stools, rhinitis and peripheral oedema. Co-administration of cilostazol with ASA or warfarin 
does not influence coagulation parameters, bleeding time or platelet aggregation (Barnett et 
al., 2004).  
 
1.6. 11 Sarpogrelate 
Sarpogrelate is a selective 5HT2A receptor antagonist that has antiplatelet, 
antithrombotic, anti-atherosclerotic and anti-anginal activity (Saini et al., 2004). In human 
beings, dogs, monkeys and rats, when given orally, sarpogrelate hydrochloride is first 
metabolized to (R,S)-1-[2-[2-(3–methoxyphenyl)ethyl]phenoxy]-3-(dimethylamino)-2-
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propanol-M-1  (Maurer-Spurej et al., 2001) by hydrolysis of its succinic ester moiety (Saini 
et al., 2004). 
There are a number of reports that support the importance of 5HT in the 
pathogenesis of atherothrombosis (Ban et al., 2007; Doggrell, 2004; Nishihira et al., 2006). 
5HT is stored in the dense granules of platelets and is secreted during platelet activation to 
stimulate smooth muscle proliferation, vascular contraction, potentiates thrombus formation 
and causes vessel occlusion (Nishihira et al., 2006). 
 
Figure1.8: Molecular structure of sarpogrelate 
 
Furthermore,  Barradas et al. (Barradas et al., 1988) as well as others (Ban et al., 
2007; Wiernsperger, 1990) demonstrated that plasma 5HT levels are higher in patients with 
diabetes mellitus and PAD, thereby providing another line of clinical evidence that 5HT is 
involved in the development of atherothrombosis (Uchiyama et al., 2007). 
5HT alone is a mild platelet agonist that only induces shape change and reversible 
aggregation (Jagroop et al., 2000d; Jagroop et al., 2000a; Jagroop et al., 2001; Qi et al., 
1996). Moreover, 5HT synergistically amplifies platelet aggregation induced by ADP, 
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collagen or epinephrine (Hara et al., 1991). Therefore, the 5HT receptor could be a good 
target for antiplatelet and antithrombotic therapy. Thus, the effect of 5HT receptor 
antagonists have been evaluated by using combinations of the platelet agonists (Jagroop et 
al., 1998; Jagroop et al., 2000b; Jagroop et al., 2001;Qi et al., 1996). 
Furthermore, sarpogrelate a selective 5HT2A receptor antagonist has been developed 
as an inhibitor of platelet aggregation, and vasoconstriction induced by 5HT and has been 
the subject of investigation. Thus, sarpogrelate was shown to inhibit two combinations of 
agonists (0.5 µmol/l 5HT plus 3 µmol/l epinephrine, and 1 µmol/l 5HT plus 3 µmol/l 
epinephrine)– induced platelet aggregation in a dose dependent manner (P < 0.025) in 
patients with ischemic strokes (Uchiyama et al., 2007). The effect of sarpogrelate on 
endothelial function in patients with PAD was investigated by Miyazaki et al (Miyazaki et 
al., 2007) who suggested that long-term oral administration of sarpogrelate improves 
vascular function in these patients. The effect of sarpogrelate on platelet function in patients 
with Buerger’s disease was investigated (Rydzewski et al., 1996). The rational was that 
these patients are more sensitive to 5HT, and spontaneously release more 5HT with 
decreased uptake of this amine (Nishikimi et al., 1992). Thus, treatment with sarpogrelate 
(100 mg, p.o., 3 times a day) for 4 weeks showed a significant decrease in plasma 5HT in 
damaged microvasculature, an effect which also lasted 8 weeks.  In addition, sarpogrelate 
showed to improve the ankle pressure index (0.85 ± 0.18 vs 0.79 ± 0.21 before treatment) 
after treatment for 8 weeks, in patients with Buerger’s disease (Rydzewski et al., 1996).  
The Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in 
Secondary Prevention of Cerebral Infarction (S-ACCESS), was a randomized double-blind 
 
 
 
 
 
 
 83 
study of sarpogrelate (selective 5-HT2A) receptor antagonist) versus aspirin in 1,510 
Japanese patients (Shinohara et al., 2008). It was reported that S-ACCESS failed to 
demonstrate non-inferiority of sarpogrelate to aspirin for preventing the recurrence of 
cerebral infarction. No specific baseline characteristic resulting in a significant difference 
between the effects of sarpogrelate and aspirin was identified. Aspirin was superior in most 
subgroups, except diabetics. However, sarpogrelate may be a useful treatment option for 
Japanese patients with diabetes (Shinohara et al., 2009). 
 
1.6.12 Nitroaspirin   
The coupling of  Non Steroidal Anti-inflammatory Drugs (NSAIDs) to appropriate 
chemical spacers bearing a nitric oxide (NO)-donating moiety, led to the birth of a new class 
of chemical entities, called NO-NSAIDs (Nitric Oxide Non Steroidal Anti-Inflammatory 
Drugs) or CINODs (Cyclooxygenase-Inhibiting Nitric Oxide Donors) (Gresele et al., 2006; 
Momi et al., 2000). Nitroaspirin (NCX 4016) is one of the leading compounds in this new 
class of drugs. NCX 4016 (2-acetoxybenzoate 2-[1-nitroxy-methyl]-phenyl ester) was 
synthesized by the ester linkage of a NO-releasing moiety to aspirin at NicOx SA Research 
Institute (Milan, Italy). The acetylsalicylic acid molecule is linked at the meta position to a 
chemical spacer (hydroxybenzylalcohol) bearing the NO-donating moiety 
(benzenemethanol-3-hydroxy-a-nitrate or NCX 4015) and the resulting molecule has a 
molecular mass 1.8 fold greater than that of aspirin (MW 331.28). The NO-NSAIDS were 
developed in an attempt to obtain safer and potentially more active compounds than the 
parent drugs (Gresele et al., 2003; Gresele et al., 2006; Momi et al., 2000). 
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Fig.1.9: The molecular structure of nitroaspiri  
Figure 1.9: Molecular structure of nitroaspirin 
Aspirin inhibits platelet aggregation by acting as a COX inhibitor and thus 
suppressing the production of TXA2, an important agonist of platelet activation and a 
vasoconstrictor (Patrono, 1994). However, the suppression of only one pathway of platelet 
activation, albeit important, may represent a limitation for effectiveness of aspirin (Gresele 
et al., 1991). These considerations have lead to the search for new drugs that could suppress 
platelet activation more effectively than aspirin.  
NO plays and significant role in preventing vasoconstriction stimulated by platelet 
released mediators at localised sites of vessel wall injury in coronary arteries (Lechi et al., 
1996a) and is also a powerful platelet inhibitor that can suppress platelet adhesion and 
activation induced by a wide range of agonists (Loscalzo, 2001). NCX 4016 the agent that 
combines a NO-donating moiety with aspirin was shown to exert a number of anti-
inflammatory activities beyond that of aspirin, to reduce ischemia/reperfusion damage, to 
correct endothelial dysfunction and to prevent oxygen radicals induced vascular remodelling 
in animal models (Gresele et al., 2003; Momi et al., 2005). The anti-thrombotic activity of 
NCX 4016, was examined in vivo in two different animal models (mice and rabbits) of 
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platelet dependent and independent pulmonary thromboembolism and compared with that of 
aspirin. The findings from this study demonstrated that NCX 4016 exerted a more 
pronounced anti-thrombotic activity than aspirin largely due to deeper inhibitory effects on 
platelets (Momi et al., 2000). 
 The antiplatelet activity of NCX 4016 as well as that of its chemically related NCX 
4215 were studied in vivo. Both drugs inhibited AA-induced platelet aggregation and TXA2 
production in a dose dependent manner and NCX 4016 proved to be significantly more 
potent than NCX 4215 (Lechi et al., 1996b).  
The effects of aspirin with those of NCX 4016 in preventing the acute, systemic 
endothelial dysfunction provoked by exercise-induced ischemia of lower limbs in patients 
with intermittent claudication was studied. After 4 weeks treatment, the impairment of flow-
mediated vasodilation induced by exercise was still present in the aspirin treated group while 
it was abolished in the NCX 4016-treated group. This study concluded that a NO-donating 
aspirin, but not aspirin alone, prevents effort-induced endothelial dysfunction (Gresele et al., 
2007).  
 
1.6.13 Trapidil 
Trapidil, an anti-platelet drug, has been shown to reduce restenosis after angioplasty. 
It exerts its action, at least in part, by inhibiting vascular smooth muscle cell proliferation 
and antagonizing PDGF. PDGF is activated in response to vascular injury and plays a 
significant role in SMC proliferation, chemotaxis of inflammatory cells, and the formation 
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of extracellular matrix. Trapidil is currently used as a coronary artery vasodilating agent and 
is also used for the prevention of ischemic symptoms of cerebral vasospasm. 
The Studio Trapidil versus Aspirin nella Restenosis Coronarica (STARC) was a 
multi-centre, randomized, double blind trial to assess the effects of trapidil in angiographic 
restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA). Trapidil 
reduced restenosis after PTCA at the dosage of 100 mg TID and favourably influences the 
clinical outcome thereafter (Maresta 1994).  
 
 
 
 
 
 
     
Figure 1.10: The molecular structure of trapidil 
 
Another study (JOVIN, 2006) investigated whether trapidil can inhibit the 
aggregation of platelets from heart transplant recipients. These patients show platelet 
hyperaggregability, which may be related to the incidence of graft vasculopathy, and is not 
corrected by aspirin. Platelet count, MPV, and adenosine diphosphate (ADP)-induced 
platelet aggregation were determined in 18 heart transplant recipients and 12 healthy 
subjects. The trapidil-treated samples showed significantly decreased platelet aggregation 
compared with the control samples (24.2 ± 12.6 vs 66.7 ± 11.7%; P < 0.001). Platelets from 
 
 
 
 
 
 
 
 87 
heart transplant recipients showed an increased MPV and increased ADP-induced 
aggregation. Trapidil effectively reduced the ADP-induced aggregation ex vivo.  
To investigate the effect of long-term trapidil on the prognosis of patients with CHD, 
a study was carried out with a mean follow up of 924 days (Hirayama et al., 2003). A total 
of 1,743 patients who showed angiographic evidence of >25% stenosis in any coronary 
artery was investigated. Patients were treated with trapidil (n=873, 100 mg, 3 times/day) and 
compared with a group who did not receive trapidil (n=870). The study concluded the long-
term intervention with trapidil in CHD reduces the incidence of cardiovascular events and 
improves the prognosis of CHD patients (Hirayama et al., 2003).   
 
1.6.14 Pentoxifylline 
Pentoxifylline (Trental), 3,7-dimetyl-1(5′-oxo-hexyl)xanthine is a haemorheologic 
drug used in the treatment of PAD. This drug works by decreasing blood viscosity, 
stimulating prostacyclin formation, increasing blood flow by increasing flexibility of RBCs, 
decreasing RBC hyperaggregation, reducing platelet aggregation and decreasing fibrinogen 
concentration (Moher et al., 2000; Samlaska et al., 1994).  
In as early as 1977, pentoxifylline was shown to be a powerful inhibitor of ADP and 
5HT-induced platelet aggregation of monkey platelets in vivo (Gastpar et al., 1977). Platelet 
aggregation studies in human PRP confirmed that pentoxifylline inhibited 5HT- as well as 
epinephrine- induced platelet aggregation in a dose dependent manner (Nenci et al., 1981). 
Pentoxifylline is metabolised in humans to at least 7 metabolites (Magnusson et al., 2008). 
Magnusson et al. investigated the relative potencies of pentoxifylline and its metabolites, 
 
 
 
 
 
 
 88 
M1, M4 and M5 to inhibit platelet aggregation in human whole blood. They concluded that: 
in the following potency order R-M1, rac-M1, pentoxifylline, S-M1 and M4 has significant 
effects on platelet aggregation in whole blood in vivo. The main in vivo effect, however, was 
caused by S-M1 and pentoxifylline (Magnusson et al., 2008). 
 
   Figure 1.11: The molecular structure of pentoxifylline 
 
In hypertensive type 2 DM patients, pentoxifylline exerted a significant anti- 
aggregatory effect in a dose dependent decrease in clot retraction in vivo but there was no 
significant change in ex vivo clot retraction. However, there were improvements in 
inflammatory markers, oxidative stress and platelet-aggregation by pentoxifylline (Maiti et 
al., 2007). In contrast, another study that compared pentoxifylline with cilostazol, failed to 
corroborate the reports that pentoxifylline improves erythrocyte membrane deformability 
and decreases viscosity in patients with intermittent claudication. However, this may be 
explained by the limitation of the small number (n=20 in each group) of patients who took 
part in the study (Dawson et al., 2002). Indeed, in a larger randomised, double blind, 
placebo-controlled trial, cilostazol therapy was associated with significantly greater 
improvement in walking distance compared with pentoxifylline and placebo (which both 
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exhibited similar effects) (Dawson et al., 2000). Thus, having investigated treatment of 
pentoxifylline on patients with intermittent claudication, attention was directed towards 
more difficult patient population, i.e. those with critical limb ischemia. A multi centre, 
double blind, placebo-controlled study of intra-venous pentoxifylline in the acute 
management of critical ischemia was carried out, by the European Study Group. Results 
showed that a significant reduction in rest pain with pentoxifylline. They suggest the urgent 
need for further study of medical management of patients with critical ischemia, possibly 
comparing medical and surgical treatment (1995, no authors listed).  
 
1.6.15 Beraprost 
Beraprost sodium (beraprost) is a stable, orally active prostacyclin (Ehrman et al., 
1980) analogue with pharmacodynamic properties similar to those of PGI2 (Melian et al., 
2002). The mechanisms of its interactions are likely to involve relaxation of vascular smooth 
cells, inhibition of platelet aggregation, and dispersion of platelet aggregates, inhibition of 
chemotaxis and cell proliferation, inhibition of production and secretion of endothelin and 
cytoprotective effects (Nishio et al., 2001; Vane et al., 1995).  
 
      Figure 1.12: The molecular structure of beraprost 
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Beraprost binds to PGI2 receptors on the platelet, thereby activating adenylate 
cyclase and increasing cyclic adenosine and guanosine monophosphate levels (cAMP and 
cGMP, respectively) in the platelet membranes of humans, dogs and rats (Kajikawa et al., 
1989). It has been suggested, that the effect of beraprost on cAMP and cGMP inhibits the 
release of Ca2+ from intra-cellular storage sites reducing the transmembrane influx of Ca2+. 
Moreover, this reduction appears to cause relaxation of the smooth muscle cells thereby 
inducing vasodilation (Melian et al., 2002).  
PGI2, an endogenous prostaglandin, is the main product of AA, primarily produced 
in endothelial cells (and to lesser extent in smooth muscle cells) of all vascular tissues 
(Weksler et al., 1977). PGI2 is the most potent endogenous inhibitor of platelet aggregation 
and causes dispersion of existing platelet aggregates in vivo as well as in the systemic 
circulation. PGI2 is involved in complex interactions of the vessel wall, blood flow and 
platelet function.  It has been hypothesised, that PGI2 antagonises the platelet aggregation 
and vasoconstriction caused by endogenous TXA2 (Sugawara et al., 2010; Vane et al., 
2003).  
 Beraprost has been indicated for use in Buerger’s disease and arteriosclerosis 
obliterans, PAD, pulmonary arterial hypertension, Reynaud’s phenomenon. In an animal 
model (rat) beraprost was shown to improve blood flow and walking disturbances associated 
with arterial occlusion (Miyamoto et al., 2006). In patients with arteriosclerosis obliterans 
who experienced intermittent claudication, beraprost tended to improve walking distance 
and relieve symptoms. In addition, there was a decrease in endothelin-1 levels which was 
measured in this study to assess the mechanism of action of beraprost (Matsumoto et al., 
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2010). In contrast, another study (Mohler, III et al., 2003) found that beraprost was not an 
effective treatment to improve symptoms of intermittent claudication in patients with PAD. 
They did however, recommend confirmation in a larger prospective investigation (Mohler, 
III et al., 2003). 
 
1.6.16 Parogrelil  
Parogrelil (NM-702), 4-bromo-6-[3-(4 chlorophenyl) propoxy]-5-[(pyridin-3-
ylmethyl) amino]pyridazin-3(2H)-one hydro chloride was synthesized as a potent 
vasodilatory and antiplatelet agent (Ishiwata et al., 2007). There are currently 2 
phosphodiesterase (PDE) inhibitors, cilostazol (see section 1.6.10) and pentoxifylline (see 
section 1.6.14) that are approved for the treatment of IC in several countries including the 
US and the UK (Ishiwata et al., 2007). This novel phosphodiesterase (PDE) inhibitor NM-
702, was also being investigated for its use in the treatment of patients with PAD (Brass et 
al., 2006). NM-702 showed improvement in laboratory- and ambulatory-based exercise 
performance in patients with claudication after being treated for 24 weeks (Brass et al., 
2006).  
 
Figure 1.13: The molecular structure of parogrelil 
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PDEs are important in cell signaling by hydrolysing cAMP and cGMP. The potency 
and selectivity of NT-702 against human PDEs is uncertain. However, in a study using 
rhPDE1 to PDE6, it was observed that NT-702 selectively and potently inhibited PDE3. The 
selectivity of NT-702 to PDEs was similar to that of cilostazol (Sudo et al., 2000). These 
findings were supported by the results from a basic pharmacological study where NT-702 
selectively inhibited PDE3 (and PDE5) purified from rabbit heart and platelets (Ikegawa et 
al., 1995). Ishiwata et al showed that NT-702 inhibited human platelet aggregation induced 
by multiple agonists. NT-702 also inhibited phenylephrine-induced vasoconstriction of the 
rat aorta. The authors propose that this may be due to the potent PD3A inhibitory activity of 
the compound (Ishiwata et al., 2007). Moreover, in comparison to cilostazol, NT-207 
inhibited platelet aggregation 250 – 520 times more potently and demonstrated 
vasorelaxation activity 42 times more. They suggested that NT-702 improved peripheral 
circulation of ischaemic hind limb and the reduced walking performance through the potent 
antiplatelet and vasorelaxant activities that can be explained by at least PDE3A inhibition 
(Ishiwata et al., 2007).  
 In addition to its anti-platelet and vasorelaxant actions, NT-702 also appeared to 
have anti-inflammatory as well as bronchodilating effects when investigated on the 
asthmatic responses in guinea pigs (Hori et al., 2009). Thus, it has been proposed that NT-
702 might be useful as a novel potent therapeutic agent, for the treatment of bronchial 
asthma, and benefits from having both bronchodilating and anti-inflammatory effects (Hori 
et al., 2009).  
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It is not clear as to which mechanisms are involved in dilation responses with NT-
702. However, findings from a study showed that NT-702 dose-dependently dilated isolated 
spinal arterioles of rabbits via endothelium-dependent and endothelium-independent 
mechanisms (Mizuno et al., 2008). In addition, the authors put forward the theory that 
protein kinase A, and tetraethylammonium sensitive k+ channels, may be involved in the 
NT-702-induced vasodilation (Mizuno et al., 2008). Further studies are needed to fully 
understand the mechanisms of NT-702 and its use in other diseases. 
 
1.6.17 Unfractionated Heparin and Low Molecular Weight Heparins 
It is of interest that agents with anti-thrombin activity may inhibit thrombin-induced 
platelet activation. For example, we previously showed that the low molecular weight 
heparin (LMWH), nadroparin (Jagroop et al., 1996) added in vivo (Jagroop et al., 1996) 
inhibits PSC and platelet aggregation. The inhibitory action of nadroparin was specific to 
thrombin since this LMWH did not influence PSC induced by other agonists. In whole 
blood, unfractionated heparin (UH) but not nadroparin, significantly enhanced spontaneous 
platelet aggregation and increased MPV when compared with LMWH. We concluded that 
LMWH, nadroparin, exerts less platelet activation than UH (Jagroop et al., 1996; Jagroop 
et al., 2007). It is noteworthy to mention here, that UH and LMWH appear to produce their 
anticoagulant effect through simultaneous inactivation of thrombin and factor X (Saucedo, 
2010). In contrast, a more targeted agent that inhibits thrombin directly is bivalirudin. There 
was a reduced risk of bleeding associated with bivalirudin when trials compared it with 
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GPIIb/IIIa inhibitors (Lincoff, 2003) Tirofiban a GPIIb/IIIa inhibitor is discussed further in 
chapter 5. 
In summation, the anti-platelets agents discussed in this chapter, significantly 
reduces the risk of vascular events. However, there is still some debate as to the possibility 
of agent superiority and the value of combination therapy. Moreover, there is a need to 
define optimal anti-platelet therapy for various conditions and in primary prevention. For 
example, what is the ideal treatment in patients at high risk of stroke, those with PAD and 
after vascular surgery or endovascular procedures? More research is needed to definitively 
answer these questions. Even then, the issue of the cost of treatment will remain paramount. 
Anti-coagulants are not discussed in more detail since they are not directly relevant to this 
thesis. 
 
1.7 Purinergic Receptors 
Purinergic receptors are present on cell surfaces and are important since signaling 
molecules, termed purines (adenosine, ADP and ADP) and pyrimidines (UDP and UTP) 
mediate diverse biological effects via these receptors (Burnstock, 2007). Currently, the sub-
classifications of purines and pyrimidine receptors are based on cloning, transduction 
mechanisms and pharmacology (Burnstock and Kennedy 1985; Burnstock, 1996). Thus, 
they are characterized as follows: the P1 (adenosine) receptor family has 4 subtypes, while 
the P2 (ATP, ADP and UTP) receptor family has been divided into P2X ionotropic receptors 
(7 subtypes, P2X1 – P2X7), and P2Y metabotrophic G protein-coupled receptors (8 
subtypes) (Burnstock 2006).  
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Four different types of P1 receptor subtypes have been cloned and characterized (A1, 
A2A, A2B and A3). They are all members of the rhodopsin-like family of the G protein-
coupled receptors (Yaar et al., 2005; Olah et al., 2000). Transgenic knockout mice were 
used to demonstrate the diverse physiological effects that are mediated by the different P1 
receptor subtypes. These properties include their role in the modulation of the cardiovascular 
system as well as the immune and central nervous systems. (Ledent et al., 1997, Sun et al., 
2001). Null mice have been generated for each of the A1, A2A, and A3 receptors. It was 
found, that in all knockout animals generated, the P1 receptors in question did not appear to 
play an important role during development (Lankford et al,. 2006). In addition, knockout 
mice have not yet been described for the A2B receptor subtype. It is noted, that P1 and P2Y 
receptors are frequently expressed in the same cells (Burnstock 2007) 
 The cloning and functional expression of a brain G-protein-coupled ATP receptor 
was identified as the P2Y1 purinoceptor (Webb et al., 1993). A P2Y2 receptor was cloned 
and characterized at about the same time, and its activation by either ATP or UTP was 
shown to elicit the mobilization of intracellular calcium (Lustig et al., 1993). Thus, presently 
the 8 subtypes of P2Y purinoceptors are as follows: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, 
P2Y13, and P2Y14 (Burnstock 2007). 
There are 2 landmark papers which cloned and characterized P2X1 and P2X2 
receptors (Brake et al., 1994; Valera et al., 1994). In 1994, Valera et al. cloned a 
complementary DNA encoding the P2X receptor from rat vas deferens and expressed it in 
Xenopus oocytes and mammalian cells. P2X receptors have been characterized on smooth 
cells, autonomic and sensory neurons, where they mediate membrane depolarization and in 
 
 
 
 
 
 
 96 
some cases Ca2+ entry (Valera et al., 1994). The structure of the P2X receptor, suggest that 
the protein (399 amino acids long) is mainly extracellular and contains 2 transmembrane 
domains plus a pore-forming motif which resembles that of potassium channels. Thus, the 
P2X receptor defines a new family of ligand-gated ion channels (Brake et al., 1994; Valera 
et al., 1994).  The new ATP-gated channels belong to an entirely different class of 
transmembrane signaling proteins. Members of this family include Na+, K+ and 
mechanosensory channels, which monitor and regulate changes in cell volume, shape and 
membrane potential. It was suggested, that a cloned P2X receptor may also play a role in 
cell death (Brake et al., 1994). It remains to be seen if further purinergic receptors will be 
discovered and classified.  
In this thesis the focus was on the roles of the P2Y1, P2Y12 and P2X1 receptors on 
platelet activation (see chapter 4). 
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CHAPTER 2 
 
General Methods 
 
 
 
 
 
 
 98 
2.1 Selection of Subjects and Collection of Samples 
Healthy volunteers who donated blood for the studies in this thesis were either 
members of staff or students of the Royal Free & University College Medical School, Royal 
Free campus, London, UK. All denied taking any drugs for at least 2 weeks prior to 
sampling. All volunteers were adults aged above 18 years at the time of sampling. Where 
appropriate the ages and genders of the volunteers are described, and written informed 
consent was attained. 
The department has permission from the Royal Free Hospital Ethical Committee to 
take small (20 ml) blood samples from healthy volunteers. These sampling were repeated at 
intervals of less than two months from the same individual  
Venous blood was collected in 3.8% tri-sodium citrate (1 part citrate to 9 parts 
blood), by venepuncture from an antecubital vein. Large vessels were used to ensure good 
blood flow and minimum stasis. Blood was obtained with a 21G butterfly in 10 or 20 ml 
plastic disposable and sterile syringes. All universal precautions were used during sample 
collection. In order to minimise platelet activation the whole blood was gently poured down 
the side of the tube containing citrate, and then carefully inverted 4-5 times to allow total 
mixing of the anti-coagulant (see Appendix A & B: reference lists authored by IA Jagroop). 
 
2.2 Preparation of Platelet Rich Plasma  
The citrated blood was centrifuged at x160 g for 15 min at room temperature. The 
PRP was then carefully collected into a sterile plastic universal container (10 ml) with a 
Pasteur pipette and aspirated gently to avoid the top ‘buffy coat’ layer either/or the red 
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cells. In order to stabilise the PRP and prevent platelet activation due to cooling, aliquots of 
PRP were put into siliconised glass cuvettes which were then placed in a Chronolog dual 
channel optical aggregometer (Coulter Electronics, Luton, Beds, UK). These aliquots were 
kept at 37oC for 15 min (without stirring) to allow stabilisation of the platelets prior to the 
start of the experiments (see Appendix A: PSC reference list with IA Jagroop). 
 
2.3 Addition of Agonists and Fixation of Samples for PSC 
At specific times after adding the agonists (as 10-50 µl volumes to achieve the final 
concentrations as shown in the relevant chapters methods), and stirring (using a Teflon-
coated metal stir bar, at 1000 rpm), 100 µl aliquots of PRP were removed and mixed with 
400µl of fixative (4% aqueous glutaraldehyde in saline). Vehicle or drugs were added (as 5-
20 µl volumes), and pre-incubated for 5 min before the addition of agonists. In order to 
prevent platelet activation due to stirring during the pre-incubation period, the magnetic 
stirring mechanism within the aggregometer was switched off after the first 30 sec, and only 
switched back on after a 4 min interval of incubating with drug.  These sampling times were 
determined in previous studies (see Appendix A: PSC reference list authored by IA Jagroop) 
and also selected to represent the time when a maximal increase in MPV is observed.  
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2.4 Platelet Counting and Particle Size Analysis Using a Coulter ZM 34  
      Counter & a C-256 Channelyzer  
The PRP sample which was fixed in gluteraldehyde (as described above in section 
2.3) was further diluted 400 fold in Isoton II (Coulter Electronics, Luton, Beds, UK) at room 
temperature. A Coulter counter ZM 34 (electrical impedance method using a 70 µm 
diameter sampling tube orifice), coupled to a Coulter C-256 high-resolution (0.07 fl) 
channelyzer (Coulter Electronics, Luton, Beds, UK) was used to assess MPV in these 
samples (Jagroop et al., 1996; Jagroop et al., 2000c; Jagroop et al., 2000d; Jagroop et 
al., 2000a; Jagroop et al., 2001) (see Appendix A PSC for full list of references authored 
by IA Jagroop).  
. 
 
Figure 2.1: A ZM34 Coulter counter coupled to a C-256 Coulter channelyzer 
A photograph of the 3-part machine used to assess platelet shape change (PSC). A  
Coulter counter ZM 34 (far right) coupled to a Coulter C-256 high-resolution  
(0.07 fl) channelyzer (far left) with the sampling stand (middle). 
 
The analyser sample “window” was set between 2.67 and 19.12 fl.  The counter-
channelyzer system was calibrated using platelet latex particles (9 fl; Coulter Electronics). 
Data was accumulated to a maximum of 500 platelets in each one of the 256 channels. The 
MPV was the volume of the channel on each side of which 50% of the platelet population 
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was distributed. All MPV readings were the average of three measurements (Jagroop et al., 
2002a; Jagroop et al., 2001; Jagroop et al., 2003a; Jagroop et al., 2008) (see Appendix A, 
for full list of PSC references authored by  IA Jagroop).   
The platelet count was monitored to ensure that significant aggregation did not 
occur. The fall in platelet count was not greater than 5 % in any of the samples included in 
these studies. Counting of particles “channelyzed” was performed automatically by the 
equipment. The ZM counter is designed so that as each platelet passes through the aperture 
it momentarily modulates the electrical impedance between electrodes. The applied current 
is constant and some of the current is diverted into a preamplifier each time a platelet passes 
through the aperture. The amplitude of the current pulse is a function of the platelet volume 
(Coulter Electronics handbook). All “platelet sizing” experiments were carried out within 2 
h of blood collection (Jagroop et al., 2008; Jagroop et al., 1996;Jagroop et al., 2000d; 
Jagroop et al., 2000a) (see Appendix A, for full list of PSC references authored by IA 
Jagroop).   
Reproducibility of MPV by this methodology has been previously evaluated, and the 
intra-assay and inter-assay coefficient of variation is 0.8 % and 2.9 %, respectively 
(Barradas MA 1992). 
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2.5 Scanning Electron Microscopy (ScEM). 
PRP was prepared (as described in section 2.2), and agonist was added (as outlined 
in 2.3). PRP was collected at the same time as for the corresponding PSC measurement. 
These samples were fixed with 950 µl glutaraldehyde (1.5%) for at least 2 h. These solutions 
were then filtered through a 13 mm, 0.6 µm nucleopore polycarbonate filter, by applying 
approximately 1 µl of the previously fixed PRP to a filter holder. This was then washed with 
20 ml of distilled water. The platelets adhering to the filter, were post-fixed with osmium 
tetroxide for 1 h and then gently washed in distilled water. These filters were dehydrated 
using graded acetone (30, 50, 70, 90 and 100%), HPLC grade (Sigma, Poole, UK). The 
filters were then treated with tetramethylsaline (Sigma, Poole, UK), and allowed to air dry 
on blotting paper. The filters were then attached to aluminum stubs with double-sided tabs 
(TAAB Laboratory Equipment Ltd, Berkshire, UK) and coated with gold using an SC500 
(EMScope) sputter coater. The stubs were examined and photographed using a Phillips 501 
scanning electron microscope (Jagroop et al., 2000a).  
 
2.6 Transmission Electron Microscopy (TEM) for Cell Suspension 
PRP was prepared (as described in section 2.2) and agonist was added (as outlined in 
2.3). PRP was collected at the same time as for the corresponding PSC measurement and 
was fixed with 950 µl glutaraldehyde (1.5%) for at least 2 h. They were centrifuged using a 
‘Whatman’ micro-centrifuge to form a pellet. The preparations were then washed with PBS 
and post-fixed using osmium tetroxide. The specimens were then further washed using 
distilled water and dehydrated using graded alcohol from 30% to 100%. The cells were left 
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in 50% alcohol/50% Lemix (Taab) epoxy-resin mixture overnight to infiltrate at 700C. Ultra-
thin (1µm) sections were cut using a diamond knife (Diatome) on a Reichert-Jung ultra-cut 
microtome and collected on 3.05 mm copper grids. These sections were stained using 1% 
toluidene blue stain. The ultra-thin sections were viewed and photographed using a Phillips 
201 transmission electron microscope (Jagroop et al., 2000a). 
 
2.6.1 The Resting Platelet Using TEM 
Ultra-thin sections were used to visualize platelet ultra-structure (the localisation of 
sub-cellular components). The examination of platelets with TEM allows the observation of 
membrane contours as well as the recognition of the inner leaflet of membranes (see figure 
1.2). The distribution of membrane or integrated macromolecules can also be visualized. 
Resting platelets are discoid in shape. The cytoplasm is filled with randomly dispersed 
organelles. A circumferential coil of microtubules lies just under the surface membrane. The 
dense granules are well preserved (see figure 1.2). The α-granules are clearly separated from 
other membranes and from the plasmalemma. The dense tubular system is ubiquitously 
distributed in the platelet (see figure 1.2).  
The plasmalemma shows a non-random distribution of phospholipids that depend on 
the functional state of platelets (Zwaal and Hemker, 1982). The openings of the surface-
connected system (SCS) into the plasmalemma (Behnke, 1970; White, 1970) are 
recognisable with ScEM and at better resolution on replicas obtained after freeze-fracturing 
with TEM (Reddick and Manson, 1973). The SCS in the cytoplasm of resting platelets 
consists of branched channels.  In human platelets the dimensions of the surface of the SCS 
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and the plasmalemma or the membrane of alpha granules is quite comparable. Some 
properties of the SCS membranes resembles those of the plasmalemma: The membrane 
glycoproteins GPIb, GPIb/IIIa, and others are localised there (Polley et al., 1981). The 
membrane GPIIb/IIIa complex is transported from the surface via the SCS to the α-granules 
of resting platelets. During stimulus-induced shape change, the SCS of resting normal 
human platelets disappears. 
The sub-membranous cytoskeleton (SMC) regulates properties of the skeleton such 
as its contours and stability and is, amongst the marginal microtubules responsible for the 
shape of a resting platelet. Within the resting platelet there is a lose network of long acting 
filaments (Mani et al., 2005). Filaments from actin and myosin molecules are present in a 
non-polymerized state and its actin is connected with the SMC (Mani et al., 2005) or with 
the cell organelles (Linnemann et al., 2008).  
 
2.6.2 The Activated Platelet Using TEM 
Using TEM it was possible to visualise the ultra-structure of resting platelets (see 
figure 1.2) and compare it with activated platelets (induced by ET-1 in combination with 
5HT, see figure 1.3).  
Ultra-thin sections of stimulus-induced, activated platelets revealed shape change 
and formation of spherical or oblong cells with pseudopodia. These spike-like surface 
extensions contained microtubules, suggesting a possible role for the tubular elements in 
development of the spiky extensions. This shape change during activation is accompanied 
by surface enlargement. Indeed it has previously been shown the  apparent ‘increase’ in 
 
 
 
 
 
 
 105 
platelet size occurs concomitantly with the pseudopodia extensions (Jagroop et al., 2000a)  
In the calculations of Frojmovic and Milton 1982, the increase of the surface area may be 
more than two-fold after shape change. 
The marginal bundle of microtubules lying under the plasmalemma supports the 
shape of the resting platelet and is required for platelet resistance to deformation. Activated 
platelets undergo a rearrangement of their microtubules and this results in a change of cell 
deformability (White et al., 1984). 
The microtubules which are associated with the outer rim of the constricting 
contractile gel are translocated centripetally from their sub-membranous site to the centre of 
the cell (Escolar et al., 1987; Stark et al., 1991). This contractile gel comprises the mass of 
cell organelles and the constriction of the gel results in organelle centralisation. Platelet 
activation induces a disintegration of the SMC by dissociation of the GPIb-actin-binding 
protein complex (Fox et al., 1990). An actin protein associated with regions of the 
plasmalemma devoid of actin filaments reversibly increases after platelet activation 
(Hartwig et al., 1989). Activating agents effect the formation of filaments from actin and 
myosin molecules. Membrane glycoproteins like the fibrinogen receptor GPIIb/IIIa can 
connect via linker proteins. Recently, it was observed that GPIb-IX-actin-binding protein 
complexes, linked to actin filaments, are pulled into the cell centre by the contractile gel. 
Thus, platelets may exert contractile tension not only on ligands of GPIIb/IIIa (fibrinogen, 
fibrin) but also on vWF bound to GPIb-IX (Kovacsovics and Hartwig, 1996). 
Membrane integrated glycoproteins are receptors for physiological platelet agonists 
(ADP, thromboxane, thrombin) adhesive proteins (fibrinogen, fibronectin, laminin, 
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thrombospodin, vitronectin, vWF) and for fibre-type ligands like collagen (Clemetson, 
1995). The intra-cellular receptor pools from the membranes of the SCS and the α-granules 
can be additionally expressed at the surface following platelet activation (Woods et al., 
1986). During stimulus-induced shape change, the SCS of the resting normal platelets 
disappears (Morgenstern et al., 1995). Morphometric measurements and findings of 
comparative studies on “normal” and “giant” platelets (reviewed in Frojmowic & Milton, 
1982) or normal “grey” platelets (Morgenstern et al., 1990), have already suggested that the 
evagination of SCS membranes causes the surface enlargement during spreading of adherent 
platelets (White et al., 1990). 
 
2.7 Whole Blood Platelet Aggregation 
 Whole blood anti-coagulated with tri-sodium citrate was collected as described in 
section 2.1. Aliquots of blood were put into plastic cuvettes. These were incubated at 370C, 
for a minimum of 15 min, on a whole blood Chronolog aggregometer (model 540). This 
stabilises the cells after blood taking. Agonists’ concentrations and volumes were added and 
stirred using a Teflon-coated magnet spinning at 1,000 rpm (as described in the relevant 
sections in this thesis). Usually saline was used as a control for agonists or drug. Samples 
were withdrawn from the cuvettes using a pipette with a plastic tip. The time between 
removing the blood from the aggregometer and aspiration into the blood counter was kept to 
a minimum of <10 sec. This was to prevent dis-aggregation from occurring upon standing 
(Jagroop et al., 1996). The timing of samples and controls are also shown in the relevant 
sections of this thesis. Platelet aggregation was measured with the use of an ACT diff 
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Analyzer (Beckman Coulter, Inc, Fullerton, CA). Platelet aggregation was calculated on the 
basis of the number of ‘free’ platelets remaining after agonists was added (i.e. whole blood-
free count, WB-FC) and was expressed as a percentage of the basal count, as below: 
 
% WB-FC =    Platelet count after adding agonists    x    100 
       Basal platelet count (before agonist) 
 
  
The basal count was defined as the count obtained 15 sec after commencing stirring 
of the WB and before addition of any agonists. All WB aggregation studies were completed 
within 2 h of sample collection. Blood was kept at 37oC throughout aggregation experiments 
since platelet function may be influenced by cooling (Mikhailidis, et al., 1983). 
 
 
2.8 Intra-platelet Serotonin  
Serotonin, or 5-hydroxytryptamine is a molecule that is found in large quanti-ties in 
the enterochromaffin cells of the gastrointestinal mucosa, in platelets, and in the 
serotoninergic neurons of the central nervous system.  5HT is synthesized via hydroxylation 
of tryptophan and subsequent decarboxylation. 
5HT is a potent vasoconstrictor and neurotransmitter, and has multiple other 
complex effects. It has been implicated in the regulation of neuroendocrine function, body 
temperature and blood pressure. The enzyme immunoassay of 5HT (Immunotech, Beckman 
Coulter, High Wycombe, Bucks, UK) is based on the competition between modified 5HT in 
the sample and the 5HT-enzyme conjugate, used as a tracer, for binding to the antibody 
 
 
 
 
 
 
 108 
coated onto microtitre plates (Fawcett & Jagroop et al., 1998; Frampton & Jagroop et al., 
2006; Jagroop et al., 2004). 
Acylated 5HT in the sample or standards and 5HT-acetylcholinesterase conjugate 
were added to the microtitre wells where they compete for a limited number of anti-body-
binding sites. After incubation, the contents of the wells were aspirated and the wells were 
washed to remove excess tracer. Bound enzymatic activity was measured by the addition of 
a chromogenic substrate.  The intensity of the colour was a function of the concentration of 
5HT in the sample. The concentration was determined from a standard curve established 
with the standards provided in the kit (Fawcett & Jagroop et al., 1998; Frampton & 
Jagroop et al., 2006; Jagroop et al., 2004). 
 
2.9 Soluble P-selectin  
P-Selectin is a cell surface glycoprotein that plays a critical role in the migration of 
lymphocytes into tissues. It is found in a pre-formed state in the Weibel-Palade bodies of 
endothelial cells and in the alpha granules of platelets. P-Selectin is mobilised to the cell 
surface within minutes in response to a variety of inflammatory or thrombogenic agents 
(Antoniades C et al., 2010).  
 Studies indicate that P-Selectin is involved in the adhesion of myeloid cells, 
along with B cells and a subset of T cells, to activated endothelium (Mestas et al., 2008; 
McGregor et al., 2006). P-Selectin is also involved in the adhesion of platelets to monocytes 
and neutrophils, playing a central role in neutrophil accumulation within thrombi. P-Selectin 
is found in the plasma of normal individuals at ‘ng/ml’ concentrations.  Circulating P-
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Selectin appears to be slightly smaller than native P-Selectin. An alternatively spliced 
mRNA encoding a form of human P-Selectin lacking the transmembrane anchoring domain 
has been reported for both megakaryocytes and endothelial cells, and evidence suggests that 
the majority of circulating soluble P-Selectin arises in this manner (Mestas et al., 2008).  A 
number of studies have reported that levels of soluble P-Selectin in biological fluids may be 
elevated in subjects with a variety of pathological conditions (Polek et al., 2009).   
Only plasma is acceptable. Plasma was collect on ice using EDTA or heparin as anti-
coagulant.  Anit-coagulated blood was centrifuge at 2-8°C for 15 min at 1000 x g within 30 
min of collection.  An additional centrifugation step of the separated plasma at 10000 x g for 
10 min at 2-8°C was recommended for complete platelet removal. The assay was either done 
immediately or aliquoted and stored at or below -20°C. Freeze-thaw cycles were avoided.  
 The assay was done with the use of the human soluble sP-selectin quantitative 
sandwich immunoassay kit (R&D Systems Europe, Oxon, UK). A monoclonal anti-body 
specific for sP-Selectin was pre-coated onto a microplate.  Standards, samples and controls 
were pipetted into the wells, together with a polyclonal anti-body specific for sP-Selectin, 
which was conjugated to horseradish peroxidase. After removal of unbound conjugated anti-
body, a substrate was added and colour was developed in proportion to the sP-Selectin 
concentration. 
 
2.10 Platelet Derived Growth Factor  
There are 3 isoforms of PDGF-AA, -AB, and –BB, which are expressed in many cell 
types. Plasma PDGF-AB is measured as this isoform is more likely to represent a human 
platelet source. PDGF acts as a growth factor in many cell types and it may also influence 
platelet activity.  
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This human PDGF-AB assay employs the quantitative sandwich enzyme 
immunoassay technique (R&D Systems Europe, Oxon, UK). A monoclonal antibody 
specific for PDGF-BB was pre-coated onto a microplate.  Standards and samples were 
pipetted into the wells and any PDGF-AB present was bound by the immobilised antibody. 
After washing away any unbound substances, an enzyme-linked polyclonal specific for 
PDGF-AA was added to the wells. Following a wash to remove any unbound anti-body-
enzyme reagent, a substrate solution was added to the wells and colour developed in 
proportion to the amount of PDGF-AB bound in the initial step. The colour development 
was stopped and the intensity of the colour was measured. 
 
2.11 Statistics in Brief 
Randomisation : Randomisation is important for the design of good experiments as 
it substantially reduces the chance of bias which could arise if subjects/samples on one 
treatment are in some way different from those on another treatment. Physical randomisation 
is fairly easy to do in ‘small’ experiments. In the clopidogrel/aspirin study (Chapter 3), a 
random number allocation procedure was applied by Ealing hospital Pharmacy. 
Power calculations: Power calculations are important to determine the appropriate 
sample size for an experiment. However, power calculations are difficult to use for pilot 
studies because the effect of the intervention is not known. In this context, in Chapter 3, the 
effect of aspirin and/or clopidogrel on PSC (as measured by MPV) was not known prior to 
the study. Hence, a power estimation was not carried out.  
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The power calculation to estimate sample size depends on a mathematical relationship 
between 6 variables, these include:  
• Variability of the material i.e. an estimate of the SD of the experimental subjects is 
necessary and comes from a previous study. 
• Effect of size of clinical or biological importance i.e. the ability to specify the 
minimum effect size likely to be of interest. 
• Significance level i.e. this is usually 0.05 but power will be higher if it is set at 0.1 
rather than 0.05.  
• Power i.e. the probability to detect the specified effect that is considered significant, 
at the designated level of significance.  
• Sidedness of the test i.e. a two-sided test is usually used except where there is a good 
biological reason why the treatment effect can only go in one direction. 
• Sample size i.e. the aim of the power analysis is usually to determine sample size of 
the study.  
Multiple Comparisons: The term "comparisons" in multiple comparisons typically 
refers to comparisons of 2 groups, such as a treatment group and a control group. "Multiple 
comparisons" arise when a statistical analysis encompasses a number of formal 
comparisons. A useful guide is to use a Bonferroni correction which states simply that if one 
is testing n independent hypothesis, one should use a significant level of 0.05/n. However, 
other methods have been described (Kusuoka et al., 2002). For example in this thesis where 
if 2, 3 or 4 pairs are compared, the level of significance is considered as 0.049, 0.047 or 
0.046 respectfully for each of the pairs (Kusuoka et al., 2002).  
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CHAPTER 3 
 
The Effect of Clopidogrel, Aspirin or Both  
Antiplatelet Drugs on Platelet Function in Patients 
with Peripheral Arterial Disease 
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3.1 (i) AIMS, BACKGROUND AND HYPOTHESIS 
Aims: The aim of this study was to investigate if clopidogrel plus aspirin combination 
therapy provides more potent platelet inhibition than monotherapy with clopidogrel or 
aspirin in patients with PAD. I also compared the effect of each monotherapy. Furthermore, 
I assessed if these antiplatelet drugs inhibit early platelet activation (i.e. PSC). 
Background: PAD patients are often prescribed aspirin. However, aspirin only affects one 
pathway of platelet activation (preventing the conversion of arachidonic acid to TXA2, a 
potent vasoconstrictor and platelet agonist). PAD patients may experience a resistance to 
aspirin. Thus, the thienopyridines (e.g. clopidogrel) may provide and effective alternative to 
aspirin. The thienopyridines were developed as other antiplatelet drugs that target other 
pivotal pathways such as those mediated by ADP. Clopidogrel (a thienopyridine) inhibits 
platelet activation by blocking the ADP P2Y12 purinergic receptor. The rational behind 
combination therapy is that aspirin and clopidogrel act via different mechanisms.   
Previous studies have shown that clopidogrel can affect platelet aggregation. But no other 
investigators have yet demonstrated any effectiveness of this drug on PSC using a high-
resolution channelyzer method. PSC is important because it is an early phase of platelet 
activation that precedes platelet aggregation.  
Hypothesis: My hypothesis was that clopidogrel would be superior to aspirin in terms of 
inhibiting platelet activity (including PSC). Furthermore, the combination of these 2 drugs 
would be superior to monotherapy.  
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3.1 (ii) INTRODUCTION 
Clopidogrel is a theinopyridines and can inhibit ADP-induced inhibition of adenylate 
cyclase, prevent the ADP-induced inhibition of cytoskeletal associated protein vasodilator-
stimulated phosphoprotein (VASP) phosphorylation and prevent the association of labeled G 
proteins with the platelet membrane (Duerschmied et al., 2010; Quinn et al., 1999). Other 
drugs belonging to this group include Prasugrel (Effient) and ticlopidine (Ticlid) (Engelen et 
al., 2010). Ticlopidine was the first of this new class of theinopyridines.  
 
 
                   Clopidogrel                                                                         Ticlopidine 
Figure 3.1: Molecular structures of clopidogrel and ticlopidine  
 
Ticlopidine gained FDA approval for clinical use in the early 1990’s. Clopidogrel 
emerged after as a promising compound structurally similar to ticlopidine. However, the 
difference is that unlike ticlopidine, clopidogrel has an additional carboxymethyl side group 
(Porto et al., 2009; Preobrazhenskii et al., 2009; Jacobson, 2004) 
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Clopidogrel is a pro-drug and needs to be converted in vivo to active metabolites by 
the hepatic cytochrome P-450 (Weksler et al., 1977; Duerschmied et al., 2010). Their active 
metabolite then binds to the P2Y12 receptor and forms a disulphide bond with a cysteine 
residue of the receptor, thereby irreversibly inhibiting it (Jacobson, 2004). Clopidogrel is 
absorbed rapidly via the oral route (Marczewski et al., 2010). Metabolism is so extensive 
that clopidogrel is difficult to detect in the circulation; the major circulating compound is the 
inactive carboxylic acid derivative SR26334 that reaches peak plasma concentration within 
1 h of ingestion (Easton, 1999).  
Clopidogrel has been approved by the FDA for reduction of thrombotic events in 
recent MI, stroke, or established PAD, and for patients with non-ST-elevation acute 
coronary syndromes including percutaneous coronary interventions (Easton, 1999; 
Jacobson, 2004).  
Clopidogrel is an effective inhibitor of platelet activity (Jagroop et al., 2007). 
Clopidogrel was more clinically effective when compared with aspirin in a very large trial (n 
= 19,185; CAPRIE) that involved patients with established vascular disease (1996, no 
authors listed). In other studies (e.g. CURE), aspirin and clopidogrel combination therapy 
was more effective than aspirin alone in patients with acute coronary syndrome (Mehta et 
al., 2000). The rationale behind combination therapy is that aspirin and clopidogrel act by 
different mechanisms. Aspirin inhibits the synthesis of thromboxane A2 (TXA2), a promoter 
of platelet aggregation (Drouet et al., 2010). In contrast, clopidogrel acts at the level of the 
platelet ADP purinergic (P2Y12) receptors (Marczewski et al., 2010; Mikhailidis et al., 
1998b). ADP acts on the P2Y12 receptor to enhance aggregation and on the P2Y1 receptors 
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to PSC and aggregation (Kim et al., 2011). PSC is an early phase of platelet activation that 
precedes aggregation and is essentially aspirin resistant in vivo (Jagroop et al., 2000d; 
Jagroop et al., 2000a; Jagroop et al.,2001; Jagroop et al., 2003a) (see Appendix A, for full 
list of PSC references authored by IA Jagroop).   
 Aspirin has been the anti-platelet drug of choice for many decades but it only affects 
a single pathway involved in platelet activation. It prevents the conversion of AA to TXA2, a 
potent vasoconstrictor and platelet agonist, by irreversibly inactivating the COX activity of 
PG H-synthase-1 and PG H-synthase-2 (also referred as COX-1 and COX-2) (Jneid, 2010; 
Mackenzie et al., 2010; Sanchez-Ross et al., 2010).  
Therefore, thienopyridines (e.g. ticlopidine and clopidogrel) which inhibit platelet 
activation through the blockade of the ADP pathway may provide an effective alternative to 
aspirin therapy (Gachet, 2001; Lubbe, 2002). 
ADP plays a major role in platelet activation. It is present in high concentrations in 
platelet dense granules. ADP is released when platelets are stimulated by other agonists (e.g. 
thrombin or collagen) or even ADP itself high to further induce platelet aggregation. ADP, 
even in low concentrations, when combined with other agonists (e.g. adrenaline or 5HT) can 
have a synergistic effect on platelets (Gachet, 2001). 
PAD is a common condition which involves the arteries of the lower limbs. PAD 
patients tend to have hyperactive platelets that may be resistant to aspirin (Matsagas et al., 
2003; Robless et al. 2001). Therefore, it is relevant to assess the effect of other platelet 
inhibitors, like clopidogrel, which acts via a different mechanism.  
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Identifying effective anti-platelet therapy in patients with PAD is potentially very 
important because this condition is associated with an increased risk of myocardial 
infarction (MI) and stroke (Barradas et al., 1994b; Robless et al., 2001; Matsagas et al., 
2002). 
We have previously shown that a loading dose of clopidogrel (300 mg) inhibited 
ADP- and 5HT-induced PSC and aggregation in patients with PAD (Matsagas & Jagroop et 
al., 2003). However, it is not know if the daily dose of clopidogrel exerts similar effects in 
patients with PAD. In addition, the effect of combination therapy (clopidogrel plus aspirin) 
has not been previously assessed with a sensitive PSC methodology. In the present study, 
these questions were addressed by comparing patients with PAD on clopidogrel or aspirin or 
on combination therapy (clopidogrel plus aspirin). 
 
3.2 METHODS 
3.2.1 Selection of Patients and Collection of Blood 
This study was approved by the Local Ethics Committee of the Ealing Hospital NHS 
Trust, London, UK and the Royal Free Hospital NHS Trust, London, UK. Written 
information was given to each participating patient who signed a consent form.  
Twenty patients, 14 men and 6 women, (mean age 69.8 years, range 58-77 years) 
with intermittent claudication took part in the study. All patients attended the vascular 
surgery clinic at Ealing Hospital. PAD was previously diagnosed by history and clinical 
examination and all patients had an Ankle-Brachial Pressure Index (ABPI) < 0.80 (median 
0.62; range 0.4-0.75) at rest. All patients had a standard treadmill exercise test (3.5 km/h, 
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10o incline), which recorded a significant post-exercise drop (>20%) in the ABPI. All 
patients were in a metabolically and clinically stable condition, with no history of recent (6 
months) cardiac events, strokes, transient ischaemic attacks or changes in their claudication 
distance. These patients had not undergone any recent (6 months) surgery, angiography or 
angioplasty.  
Seven of the patients were never treated with any anti-platelet agent in the past, 11 
were on aspirin 75 mg per day, while two of them were receiving the combination of aspirin 
75 mg per day and dipyridamole 200 mg twice per day. These last 13 patients had to 
discontinue their anti-platelet therapy for at least 10 days before taking part in the study. 
None of the patients had renal impairment. A total of 6 patients had type 2 (non-insulin 
dependent) diabetes mellitus, (NIDDM) 12 were being treated for hypertension and 8 for 
ischaemic heart disease (IHD).  
Randomisation is essential for any experiment as it minimizes the chance of a biased 
result. Patients were randomised for treatment with either aspirin or clopidogrel or both 
drugs together. Randomization was carried out by the Pharmacy Dept. at Ealing Hospital 
according to the usual procedure (random number allocation). Myself and the patients were 
blinded to this information, until the end of the study. Placebo was given with either aspirin 
or clopidogrel, so that 2 tables were always given to the patients. In the phase of 
combination therapy (aspirin plus clopidogrel) both tablets consisted of active treatment (i.e. 
one tablet was aspirin and one tablet was clopidogrel). This was known to the investigators 
and patients. In other words the second phase of this study was not blinded.  
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There were no differences in sex or DM distribution between the two groups. All 
patients were transported to the Department of Clinical Biochemistry at the Royal Free 
Hospital and a baseline citrated venous blood sample was collected after resting for 15 min. 
Group A patients were given clopidogrel (Plavix, Sanofi-Synthelabo, Paris, France) 75 
mg/day and placebo for 8 days.  
In group B, patients were given aspirin (75 mg/day) and placebo for 8 days. On day 
8, blood samples were collected in a similar way from all patients, 4 h ± 30 min after the last 
medication had been taken. After that, all patients in both groups took the combination of 
the two drugs (aspirin 75 mg/day plus clopidogrel 75 mg/day) for 8 more days. On the last 
day, 4 h ± 30 min after both medications were taken, a blood-sample was collected.  
 
3.2.2 Platelet Aggregation 
Platelet aggregation was measured in citrated (3.8 %) whole blood (WB) using an 
MD18 Coulter counter (Coulter Electronics, Luton Beds, UK). Agonist-driven aggregation 
was assessed (see Appendix B: Platelet aggregation reference list with IA Jagroop) by 
counting the number of free platelets (as the % free platelet count, FPC), remaining in the 
stirred sample (at 37oC), after adding adenosine diphosphate (ADP; 5-10 µmol/l) or 5HT 
(5.0 µmol/l). Spontaneous platelet aggregation (SPA) was followed up for 15 min at specific 
sampling time points (0, 3, 6 and 15 min). The rationale was to assess platelet aggregation 
that has been reported as enhanced in patients with PAD (Matsagas, et al., 2002; 
Mikhailidis, et al., 1998; Robless, et al., 2003). In addition, SPA is substantially ADP-
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dependent and aspirin resistant (Matsagas, et al.,. 2002; Robless, 2003) SPA (in PRP) has 
been shown to be a predictor of the risk of a vascular event (Thaulow, et al.,. 991) 
 
3.2.3 Platelet Shape Change   
We used a high-resolution (0.07 fl) C256 channelyzer (electrical impedance method 
with a 70µm diameter sampling tube orifice) coupled to a ZM34 Coulter counter (Coulter 
Electronics, Luton Beds, UK) to determine MPV of human platelets (as described in General 
Methods chapter 2). PSC is an early phase of platelet activation that precedes aggregation 
(see Appendix A: PSC reference list with IA Jagroop).  PSC may be associated with platelet 
adhesion to the vascular wall (Rosenfeld et al., 1997). Citrated (3.8 %) PRP was incubated 
at 37oC for 15 min, prior to the start of the experiment. Agonists (5HT 0.5 µmol/l, ADP 0.4-
0.8 µmol/l) were added to PRP and stirred at 1000 rpm. These agonists concentrations and 
sampling times were determined in previous studies; they generate the most reproducible 
results. The percentage increase in MPV was calculated by using the saline control as 
baseline, and comparing this value with agonist- induced MPV (see Appendix A: PSC 
reference list authored by IA Jagroop).  
 
 
3.2.4 Intra-platelet 5HT Measurement 
3.2.4.1 Collection and Processing of Specimen 
Blood was collected in cold (2-80C) polystyrene tubes (as described in General 
Methods Chapter 2), with a specific solution (Gow et al., 1988) that inhibits the enzymatic 
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oxidation and cellular uptake of 5HT (9 parts blood to 1 part solution) which contained the 
following dissolved in physiological saline (Fawcett and Jagroop et al., 1998; Frampton 
and Jagroop et al., 2006; Jagroop et al., 2004). 
EDTA 50 mM   PGE1 500 nM  
clorgyline 100 µM   chlorimipramine 100 µM  
pargyline 100 µM 
The tubes were mixed gently by inversion and centrifuged immediately in a cold 
centrifuge (4oC) at x120g, for 15 min, to obtain PRP. Each sample was analysed for a 
platelet count using the Coulter MD18. This count was recorded, as it is necessary to 
calculate the platelet 5HT concentration later in the assay. 1 ml aliquots of PRP were put 
into cold Eppendorf tubes and microcentrifuged (x10,000g) for 2 min to prepare a platelet 
pellet. The platelet poor palette (PPP) was carefully collected, using a Pasteur pipette and 
stored at -20oC. The remaining pellet was washed with Isoton II, and stored at -20oC. Each 
Eppendorf tube containing the pellet was resuspended in 1 ml physiological saline (0.9% 
w/v) and a platelet lysate prepared by freeze thawing 3 times followed by ultrasonication (3 
x 10 sec at an amplitude of 18 microns) using an MSE-Soniprep probe-sonicator (Fawcett 
and Jagroop et al., 1998; Frampton and Jagroop et al., 2006; Jagroop et al., 2004). In 
order to ensure full disruption of the platelets, the platelet populations were counted and 
sized before and after sonication using a Coulter counter coupled to a channelyzer (see 
Chapter 2, section 2.4). If the platelet count following this procedure was reduced to <5% of 
the original, the platelet volume was disregarded since it became unmeasurable. 
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3.2.4.2 Intra-platelet 5HT Enzyme Immunoassay 
Intra-platelet 5HT concentrations were determined using an enzyme immunoassay 
kit (Immunotech-Beckman Coulter). The principle of this assay is based on the competition 
between modified 5HT in the sample and the 5HT-enzyme conjugate, used as a tracer, for 
binding to the anti-body coated onto microtitre plates (Fawcett and Jagroop et al., 1998; 
Frampton and Jagroop et al., 2006; Jagroop et al., 2004). 
 
3.2.5 Soluble P-Selectin (sP-Selectin) Immunoassay 
See General Methods (Chapter 2) (Jagroop et al., 2004; Mohan and Jagroop et al., 2008).  
 
3.2.6 Platelet-derived growth factor-AB (PDGF) immunoassay 
See General Methods (Chapter 2) (Jagroop et al., 2004). 
 
3.2.7 Statistical Analysis  
Results are presented as mean ± SD in tables 3.1-3.5 where comparisons are made 
using a paired t-test (two-tailed). In tables 3.3 and 3.4 results are expressed as median and 
range the P values were derived by non-parametric analysis (paired Wilcoxon tests, two 
tailed). 
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3.3 RESULTS 
 3.3.1 Platelet Aggregation  
3.3.1.1 Spontaneous Platelet Aggregation 
There was no significant change in SPA after taking clopidogrel or aspirin alone for 
8 days (table 3.1). However, after combination therapy (clopidogrel plus aspirin) SPA was 
significantly inhibited (6 min; P = 0.02 and 15 min; P = 0.001) in both groups, i.e. whether 
the patients were initially assigned to aspirin or clopidogrel; n = 10 for each group and n = 
20, when grouped together (see table 3.3).  
 
Table 3.1: Spontaneous Platelet Aggregation  
 
  
3 min 
 
 
6 min 
 
15 min 
Clopidogrel 
V1  
vs 
V2 
P Value 
 
87 ± 9 
vs 
88 ± 11 
NS 
 
73 ± 9 
vs 
78  ± 12 
NS 
 
58 ± 13 
vs 
66 ± 18 
NS 
Aspirin 
V1  
vs  
V2 
P Value 
 
84 ± 15 
vs 
84 ± 11 
NS 
 
74 ± 20 
vs 
78 ± 20 
NS 
 
63 ± 17 
vs 
58 ± 24 
NS 
 
Clopidogrel V2 
vs 
Aspirin V2 
P Value 
 
88 ± 11 
vs 
84 ± 11 
NS 
 
78  ± 12 
vs 
78 ± 20 
NS 
 
66 ± 18 
vs 
58 ± 24 
NS 
 
Spontaneous platelet aggregation (SPA) is measured as % free platelet count. Results are 
expressed as mean ± SD (n = 10 for each drug), using a paired t-test. Comparing visit 1 (V1, 
baseline) with visit 2 (V2, after taking clopidogrel or aspirin for 8 days). Also comparing 
taking clopidogrel or aspirin after 8 days (V2 on clopidogrel vs V2 on aspirin). Results are 
expressed as mean ± SD (n = 10 for each drug), using a paired t-test.  
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3.3.1.2 ADP-induced Aggregation 
After taking clopidogrel for 8 days there was a significant decrease (P = 0.001 -
0.0003 at 3, 6 and 15 min) in ADP (5 µmol/l)-induced aggregation (table 3.2). In contrast, 
no significant inhibition of aggregation was observed after taking aspirin for the same time. 
This effect appeared more obvious when those patients who took aspirin only at visit 2 (after 
8 days), were compared with those who took clopidogrel only at the same visit. ADP (5 
µmol/l)-induced aggregation was significantly decreased for the group on clopidogrel at all 
the time points measured (e.g. P = 0.003 at 3 min; table 3.2). This trend was repeated with a 
concentration of 10 µmol/l ADP-induced aggregation (table 3.3b).  
Taking combination therapy (clopidogrel plus aspirin) after 8 days showed that 
ADP-induced aggregation (at both concentrations of 5 µmol/l and 10 µmol/l), was 
significantly (P <0.03 to P = 0.0004) inhibited in both patient groups (i.e. whether the 
patients were assigned to aspirin or clopidogrel; n= 10 for each group (see table 3.3b).  
When the patients were grouped together (n = 20), taking combination therapy 
(clopidogrel plus aspirin) after 8 days showed that ADP-induced aggregation (at both 
concentrations of 5 µmol/l and 10 µmol/l), was significantly (e.g. P ≤ 0.0001 - 0.0003) 
inhibited (see table 3.3a)   
 
 
 
 
 
 
 125 
 
Table 3.2: ADP (5 µmol/l)-induced Platelet Aggregation 
    
  
3 min 
 
 
6 min 
 
15 min 
 
Clopidogrel 
V1 vs V2 
P Value 
 
46 ± 22   vs  83 ± 13 
0.0001 
 
42 ± 11 vs  77 ± 15 
0.0003 
 
43 ± 12  vs   72 ± 14 
0.001 
Aspirin 
V1 vs V2 
P Value 
 
43 ± 24  vs  56 ± 21 
NS 
 
45 ± 20  vs 57 ± 21 
NS 
 
43 ± 16  vs  48 ± 18 
NS 
 
Clopidogrel V2 
vs 
Aspirin V2 
P Value 
 
83 ± 13 
vs 
56 ± 21 
0.003 
 
77 ± 15 
vs 
57 ± 21 
0.03 
 
72 ± 14 
vs 
48 ± 18 
0.005 
 
Platelet aggregation (measured as % free platelet count).  
Comparing visit 1 (V1, baseline) with visit 2 (V2, after taking clopidogrel or aspirin for 8 
days). Also comparing taking clopidogrel or aspirin after 8 days (V2 on clopidogrel vs V2 
on aspirin). Results are expressed as mean ± SD (n = 10 for each drug), using a paired t-test.  
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                Table 3.3a: Spontaneous and Agonist-induced Platelet Aggregation 
          (Effect of Clopidogrel plus aspirin combination, n=20) 
 Baseline,V1 
vs 
Clopidogrel plus Aspirin combination,V3 
SPA 
3 min 
6 min 
15 min 
 
85 ± 12 vs 87 ± 9             P = NS 
73 ± 15 vs 83 ± 10           P = 0.02 
60 ±15 vs 77 ± 12            P = 0.001 
ADP 5 µmol/l  
3 min 
6 min 
15 min 
 
44 ± 23 vs 76 ± 17          P = 0.0003 
43 ± 16  vs 76 ± 17         P = 0.0001 
43 ±  13 vs 73 ± 18         P = 0.0001 
ADP 10 µmol/l 
3 min 
6 min 
15 min 
 
31 ± 27 vs 70 ± 21          P ≤ 0.0001 
35 ± 19  vs 70 ± 16         P ≤ 0.0001 
34 ±  20 vs 68 ± 16         P ≤ 0.0001 
5HT 5 µmol/l 
6 min 
15 min 
 
 65 ± 17 vs 72 ± 21          P =  NS 
50 ±  19 vs  64 ± 15         P = NS 
 
Baseline (V1) is compared with taking a combination of clopidogrel plus  
aspirin (V3).Results are expressed as mean ± SD (measured as % free platelet  
count, n=20), using a paired t-test.  
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Table 3.3b: Spontaneous and Agonist-induced Platelet Aggregation 
                     (Effect of Clopidogrel plus aspirin combination, n=10) 
 
SPA, ADP- and 5HT-induced platelet aggregation (measured as % free platelet count) after taking aspirin plus 
clopidogrel (V3) versus no treatment in those who were initially assigned clopidogrel mono-therapy. The same 
comparison was also carried out in those initially assigned aspirin mono-therapy. Results are expressed as 
mean ± SD (n = 10). The P value was derived using a paired t-test.  
V1, baseline sample (pre-treatment); V3, treatment with aspirin plus clopidogrel. 
                                             
                                             V1 v V3             V1 v V3  
(group initially  assigned  (group initially  assigned 
      to clopidogrel)             to aspirin)  
    SPA 
    3 min  87 ± 9 v 89 ± 12 P=NS  84 ± 15 v 85 ± 6 P=NS 
    6 min  73 ± 9 v 88 ± 12 P = 0.006 66 ± 19 v 86 ± 8 P=0.03  
   15 min  58 ± 13 v 79 ± 11 P=0.002 56 ± 17 v 77 ± 11 P=0.01 
   ADP (5µM)    
   3 min  46 ± 22 v 78 ± 14 P=0.003 43 ± 24 v 72 ± 20 P=0.014 
   6 min  42 ± 10 v 77 ± 14 P=0.0004 45 ± 20 v 73 ± 23 P=0.004 
   15 min  43 ± 11 v 73 ± 15 P=0.0004 43 ± 16 v 64 ± 24 P=0.001 
   ADP (10µM) 
   3 min  37 ± 30 v 80 ± 8 P=0.01 25 ± 23v 58 ± 25 P=<0.02 
   6 min  37 ± 19 v 75 ± 12 P=0.001 33 ± 21 v 55 ± 18 P=<0.03 
   15 min  34 ± 9 v 70 ± 13 P=0.002 30 ± 15 v 58 ± 20 P=0.001 
   5HT (5µM) 
   6 min  68 ± 17 v 79 ± 13 P=NS  63 ± 18 v 69 ± 15 P=NS 
   15 min  56 ± 16 v 74 ± 16 P=<0.02 45 ± 20 v 63 ± 14 P=0.03 
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Table 3.4: ADP (10 µmol/l)-induced Aggregation    
 3 min 6 min 15 min 
Clopidogrel 
V1 vs V2 
P Value 
 
37 ± 30 vs 71 ± 9 
0.004 
 
37 ± 19 vs 68 ± 9 
0.005 
 
34 ± 9 vs 66 ± 13 
0.0006 
Aspirin 
V1 vs V2 
P Value 
 
25 ± 22 vs 33 ± 24 
NS 
 
33 ± 21 vs 34 ± 22 
NS 
 
34 ± 22 vs 38 ± 20 
NS 
Clopidogrel V2 
vs 
Aspirin V2 
P Value 
71 ± 9 
vs 
33  ±  24 
0.0002 
68 ± 9 
vs 
34  ± 22 
0.014 
66 ± 13 
vs 
38  ± 20 
0.005 
 
Platelet aggregation (measured as % free platelet count).  
Comparing visit 1 (V1, baseline) with visit 2 (V2, after taking clopidogrel or aspirin for 8 
days). Also comparing taking clopidogrel or aspirin after 8 days (V2 on clopidogrel vs V2 
on aspirin). Results are expressed as mean ± SD (n = 10 for each drug), using a paired t-test.  
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3.3.1.3 5HT-induced Aggregation 
5HT-induced aggregation was not significantly inhibited by either clopidogrel or 
aspirin (table 3.5) on their own. The combination therapy, clopidogrel together with aspirin, 
also appeared to demonstrate no significant effect on 5HT-induced platelet aggregation, 
when both patients groups (i.e. those initially assigned aspirin, n=10, plus those initially 
assigned clopidogrel, n=10) were pooled, before they  were given combination therapy, 
(n=20) (see table 3.3a). However, when the 2 patient groups were considered individually 
(see table 3.3b), after taking combination therapy for 8 days. 5HT-induced aggregation was 
significantly (P=0.03 to P<0.02) inhibited at 15 min, in both patient groups (i.e. whether the 
patients were initially assigned to aspirin or clopidogrel; n=10 for each group, before being 
given the combination therapy) (see table 3.3.b). 
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   Table 3.5: 5HT (5 µmol/l)-induced Aggregation    
 6 min 15 min 
Clopidogrel 
V1 vs V2 
P Value 
 
68 ± 17    vs     79 ± 10 
NS 
 
56 ± 16    vs     67 ± 15 
NS 
Aspirin 
V1 vs V2 
P Value 
 
63 ± 18     vs      68 ± 18 
NS 
 
45 ± 20     vs      55 ± 17 
NS 
Clopidogrel V2 
vs 
Aspirin V2 
P Value 
79 ± 10 
vs 
68 ± 18 
NS 
67 ± 15       
vs      
55 ± 17 
NS 
 
Platelet aggregation (measured as % free platelet count).  
Comparing visit 1 (V1, baseline) with visit 2 (V2, after taking clopidogrel or  
aspirin for 8 days). Also comparing taking clopidogrel or aspirin after 8 days 
(V2 on clopidogrel vs V2 on aspirin). Results are expressed as mean ± SD  
(n = 10 for each drug), using a paired t-test.  
 
 
 
3.3.2 Platelet Shape Change Results 
3.3.2.1 ADP-induced PSC 
PSC induced by ADP (0.8 µM, at 30 and 60 sec) was more significantly inhibited (P 
= 0.004) by clopidogrel alone than by aspirin alone (P = 0.01, table 3.6). With combination 
therapy (table 3.7), ADP-induced PSC was even more significantly inhibited (P = 0.0002), 
than by either drug on its own. 
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3.3.2.2 5HT-induced PSC 
5HT-induced PSC was significantly inhibited by clopidogrel as well as by aspirin 
(table 3.6), but only at the 30 sec time point. With combination therapy (table 3.7), 5HT-
induced PSC at both time points (30 and 60 sec) was also significantly inhibited (P = 0.0006 
and P = 0.001, respectively). 
Table 3.6: Agonist-induced Platelet Shape Change Pre- and  
      Post-aspirin or Clopidogrel 
 Base (V1)  
vs  
Clop (V2) 
 
P value 
Base (V1)  
vs  
ASA (V2) 
     
P value 
ADP 0.4 µM 
 
30 s 
 
 
 
60s 
 
4.9 (3.3 -11.0) 
vs 
2.4 (0 -9.3) 
 
6.1 (3.4 - 10.2) 
vs 
2.3 (0- 9.9) 
 
 
 
P = 0.01 
 
 
 
P = 0.01 
 
6.7 (3.3 - 21.8) 
vs 
5.2 ( 1.0 - 13.9) 
 
7.1 (3.8 - 16.0) 
vs 
5.7 (2.0 - 15.2) 
 
 
 
P = NS 
 
 
 
P = NS 
ADP 0.8 µM 
 
30 s 
 
 
 
60 s 
 
10.1 ( 3.5 - 18.6) 
vs 
6.4 (0.3 - 9.7) 
 
10.5 ( 2.9 - 14.5) 
vs 
5.6 ( 0 - 14.2) 
 
 
 
P = 0.004 
 
 
 
P = 0.004  
 
10.3 (6.7 - 20.9) 
vs 
7.5 (2.1 - 11.8) 
 
10.1 (7.5 - 23.9) 
vs 
7.5 (3.8 - 12.01) 
 
 
 
P = 0.01 
 
 
 
P = 0.01 
5HT 0.5 µM 
 
30 s 
 
 
 
60 s 
 
8.3 ( 4.9 - 14.4) 
vs 
6.6 ( 2.2 - 8.7) 
 
8.0 ( 6.0 - 14.6) 
vs 
5.8 (1.8 - 12.0) 
 
 
 
P = 0.01 
 
 
 
P = NS 
 
11.7 (5.0 - 18.4) 
vs 
6.2 (0.5 - 10.8) 
 
9.9 (5.31 - 14.5) 
vs 
6.2 (1.9 - 11.8) 
 
 
 
P = 0.03 
 
 
 
P = NS 
 
Platelet shape change (PSC, using % increase in median platelet volume-MPV). 
Comparing Baseline (V1) with either clopidogrel or aspirin after 8 days (V2). 
Results expressed as median using non-parametric Wilcoxon matched pairs (n= 10 for each 
drug).
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Table 3.7: Agonist-induced Platelet Shape Change Pre- and Post-  
      Combination Treatment 
 
 Base (V1)  
Vs  
Clopidogrel + Aspirin 
combination (V3) 
 
 
P  
ADP 0.4 µM 
 
30 s 
 
 
 
60s 
 
5.5 (3.3 - 21.8) 
vs 
2.3 (0 - 12.3) 
 
6.8 (3.4 - 16.0)  
vs 
1.7 (0 - 8.8) 
 
 
 
P = 0.001 
 
 
 
P = 0.0005 
ADP 0.8 µM 
 
30 s 
 
 
 
 
60 s 
 
10.2 (3.5 - 20.9) 
vs 
5.3 (0 - 16.2) 
 
10.4 (2.9 - 23.9) 
vs 
3.3 (0 - 18.0) 
 
 
 
 
P = 0.0002 
 
 
P = 0.001 
5HT 0.5 µM 
 
30 s 
 
 
 
60 s 
 
8.7 ( 4.9 - 18.4) 
vs 
4.5 (0 -12.0) 
 
8.4 (5.3 - 14.6) 
Vs 
3.8 (0 - 12)  
 
 
 
P = 0.0006 
 
 
 
P = 0.001 
 
Platelet shape change (PSC, using % increase in median platelet volume-MPV). 
Comparing baseline (V1) with clopidogrel plus aspirin combination (V3). 
Results expressed as median using non-parametric Wilcoxon matched pairs (n=20). 
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3.3.3 Intra-platelet 5HT Enzyme Immunoassay 
 Intra-platelet 5HT concentration showed no significant difference when comparing 
V1 with V3; from 1.0 (0.6 – 19.5) to 0.9 (0.2 – 5.5) nM/109 platelets.  
 
3.3.4 Soluble P-Selectin (sP-Selectin) Immunoassay 
 A comparison was made with baseline values (V1) when patients were not on 
treatment, to when they were on combination therapy (V3). There was a significant decrease 
(P = 0.04) in sP-selectin (from 32 ± 24 to 25 ± 17 ng/ml. The comparison of baseline (V1) 
values with either drug alone (V2), was not considered as the numbers would have been too 
small (n=10), and therefore, weakening the strength of the stastical test. 
 
3.3.5 Platelet-Derived Growth Factor-AB Immunoassay 
 There was no significant difference in plasma PDGF-AB when comparing baseline 
(V1) with the end of the study values (V3); from 92 (0 – 694) to 80 (2 – 1314) pg/ml. The 
range of the assay is wide ranging from non-detectable to 1143 pg/ml. Baseline values (V1) 
were again not compared with V2 for the reasons outlined (in 3.3.4) above. 
 
3.4 SIDE EFFECTS 
None of the patients developed any adverse events during the study. All the patients 
were followed up for an additional 2 weeks, but no side effects were reported. Of the 20 
patients, 13 went back to their original medication, while the 7 who were previously not on 
anti-platelet therapy started taking aspirin (75 mg/day). 
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3.5 DISCUSSION 
The results from this study indicate that combination therapy (clopidogrel plus 
aspirin) provides more potent platelet inhibition than monotherapy (clopidogrel or aspirin) in 
patients with PAD.  
ADP-induced platelet aggregation was significantly inhibited by clopidogrel but not 
by aspirin. Thus, as expected, there is some degree of ADP-specificity for clopidogrel 
compared to aspirin (Gachet, 2001b; Lubbe et al., 2002). This is noteworthy, because 
activated platelets release ADP which potentiates the effect of other agents including weak 
agonists (e.g. 5HT or adrenaline) (Daniel et al., 1998; Gachet, 2001b). It may be a 
disadvantage that a commonly used inhibitor like aspirin does not exert a more powerful 
effect on ADP-induced platelet responses. 
It was also detected that when combination therapy (clopidogrel plus aspirin) was 
used, ADP-induced aggregation was inhibited to a greater extent than with clopidogrel 
alone. Therefore, combination therapy is more effective than monotherapy even when ADP-
induced aggregation is assessed.  
Either drug alone did not inhibit SPA. However, SPA was significantly inhibited 
with combination therapy (clopidogrel plus aspirin). SPA (in PRP) predicts a higher risk of 
coronary events and mortality in patients who survived a recent MI (Trip et al., 1990; 
Wallace et al., 1998). 
There was a significant inhibition of ADP (0.4 µmol/l)-induced PSC with 
clopidogrel but not with aspirin. This lends further evidence to the concept that clopidogrel 
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exerts a more specific inhibitory action on ADP-induced platelet responses as compared to 
aspirin (Drouet et al., 1998; Duerschmied et al., 2010; Foster et al., 2001; Gachet, 2001a). 
However, with the higher ADP concentration (0.8 µmol/l), some inhibition of PSC with 
aspirin only was observed. Nevertheless, clopidogrel remained the more potent inhibitor of 
PSC even at this high concentration of ADP. It is possible that aspirin-induced inhibition of 
PSC is only visible when the increase in MPV is substantial. ADP-induced PSC was more 
obviously inhibited with combination therapy than with monotherapy. Another study done 
in relation to this one, previously reported significant inhibition of ADP-induced PSC 
following a loading dose of clopidogrel in patients with PAD (Matsagas and Jagroop et al., 
2003). It was also demonstrated, that a P2Y12 receptor inhibitor (AR-C66931MX) added in 
vitro inhibited the early phase of PSC induced by ADP (Jagroop et al., 2003a). 
Either drug alone or in combination did not significantly inhibit 5HT-induced 
aggregation in whole blood. However, another study showed that clopidogrel not only 
inhibited ADP-induced platelet aggregation, but also reduced platelet aggregation induced 
by a thromboxane mimetic (U46619) or 5HT in dogs (Yao et al., 1992). The fact that in this 
study,  a  dose of 75 mg/day of oral clopidogrel was used, as compared to 10 mg/kg i.v. 
bolus plus 2.5 mg/kg/h infusion (for 3 h) may be a contributing factor to the inconsistency 
between these studies(Yao et al., 1992).  Apart from the greater drug availability via the i.v. 
route, the equivalent dose of clopidogrel (75 mg orally, once daily) in these patients 
(average weight: 75 kg) is much lower. However, when we used a loading dose of 
clopidogrel we did see inhibition of 5HT-induced aggregation (Matsagas and Jagroop et al., 
2003). 
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In contrast to 5HT-induced aggregation, 5HT-induced PSC was significantly 
inhibited by either drug alone (at 30 sec) or both drugs in combination. This may be because 
PSC is a more sensitive technique of assessing platelet activation. Much lower doses of 
agonists are required to induce PSC (see Appendix A: PSC reference list authored by IA 
Jagroop; Barradas et al., 1992) than are necessary for platelet aggregation (see Appendix B: 
platelet aggregation reference list authored by IA Jagroop). For example, 0.5 µmol/l of 
5HT was used to stimulate PSC as compared to 5-10 µmol/l, which was required to induce 
aggregation. It has also previously been reported that a significant inhibition of 5HT-induced 
PSC after a loading dose (300 mg) of clopidogrel in patients with PAD (Matsagas, Jagroop 
et al., 2003).  
Several trials evaluated the benefit and safety of clopidogrel alone or with aspirin for 
the prevention of cardiovascular events (Bakhru et al., 2008; Mohler, III, 2009; Squizzato et 
al., 2011). For example, CAPRIE (n = 19,185; Clopidogrel versus Aspirin in Patients at 
Risk of Ischaemic Events), where the PAD subgroup considered 6,452 patients and found 
that clopidogrel significantly (P = 0.0028) reduced (by 23.8%), the relative risk of vascular 
events compared with aspirin (1996, no authors listed). However, this subgroup analysis is 
limited by the fact that it was not included in the original CAPRIE protocol. 
CURE (Clopidogrel in Unstable angina to prevent the Recurrent ischemic Events) 
(Yusuf et al., 2001) was a large (n = 12,562) study to determine if acute and long-term 
treatment with the combination of clopidogrel and aspirin is superior to aspirin alone in 
patients with acute coronary syndrome. Combination therapy proved to be more effective 
than aspirin alone (Yusuf et al., 2001). 
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The CREDO trial (Clopidogrel for Reduction of Events During Observation) 
(Steinhubl et al., 2002) considered 2116 patients after percutaneous coronary intervention, 
and evaluated the effect of clopidogrel (75 mg/day and a loading dose of 300 mg) in 
addition to aspirin. CREDO showed that long-term (1 year) clopidogrel plus aspirin reduced 
the risk of ischaemic events, and that a longer interval (> 6h) between the loading dose of 
clopidogrel and PCI may also reduce events (Steinhubl et al., 2002). 
The efficacy of aspirin mono-therapy is well documented by a multitude of trials 
(2002, no authors listed). Furthermore, when patients were put on aspirin the platelet half-
life was prolonged. In addition, a recent meta-analysis concluded that platelet inhibitors 
significantly reduce events in patients with PAD (2002 no authors listed).  
From the present study we conclude that clopidogrel is a more powerful platelet 
inhibitor than aspirin in patients with PAD. This conclusion is compatible with the CAPRIE 
subgroup findings mentioned above (1996, no authors listed). Moreover, the clopidogrel and 
aspirin combination was more potent than either drug alone (Bakhru et al., 2008; Mohler, 
III, 2009;Mohler, III et al., 2003; Squizzato et al., 2011). Whether this translates into 
additional clinical benefit in PAD is not established. Nonetheless, the results of CURE 
(Yusuf et al., 2001) and CREDO (Steinhubl et al., 2002) suggest that such additional 
inhibition is beneficial. 
Any increased platelet inhibition needs to be balanced against a potential greater risk 
of bleeding. These issues can only be clarified by an extensive trial in patients with PAD. 
However, if combination therapy (clopidogrel plus aspirin) is proven to be more effective 
than mono-therapy (clopidogrel or aspirin) then the benefits may be considerable because 
 
 
 
 
 
 
 138 
PAD is both common and associated with an increased risk of vascular events (Barradas et 
al., 1994b; Matsagas et al., 2002; Reininger et al., 1999; Robless et al., 2001). Until such 
evidence becomes available, using either drug alone or in combination in PAD, must remain 
the decision of the prescribing physician. The decision may be influenced by vascular events 
occurring while on mono-therapy or by intolerance to aspirin.  
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CHAPTER 4 
 
Both ADP Receptors, P2Y1 and P2Y12, Play a Role 
in Controlling Shape Change in Human Platelets 
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4.1 (i) AIM, BACKGROUND AND HYPOTHESIS 
Aim: The aim of this study was to assess the role of platelet purinergic receptors (i.e. P2Y12, 
P2Y1 and P2X1) on PSC. 
Background: Clopidogrel acts via P2Y12 purinergic receptors. Furthermore, in my previous 
studies this drug, when administered in vivo, had an inhibitory effect on PSC. Thus, I 
wanted to investigate the involvement of P2Y12 purinergic receptors as well as others, 
namely P2Y1 and P2X1 on the PSC. Others have implicated the P2Y1 purinergic receptor in 
PSC, with the use of the less sensitive method of optical transmission aggregometry. Further 
evidence suggests that the measurements that were thought to represent PSC, actually 
showed the formation on platelet microaggregates. Thus, using my more sensitive and 
quantitative method to assess PSC (i.e. a channelyzer), it is of interest to show if the 
purinergic receptors P2Y1, P2Y12 and P2X1 do play a role in PSC. This can be done with the 
use of specific purinergic receptor inhibitors (MRS2179 for P2Y1, ARC 69932IMX for 
P2Y12 and TNP-ATP for P2X1). 
Hypothesis: My hypothesis was that several platelet purinergic receptors can influence PSC. 
Moreover, my method to assess PSC would be able to determine the effectiveness (IC50) of 
purinergic receptor inhibitors. 
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4.1 (ii) INTRODUCTION  
Purinergic receptors (Ralevic et al, 1998) are potential targets for anti-thrombotic 
drugs, since ADP plays a crucial role in platelet activation (Burnstock, 1989). Two types of 
ADP receptors, P2Y1 and P2Y12, contribute to platelet aggregation (Li et al., 2010; Remijn 
et al., 2002; Storey et al., 2001). The P2Y1 receptor is involved in the initiation of 
aggregation by mobilizing calcium stores (Storey et al., 2001). The P2Y12 receptor is 
necessary for the completion and amplification of aggregation by inhibiting adenylyl cyclase 
activity (Gachet, 2008; Gachet, 2001b; Storey, 2001). The P2X1 receptor is also present but 
by the year 2001 its role, in terms of platelet function, had not yet been defined (Gachet, 
2001b). However, present knowledge suggests that the identified platelet P2X1 receptor may 
be a target in the management of thrombosis, and its inhibition is potentially capable of 
platelet function modulation (Hu et al., 2010). 
The ATP contained in the platelet dense granules is released upon platelet activation 
into the extracellular space of the platelet (Hu et al., 2010). Up until about 30 years ago, the 
role of ATP in haemostasis was vague. It is now understood, that the extracellular ATP can 
induce platelet activation signals, upon interaction with specific receptors that belongs to the 
P2X class of non-selective ATP-gated cation channels (North, 2002). MacKenzie et al. 
(MacKenzie et al., 1996) demonstrated ATP-operated cation channel in platelets, which was 
linked to P2X1 receptor and thus indicated that there was a role for ATP in platelet 
activation. Vial et al. (Vial et al., 1997) suggested that there is a unique presence of P2X1 
receptors in human platelets and that this ion channel was the sole ATP-operated P2-
receptor on platelets.     
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The initial functional response of platelets to ADP is shape change. These cells 
undergo cytoskeletal re-organisation resulting in spheration, contraction and generation of 
pseudopodia (Daniel et al., 1998). PSC precedes aggregation and, in vitro, this process is 
essentially aspirin resistant (see Appendix A: PSC reference list authored by IA Jagroop). 
Several studies that assessed PSC used light transmission aggregometery (Ehrman, 1980; 
Maurer-Spurej, 2001; Wilde, 2000). This technique is not as sensitive as using a high-
resolution channelyzer (see Appendix A: PSC reference list authored by IA Jagroop). 
Therefore, aggregometry may not have detected small variations in platelet size.   
More deficiencies can be attributed to the optical method used to assess PSC. Indeed, 
Maurer-Spurej (2001) and others (Gabbasov, 1989; Maurer-Spurej, 2001) proposed that a 
decrease in light transmission actually represents the formation of platelet-microaggregates 
rather than PSC. We have shown, using a high-resolution channelyzer, that an increase in 
MPV as an indicator of PSC occurs concomitantly with morphological changes seen by 
electron microscopy (Jagroop et al., 2000a). 
Since the channelyzer method used in this study is reproducible and sensitive (see 
Appendix A: PSC reference list authored by IA Jagroop), it was used to evaluate the role of 
the P2Y1, P2Y12 and P2X1 receptors in mediating human PSC. In order to achieve this 
objective, the following specific purinergic receptor antagonists: MRS 2179 for P2Y1 
receptors (Boyer, 1998), AR-C69931MX for P2Y12 receptors (Humphries, 1994), and TNP-
ATP for P2X1 receptors (Virginio, 1998) were used. 
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4.2 METHODS 
Collection of blood and MPV measurement were carried out (as outlined in chapter 
2, General Methods), and any alterations to these general methods are described below.   
 
4.2.1 Obtaining an IC50 is for the P2Y1 ADP Receptor Antagonist 
PRP was prepared from 7 healthy volunteers (6 men and 1 woman; mean age: 38 
years, range: 26 – 57) (as outlined in chapter 2, General Methods). PRP was stimulated with 
ADP, at a final concentration (fc) of 0.2 or 0.4 µmol/l for 30 sec and the platelet MPV was 
assessed using a Coulter ZM 34 counter, coupled to a C-256 channelyzer. This dose of ADP 
was selected to cause a 5 to 15% increase in MPV when compared with the physiological 
saline (control). This range was selected to provide a sub-maximal increase that is within the 
detection capacity of the high-resolution channelyzer, and can still allow for any inhibitory 
responses with antagonists to be detected. Saline control was added to samples to match 
those of the agonist (as 10 - 50 µl volumes) (see Appendix A: PSC reference list authored by 
IA Jagroop). In order to obtain an IC50 for the P2Y1 ADP receptor antagonist, MRS 2179, 
PRP was incubated for 1 min with increasing doses of MRS 2179 ranging from 0.62 - 20 
µmol/l in each of the 7 individuals, before adding ADP. These increasing doses of MRS 
2179 were used, until the measured MPV value returned to that observed for the saline 
control (see figure 4.1).  
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4.2.2 The Effect of the P2Y1 Receptor Antagonist on a Combination of ADP- and 5HT-
induced PSC 
PRP was prepared from 7 healthy volunteers (6 men and 1 woman; mean age of 38 
years, range: 26 – 57) (as outlined in chapter 2, General Methods).  PSC was stimulated with 
ADP only (fc 0.2 µmol/l), 5HT only (fc 0.03 - 0.25 µmol/l), and then ADP combined with 
5HT. The increase in MPV induced by either ADP or 5HT was of the order of 1 – 3%. This 
range was selected to provide a sub-maximal increase that is within the detection capacity of 
the high-resolution channelyzer and can still allow for an additive of synergistic effect. For 
each individual, the dose of MRS 2179 that resulted in 100% inhibition of ADP-induced 
PSC (as described in section 4.2.1 above) was determined. This maximum dose of MRS 
2179 ranged from fc 5 to 20 µmol/l. The selected dose was then incubated with PRP for 1 
min before adding ADP combined with 5HT, the MPV was assessed 30 sec later. 
 
4.2.3 The Effect of the P2Y12 ADP Receptor Antagonist on PSC 
PRP was prepared (as outlined in chapter 2, General Methods), from 12 healthy 
volunteers (7 men and 5 women; mean age of 32 years, range: 23 – 54). ADP alone (fc. 0.2 - 
0.4 µmol/l) then ADP together with AR-C69931MX (10 µmol/l) was added to PRP. The 
MPV was analyzed (as described in Chap 2) 10, 15 and 30sec after adding these agents.  
 
4.2.4 The Effect of a P2X1 ADP Receptor Antagonist (TNP-ATP) on PSC 
PRP was prepared from 7 healthy volunteers (6 men and 1 woman; mean age of 38 
years, range: 26 – 57) (using the method described in chapter 2). PRP was stimulated with 
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ADP (fc) 0.2 or 0.4 µmol/l for 30 sec and the MPV assessed. This dose was selected to 
cause a 4 - 12% increase in MPV. This range was selected to provide a sub-maximal 
increase that is within the detection capacity of the high-resolution channelyzer and can still 
allow for any inhibitory responses with antagonists. To determine if there were any 
responses with TNP-ATP, PRP was incubated for various times (30 sec - 3 min) with a 
range of doses of TNP-ATP (26 - 102 µmol/l) before the addition of ADP (n = 7), or a 
combination of ADP plus 5HT (n = 5).  
 
4.2.5 The Effect of a P2X1 ADP Receptor Agonist α,β-methylene ATP  
(α,βmeATP) on PSC 
PRP was prepared from 7 healthy volunteers (3 men and 4 women; mean age of 36 
years, range: 28 – 56) (as outlined in chapter 2, General Methods). PRP was stimulated with 
α,βmeATP in increasing doses ranging from 0.5 µmol/l to 20 µmol/l. PRP was incubated 
with α,βmeATP for various times (10, 15 and 30 sec) and the MPV was assessed. These 
times were selected on the basis of previous research showing that the response of this 
receptor is very rapid (Takano et al., 1999; Vial et al., 2002).  
4.2.6. Statistical Analysis: The results are presented as median and range. Statistical 
comparisons are by Wilcoxon paired test. 
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4.3 RESULTS 
4.3.1 Obtaining an IC50 for the P2Y1 ADP Receptor Antagonist 
MRS 2179 inhibited ADP-induced PSC by 100% in each of the 7 subjects tested. 
The median IC50 for MRS 2179 was 3.16 (1.06 - 10.25 µmol/l). Therefore, the range for IC50 
of MRS 2179 showed a 10-fold variation when all 7 subjects were considered. A 
representative dose response curve is shown in figure 4.1 (next page). In this subject, the 
control MPV is 5.44 fl. By inducing PRP with ADP, the MPV increases to 6.06 fl which is 
inhibited by increasing concentrations of MRS 2179.  
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Figure 4.1: A representative curve showing the IC50 of MRS 2179  
(3.33 µmol/l) on ADP-induced PSC 
 
 
 
 
 
 
 
A representative dose response curve of one subject showing that an IC50                    
(3.33 µmol/l)) of a P2Y1 receptor antagonist (MRS 2179) was obtained.  In this 
subject, the control MPV was 5.44 fl. By inducing PRP with ADP, the MPV 
increased to 6.06 fl, which was inhibited by increasing concentrations of MRS 2179.  
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4.3.2 The effect of the P2Y1 ADP Receptor Antagonist on a Combination of ADP and 
5HT- induced PSC 
The ADP-induced increase in MPV was of the order of 2% greater than that for the 
saline control. For 5HT, the increase was of the order of 1%. In combination, ADP plus 5HT 
caused a synergistic increase in MPV of 8%. This increase was significantly (P = 0.01) 
inhibited by MRS 2179 (see table 4.1), (at a dose that abolished PSC-induced by ADP 
alone).  
 
 
Table 4.1 Effect of MRS 2179 on a Combination of 5HT plus ADP-induced PSC 
  
MPV (fl), median (and range) 
 
Saline 
ADP 
5HT 
ADP + 5HT 
MRS 2179 with ADP plus 5HT 
 
6.18 (5.36 - 6.44) 
                    6.31 (5.6 - 6.88) 
6.25 (5.55 - 6.82) 
6.69 (6.18 - 7.14) 
6.44 (5.93 - 6.69)* 
 
* ADP plus 5HT vs MRS 2179 with ADP plus 5HT, (n = 7, in each group), P = 0.01  
The results are presented as median and range. Statistical comparisons are by  
Wilcoxon paired test. 
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4.3.3 The effect of the P2Y12 ADP Receptor Antagonist on PSC 
ADP-induced PSC showed a 4 - 6% increase in MPV (fl) when compared with the 
saline controls. The ADP (0.2 µmol/l)-induced increase in MPV was significantly inhibited 
by AR-C69931MX (10 µmol/l) (see table 4.2). AR-C69931MX also inhibited ADP-induced 
PSC up to 5 min, but with increasing time, the inhibition was less (figure 4.2.) This same 
trend in inhibition was seen for 0.4 µmol/l.  
Although AR-C69931MX inhibited ADP-induced PSC 30 sec after its initiation, the 
inhibitory effect gradually decreased so that it was no longer evident at 5 min. 
 
Table 4.2 The Effect of AR-C69931MX on ADP-induced PSC 
 
Time (sec) 
 
 
10 sec 
 
15 sec 
 
30 sec 
 
Saline 
5.88 
(4.78 - 6.95) 
 
5.85  
(4.95 - 6.76) 
5.90 
(4.78 - 6.69)  
 
ADP 
6.12  
(5.48 - 7.01) 
6.19 
(5.48 - 7.07)  
 
6.24  
(5.55 - 7.20) 
 
AR-C69931MX 
+ ADP 
 
5.94  
(5.42 - 6.76) 
 
6.08 
(5.47 - 6.84)  
 
6.10  
(5.48 - 7.01) 
 
P value 
 
P = 0.009 
 
P = 0.001 
 
P = 0.010 
 
 
The P values are a comparison of ADP vs ADP plus AR-C69931MX at 10, 15 and 30 sec. 
Results are expressed as MPV (fl), n = 12. The results are presented as median and range. 
Statistical comparisons are by Wilcoxon paired test. 
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Figure 4.2 A representative curve (n = 2) of the effect of AR-C69931MX  
(10 µmol/l) on ADP (0.2 µmol/l)-induced PSC 
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4.3.4 The effect of a P2X1 Receptor Antagonist (TNP-ATP) on PSC 
There was no significant effect (n = 7) on ADP-induced shape change, (6.31; 6.12 - 
6.88 fl) after adding TNP-ATP (6.36; 6.18 - 7.01 fl).  
There was also no significant effect (n = 5) of TNP-ATP (6.61; 6.12 - 6.95 fl) on 
PSC-induced by the combination of ADP plus 5HT (6.57; 6.18 - 7.07 fl). 
 
4.3.5 The effect of a P2X1 ADP Receptor Agonist (α,βmeATP)  on PSC 
There was no effect of α,β-methylene ATP (α,βmeATP) on MPV at any of the time 
points, or concentrations assessed (e.g. saline control at 10 sec, 5.87; 5.36 - 6.66 fl vs 
α,βmeATP at 10 sec, 5.87; 5.36 - 6.63 fl). 
 
4.4 DISCUSSION 
In this study, using a P2Y1 receptor-blocker, 100% inhibition of ADP-induced PSC 
was achieved. Others have also shown that ADP-induced  PSC, occurs via the P2Y1 receptor 
(Chang et al., 2010; Mangin et al., 2004; Storey et al., 2001). However, some of these 
authors (Storey et al., 2001) measured PSC using light transmission aggregometry and it has 
been suggested that the aggregometer tracing taken to represent PSC rather reflects the 
formation of platelet micro-aggregates (Maurer-Spurej, 2001). The P2Y1 receptor is also 
essential for platelet aggregation (Baurand, 2001; Raboisson, 2002). Therefore, antagonists 
to this receptor may become useful anti-platelet agents (Raboisson, 2002). 
In these experiments, the IC50 for MRS 2179 varied between 1.06 - 10.25 µmol/l (i.e. 
a 10-fold variation in IC50 when all 7 subjects were considered); the median IC50 was 3.16 
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µmol/l. To my knowledge, an IC50 has not been derived before for a P2Y1 receptor-blocker 
using the human PSC phenomenon. An IC50 for P2Y1 receptor-blockers can now be derived 
using a channelyzer because of the high-resolution (0.07 fl) and reproducibility of this 
technique (Jagroop et al., 1996; Jagroop et al., 2000c; Jagroop et al., 2000a; see Appendix 
A: PSC reference list authored by IA Jagroop et al.).  
In some of these experiments, the effect of ADP on a preparation of PRP was 
observed. It is know that the initial functional response to ADP is shape change, where 
platelets go through cytoskeletal reorganization, ending up in spheration, contraction and 
pseudopodia generation (Fox, 2001). It is thought that phosphorylation of the myosin light 
chain (MLC) may have a central role in PSC (Daniel et al., 1998). Phosphorylation may 
happen when there is an elevation of calcium through calmodulin-dependent activation of 
MLC-kinase (MLCK) (Wilde et al., 2000). Moreover, others have shown that in another cell 
type, Rho-kinase directly phosphorylates MLC and inactivates MLC-phosphatase (Essler, 
1998; Kureishi, 1997). This resulted in an increase in MLC phosphorylation. When 
considering platelets, it has been observed that the Rho-kinase, RhoA (a Rho-kinase) and the 
myosin binding subunit of MLC-phosphatase tends to create a complex, which ends up as 
the phoshorylation of MLC-phosphatase and a reduction in its activity (Suzuki, 1999). 
In this work, it was demonstrated that AR-C69931MX inhibited ADP-induced PSC, 
in a time-dependent manner, in samples collected from healthy volunteers. This is the first 
study that actually quantifies PSC inhibition by this or any other P2Y12 receptor blocker. 
Others have shown, using an optical aggregometer and washed platelets, that another P2Y12 
receptor antagonist (AR-C66096) caused a more rapid reversion of platelets to the discoid 
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form (Wilde, 2000). There was also evidence that PSC was inhibited by cAMP. This finding 
may explain why blocking the P2Y12 receptor results in inhibition of PSC, since stimulating 
the P2Y12 receptor inhibits cAMP synthesis (Wilde, 2000).  
When using two agonists (i.e. ADP plus 5HT) in combination in the presence of the 
maximal dose of the P2Y1 receptor-blocker, the mean MPV was greater than that with 5HT 
alone. This finding suggests that the unblocked P2Y12 purinergic receptor can enhance the 
5HT-mediated PSC response. Therefore, it would seem that the P2Y12 receptor is involved 
when ADP acts as a co-stimulus in the presence of low concentrations of other agonists, as 
previously suggested (Gachet, 2001). 
The first observations of the functional involvement of the P2X1 receptor in platelets 
were seen in 1995 (Humphrey et al., 1995; Surprenant et al., 1995). Moreover, the P2X1 
receptor could be implicated in PSC (Rolf, 2001). However, in spite of the already 
demonstrated functionality, many investigators failed to find any physiological activity for 
that purinergic receptor other than calcium influx (Daniel, 1998; Vial, 1997). It was 
indicated that the physiological role of P2X1 receptor in platelet function, might have 
remained concealed by other investigators, due to the rapid P2X1 receptor desensitization 
when the platelets are prepared in vivo (Hu et al., 2010; Rolf et al., 2001).  
An effect of the P2X1 receptor on PSC (after using both a specific antagonist and 
agonist) was absent. This supports the others who show that the receptor is involved with 
very rapid actions (Vial, 1997). In addition, the sampling times used in these experiments, 
was limited by the capacity of human operators. Citrated PRP was used, and this may have 
masked any Ca2+-mediated effect.  
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This work supports the theory that the P2X1 receptor becomes rapidly desensitized 
and it is therefore difficult to assess its effect on platelets in vitro (Gachet, 2001). Rolf et al. 
were able to prevent this desensitization of P2X1 receptor by using a high concentration of 
apyrase (ATP-diphosphohydrolase E.C.3.6.1.5.) (Rolf et al., 2001). The selective P2X1 
receptor agonist α,β-meATP, induced a rapid Ca2+-influx that was associated with a transient 
shape change in human platelets. There is evidence suggesting that the morphological 
changes mediated by P2X1 receptor activation, involves rapid pseudopodia formation, a fast 
and reversible centralisation of secretory granules, platelet spearing and short filopodia 
formation (Toth-Zsamboki et al., 2003; Vial et al., 2003).  
It was important to exclude an effect of the P2X1 receptor on PSC within this 
experimental design because the P2Y1 receptor-blocker used in these experiments may also 
exert some action on the P2X1 receptor (Horner, 2005d; Gachet, 2005). However, any such 
interference is unlikely to have occurred because the P2X1 receptor showed no effect on PSC 
(after using both a specific antagonist and agonist). Furthermore, in another experiment (rat 
vas deferens), MRS 2179 at concentrations of 100 µmol/l did not exert any action on the 
P2X1 receptor (Horner, 2002). The maximal concentration of MRS 2179 we used was 20 
µmol/l. 
This channelyzer method was previously used to demonstrate the action of drugs 
(added in vitro at therapeutic concentrations) on platelets (Jagroop et al., 1996; Jagroop et 
al., 2000c; Jagroop et al., 2000a; see Appendix A: PSC reference list authored by IA 
Jagroop et al.) when other methods only detected an effect at unrealistically high 
concentrations. These findings are of clinical relevance because PSC is an early phase of 
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platelet activation that precedes aggregation and it is essentially aspirin resistant (Jagroop et 
al., 1996; Jagroop et al., 2000c; Jagroop et al., 2000a; see Appendix A: PSC reference list 
with IA Jagroop et al.) at least in vitro.  
These findings suggest that P2Y12 receptor antagonists are clinically useful since 
they inhibit both early and late platelet activation. This concept is supported by clinical trials 
(Puri, 1997).  For example, there is extensive trial-based evidence showing that clopidogrel 
(a P2Y12 receptor antagonist) significantly decreases the risk of vascular events when 
administered alone or in combination with aspirin (1996 no authors listed; Yusuf, 2001). 
Unfortunately, the inhibitory effect of clopidogrel cannot be assessed in vitro because it 
requires to be metabolized before exerting its actions (Mikhailidis and Jagroop, 1998; 
Jagroop et al. 2004). Whether P2Y1 or P2Y12 receptor antagonists will prove superior to 
other anti-platelet agents in certain disease states, remains to be proven (Robless, 2001). In 
addition, there is a need to establish whether the contribution of different platelet purinergic 
receptors is altered in various types of vascular disease.  
Assessing the effect of clopidogrel on the P2Y12 receptor is limited because this anti-
platelet agent is inactive in vitro (Savi, 2000). Clopidogrel needs to be metabolized by the 
liver before becoming active. At least one of the active metabolites of clopidogrel has been 
purified and shown to be active in vitro (Savi, 2000). However, the production of this 
metabolite requires incubation with human liver microsomes followed by a purification 
process. In addition, this metabolite is highly unstable (Savi, 2000).  It follows that the use 
of this metabolite is limited.  
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In conclusion, platelet receptor antagonists will exert different actions on human 
platelets. Both the P2Y1 and P2Y12 receptors appear to be involved in mediating PSC in 
human platelets (Jagroop et al.,, 2002d; Jagroop et al.,  , 2003).  The channelyzer method 
provides a useful tool to assess the platelet inhibitory action of these drugs (Jagroop et al., 
1996;Jagroop et al., 2000c; Jagroop et al., 2000a; see Appendix A: PSC reference list 
authored by IA Jagroop et al.). 
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CHAPTER 5 
 
 
 
The Effect of Tirofiban on Fibrinogen- 
and Agonist-induced Aggregation and 
Platelet Shape Change 
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5.1 (i) AIM, BACKGROUND AND HYPOTHESIS 
Aim: The aim of this study was to assess if a GPIIb/IIIa receptor antagonist, tirofiban, had 
an effect on fibrinogen- and agonist-induced PSC, an early phase of platelet activation that is 
essentially aspirin resistant.  
Background: It is usual for PAD patients, to be on antiplatelet therapy like aspirin or 
clopidogrel (or even both). However, these patients may be resistant to aspirin and/or 
clopidogrel. It therefore makes sense to consider other antiplatelet drugs that act via other 
receptors. Hence, in this study I investigated the effect of a GPIIb/IIIa receptor antagonist, 
tirofiban, on fibrinogen- and agonist-induced PSC and aggregation. Raised plasma 
fibrinogen levels and platelet hyperactivity have been shown to be linked with vascular 
events. One way to inhibit platelets is to block the platelet GPIIb/IIIa receptor, which binds 
circulating fibrinogen or von Willebrand factor and cross links platelets at the final common 
pathway to platelet aggregation. It is not known if fibrinogen affects PSC in human (or 
animal) platelets. Therefore, I also assessed this process. The use of the GPIIb/IIIa 
antagonists (like tirofiban, abciximab and eptifibatide) has not been as widespread as 
previously forecasted, they appear to have low bioavailability, and have the ability to exert 
partial agonism. This study may lend some evidence as to why that is. 
Hypothesis: My hypothesis was that GPIIb/IIIa antagonists like tirofiban do not affect PSC 
and that this may be a reason for their diminished efficacy.  
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5.1 (ii) INTRODUCTION 
 
There is evidence linking platelet hyperactivity with vascular events (Valgimigli, 
2010; Robless et al., 2003). For example, patients with more activated platelets had a higher 
incidence of myocardial infarction (MI) and early restenosis (1997 no authors listed). 
Platelet activation may also play a role in the pathogenesis of complications after 
percutaneous coronary intervention and stent implantation (Valgimigli et al., 2010; Yip et 
al., 2005). Patients with hyperactive platelets may benefit more from intensive anti-platelet 
therapy as platelet inhibitors significantly reduce the risk of vascular events (Ferguson, 
2006; Robless et al., 2003). 
One way to inhibit platelets is to block the platelet membrane glycoprotein (GP) 
IIb/IIIa receptor, which binds circulating fibrinogen (fib) or von Willebrand factor (vWF) 
and crosslinks platelets as the final common pathway to platelet aggregation (Huang et al.,  
2004). Activated platelets express the integrin αIIb β3 (also known as the activated platelet 
membrane glycoprotein receptor GPIIb/IIIa) on their surface, which binds fib (Kakafika  et 
al.,  2007). Raised plasma fib concentrations increases the risk of vascular events 
(Mikhailidis et al., 1986). Moreover, platelet hyperactivity has also been reported in most of 
the conditions where plasma fib concentrations are increased (Kakafika et al., 2007; 
Mikhailidis et al., 1986; Tsiara et al. 2003).  
  GPIIb/IIIa receptor antagonists are potent inhibitors due to the critical role that fib 
binding plays in platelet aggregation (Huang et al., 2004). To date, the US Food and Drug 
administration have approved 3 GPIIb/IIIa antagonists: abciximab (a chimeric monoclonal 
anti-body 7E3 Fab fragment), eptifibatide (a cyclic heptapeptide based on the KGD amino 
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acid sequence) and tirofiban (a non peptide tyrosine derivative) (Huang et al., 2004; 
Jennings et al., 2002).  
Tirofiban hydrochloride, L-tyrosine-N-(butylsulfonyl)-O-[-4-(4-piperidinylbutyl)] 
monohydrochloride, is a potent and specific fib receptor antagonist, and is approved (under 
the name Aggrastat) for use in the prevention of the progression of unstable angina to MI 
(Bukow et al., 2006; Huang et al., 2004; Jennings et al., 2002) .  
                                                         
Figure.5.1 Molecular structure of tirofiban 
 
Other intra-venous agents directed against the GPIIb/IIIa receptors include 
abciximab, eptifibatide and a non-peptide mimetic, lamifiban (Westerhout et al., 2003). 
Clinical trials including more than 18,000 patients have shown the benefits of intra-venous 
GPIIb/IIIa blockade (Mak et al., 1999a). Overall, at 30 days, 13 fewer deaths or MIs 
occurred for every 1000 patients treated in these trials. This favorable outcome was 
extended to 6 months, resulting in 16 fewer such events per 1000 patients treated. 
Importantly, these benefits were not accompanied by an excessive occurrence in bleeding 
complications or thrombocytopenia. The safety and efficacy of these GPIIb/IIIa antagonists 
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have been evaluated initially in patients undergoing percutaneous coronary intervention. 
Over 20,000 patients were enrolled in 9 major studies of abciximab, eptifibatide and 
tirofiban. The result of all these trials was the widespread use of GPIIb/IIIa antagonists 
(1994; 1997b; 1997a no authors listed).  
In the present study, the effect of tirofiban on spontaneous platelet aggregation 
(SPA), as well as fib-, 5HT- and ADP-induced aggregation, was assessed. Various agonists 
were used alone and in combination.  The rationale was that since ADP is an important 
aggregating agent, and raised plasma fib concentrations increases the risk of vascular 
disease, it would be useful to evaluate the inhibitory effect of tirofiban in this model. Also 
circulating levels of agonists like 5HT or ADP on its own may not have any effect on 
platelets but in combination may produce a synergistic harmful effect (e.g. stimulating 
vascular smooth muscle proliferation and inducing vasoconstriction in atheromatous 
coronary vessels) (Akopov et al., 1992). The effect of tirofiban on a combination of fib and 
ADP at sub-threshold concentrations, was also investigated. Others have shown that optimal 
platelet aggregation occurs between pairs of agonists (e.g. ADP-epinephrine and 
epinephrine-collagen) even when each of the agonists is added to the other at sub threshold 
doses (Razi et al., 2004).  
Another study demonstrated that the platelet surface expression of the functional 
GPIIb/IIIa is required for 5HT release from delta-granules (Gobbi et al., 2006). Therefore, 
the effect of tirofiban on 5HT-induced platelet aggregation was investigated. 
The effect tirofiban on 5HT- and ADP-induced PSC an early phase of platelet 
activation, that precedes aggregation was also measured (Jagroop et al., 1996; Jagroop et 
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al., 2000c; Jagroop et al., 2000a; see Appendix A: PSC reference list authored by IA 
Jagroop et al.,). This work also investigated whether fib alone or in combination with 
another agonist affects PSC. To my knowledge, this has not yet been investigated using a 
high-resolution channelyzer. 
                                                                                                                                                                                                                                                                                                          
5.2 MATERIALS - See Appendix D  
 
 
5.3 METHODS 
5.3.1 Whole Blood Aggregation 
Venous blood was collected and whole blood (WB) aggregation was performed (as 
described in Methods Section, Chapter 2) as in previous studies (Jagroop et al., 1996; 
Jagroop et al., 2002b; Jagroop et al., 2007; Robless et al., 2003). Details of the volunteers 
used in each part of this study are given in the relevant results sections below. The effect of 
tirofiban on SPA was assessed after WB was stirred at specific time points (0, 5, 10, 15 and 
20 min) with the following combinations, saline control/SPA; tirofiban only (50 ng/ml). The 
effect of tirofiban on fib only was also assessed when WB was stirred with fib only, and 
then tirofiban (500 ng/ml) plus fib.  Then aggregation was measured at the same time points 
(0, 5, 10, 15 and 20 min) as above.  
ADP (5 µM)-induced aggregation was also evaluated. WB was then incubated with 
tirofiban (500 ng/ml) for 5 min after which ADP (5 µM) was added and aggregation 
determined at the (0, 5, 10, 15 and 20 min) (see Chapter 2). Briefly, the blood samples were 
placed in siliconised aggregometer cuvettes and stirred using a Teflon-coated magnetic 
stirrer during the experiments. The samples were maintained at 370C in a Chronolog whole 
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blood aggregometer 540 (Coulter Electronics, Luton, Beds, UK) throughout the 
experiments. Blood samples from the aggregometer cuvettes were then presented to the 
Coulter®ACT Diff Analyzer (Coulter Electronics, Luton, Beds, UK) which allows open tube 
analysis and the platelet count determined. The results are expressed as % free platelet 
count. For example, if the baseline count was 300 x109/l and this fell to 200 x109/l at a later 
time then the % free count is 200/300 x 100 = 66.6%.  
The effect of tirofiban on WB aggregation-induced by a combination of agonists at 
sub-threshold concentrations was measured over a specified time period (1, 3, 5, 10, 15 and 
20 min). Thus, saline (control); ADP (1 µM); fib (0.5 g/l); a combination of ADP (1 µM) 
plus fib (0.5 g/l) was assessed. Since lower doses of agonists were used,  the effect of the 
lower dose of tirofiban (250 ng/ml) on this combination by firstly incubating WB with 
tirofiban (250 ng/ml) for 5 min before adding the combination of ADP (1 µM) plus fib (0.5 
g/l) was assessed.  
To observe the effect of tirofiban on 5HT-induced aggregation, 5HT (5 µM) was 
added and aggregation assessed at the several time points (1, 3, 5, 10, 15 and 20 min) as 
previously described (Barradas et al.,, 1994). Then WB was incubated with tirofiban (500 
ng/ml) for 5 min and 5HT (5 µM) was added before measuring aggregation again.    
 
5.3.2 Median Platelet Volume Measurement 
Venous blood collection, preparation of platelet rich plasma (PRP) and details of 
median platelet volume (MPV) measurement in are described in Chapter 2. The number of 
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volunteers used in each experiment is given in the relevant sections below. PRP was 
collected from 7 healthy volunteers, and was incubated with tirofiban (50 - 500 ng/ml) for 3-
5 min without stirring and then either ADP (0.2 –0.4 µM) or 5HT (0.25- 0.5 µM)-induced 
PSC was measured after 30s and 1 min as outlined below. ADP- or 5HT- induced PSC was 
again assessed at the same concentrations but without tirofiban. 
The effect of fib (1 – 8 g/l)-induced PSC with and without tirofiban (125 – 500 
ng/ml) at various time points (between 30 s and 20 min) was also assessed. In addition, 
lower concentrations of fib (0.5 – 1.5 g/l) was used in combination with 5HT (0.25 µM) or 
ADP (0.2 µM). The MPV was assessed (after 30 sec and 1 min), using a Coulter ZM counter 
(electrical impedance method with a 70 µm diameter sampling tube orifice) coupled to a C-
256 channelyzer (Coulter Electronics, Luton, Beds, UK) (as described in Chapter 2, section 
2.4). The specific times for adding agonists and antagonists and were based on preliminary 
experiments and our previous publications (Jagroop et al., 1996; Jagroop et al., 2000c; 
Jagroop et al., 2000a; see Appendix A: PSC reference list authored by IA Jagroop et al.,). 
Moreover, the concentration of agonists and sampling times to obtain a middle range 
response that could be either inhibited or enhanced were also determined in previous studies 
(Jagroop et al., 1996; Jagroop et al., 2000c; Jagroop et al., 2000a; see Appendix A: PSC 
reference list authored by IA Jagroop et al.,). 
  The increase in MPV was taken as representing the PSC. Saline (control) was added 
to samples to match those of the agonist (as 10 - 50 µl volumes) at the same time points. The 
platelet count was monitored throughout the experiment to exclude PRP samples where 
significant (>5%) aggregation occurred. 
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5.3.3 Statistical Analysis and Presentation of Results 
Statistical analysis was performed using GraphPad Prism Version 4 (Graph Pad 
Software, Inc, San Diego, California, USA). Comparisons were carried out using paired t-
tests (or non-parametric tests) Results are expressed as mean and ± SD and a P<0.05 was 
considered significant. The results in the figures are expressed as median percentage free 
platelet count. 
 
 
 
5.4 RESULTS 
 
 
5.4.1 Whole Blood Aggregation 
 
Tirofiban (50 ng/ml) significantly inhibited SPA at all time points (5 to 20 min). 
Table 5.1 shows statistical comparisons and figure.5.1 shows a representative curve of this 
effect.  
The (2 g/l) concentration of fib demonstrated a similar trend of platelet aggregation 
over time as the saline control. In contrast, fib 4 g/l significantly increased platelet 
aggregation after 5 min (P = 0.002), 10 min (P = 0.033) and 15 min (P=0.05, n=8) (see table 
5.2). Tirofiban (500 ng/ml) significantly inhibited the fib (4 g/l)-induced platelet 
aggregation. A similar pattern of aggregation and inhibition of aggregation was observed 
with fib 8 g/l and tirofiban (500 ng/ml) respectively. The addition of tirofiban to WB 
produced aggregation that was even less than that observed with the saline control (table 5.2 
shows statistical comparisons and figure.5.2 is a representative curve of this effect). There 
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was significant inhibition of ADP (5 µM)-induced platelet aggregation by tirofiban (500 
ng/ml) at all time points (see table 5.3). 
A lower concentration of fib (0.5 g/l) demonstrated a similar platelet aggregation 
pattern as the saline control. ADP (1µM)-induced platelet aggregation showed an expected 
transient significant increase in aggregation as compared with the saline control at 1 min and 
3 min (96 ± 5 vs 39 ± 21, P = 0.001 and 92 ± 4 vs 71 ± 17, P = 0.035, respectively). 
 Beyond these sampling times there was aggregation but it was not significant in 
comparison with saline (see figure 5.3). The effect of a very low dose of ADP (1 µM) in 
combination with a very low dose of fib (0.5 g/l) on platelet aggregation followed a similar 
pattern as ADP over time with no significant additive aggregating effect (figure 5.3). 
Tirofiban (250 ng/ml) significantly inhibited platelet aggregation induced by this ADP plus 
Fib combination at all time points to a level that was even better than saline on its own (see 
table 5.4 for statistical analysis). There was an expected increase in 5HT (5 µM)-induced 
aggregation over time in comparison with the saline control. This aggregation was 
significantly inhibited by tirofiban (500 ng/ml) (table 5 shows statistical comparisons). 
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Table 5.1 The Effect of a Lower Dose of Tirofiban (50 ng/ml) on SPA. 
    
 
Time (min) 
 
Saline alone 
(control) 
 
Saline + tirofiban 
 
P value 
 
5 
10 
15 
20 
87 ± 8 
80 ± 14 
71 ± 13 
64 ± 19 
      99 ± 2 
      99 ± 2 
98 ± 2 
98 ± 2 
 0.006 
0.01 
 0.001 
0.005 
 
Results are expressed as mean and ± standard deviation and compare the percentage  
free platelet counts at different times. 7 healthy volunteers were evaluated.  
Spontaneous Platelet Aggregation (SPA, Saline Control). 
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Table 5.2 The Effect of Fibrinogen on SPA, and of Tirofiban  
    on Fibrinogen-induced Platelet Aggregation over Time 
 
 
Time (min) 
 
Saline    vs    Fib 
 
 
Fib     vs   Fib + Tirof 
5 
 
10 
 
15 
 
20 
80 ± 10   vs   66 ± 6 
P = 0.002 
72 ± 15   vs   57 ± 5 
P = 0.03 
68 ± 14   vs   48  ± 10 
P = 0.04 
56 ± 19   vs   45 ± 10 
NS (0.23) 
66 ± 6   vs   86 ± 13 
P = 0.011 
57 ± 5   vs   87 ± 11 
P = 0.0006 
48 ± 10 vs   88 ± 10 
P = 0.0001 
45 ± 10 vs   88 ± 12 
P < 0.0001 
 
Results are expressed as mean and ± standard deviation and compare the percentage free 
platelet count. 8 healthy volunteers were evaluated.  
 
Note: fib = fibrinogen (4 g/l); tirof = tirofiban (500 ng/ml); NS = not significant. 
 SPA = Spontaneous Platelet Aggregation (i.e. saline control) 
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Figure 5.2: The effect of fibrinogen on platelet
aggregation over time.
The representative curve shows the effect of fibrinogen (2 and 4 g/l)
on platelet aggregation over time as compared with saline control. The
inhibition of fibrinogen-induced aggregation by tirofiban (results are
expressed as percentage median free platelet count, n=8).
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Table 5.3 The Effect of Tirofiban on ADP-induced Platelet Aggregation over Time 
 
 
Time (min) 
 
Saline    vs   ADP 
 
ADP     vs   ADP + Tirof 
 
5 
 
10 
 
15 
 
20 
83 ± 11   vs  31± 13 
P = 0.0001 
72 ± 15   vs  30 ± 12 
P = 0.0001 
64 ± 14   vs  31 ± 13 
P = 0.0001 
54 ± 16   vs  34 ± 14 
P < 0.007 
31 ± 13    vs   86 ± 8 
P< 0.0001 
30 ± 12    vs   85 ± 10 
P< 0.0001 
31 ± 13    vs   87 ± 11 
P< 0.0001 
34 ± 14    vs   94 ± 7 
P< 0.0001 
Results are expressed as mean and ± standard deviation and compare the percentage free 
platelet count. 8 healthy volunteers were evaluated 
 
Notes: ADP = adenosine diphosphate (5 µM); tirof = tirofiban (500 ng/ml). 
.  
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Table 5.4 The Effect of Tirofiban on the Combination of ADP plus Fibrinogen. 
 
 
Time (min) 
 
ADP + Fib vs ADP + Fib + Tirof 
 
 
P = Value 
 
1 
3 
5 
10 
15 
20 
 
38 ± 13 vs 90 ± 4 
68 ± 16  vs  92 ± 5 
70 ± 12  vs  92 ± 2 
68 ± 11  vs  90 ± 5 
66 ± 12 vs 93 ± 5 
65 ± 11 vs 94 ± 6 
 
<0.0001 
0.011 
0.003 
0.005 
0.002 
0.002 
 
Results show platelet aggregation for ADP (1 µM) plus fib (0.5 g/l) combination, compared 
with the effect of tirofiban (250 ng/ml) on this combination of agonists over time. 
Results are expressed as mean and ± standard deviation and compare the percentage free 
platelet count. 7 healthy volunteers were evaluated.  
 
Notes: ADP = adenosine diphosphate; fib = fibrinogen; tirof = tirofiban. 
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Fig 5.3: The effect of tirofiban on ADP+Fib-induced platelet 
          aggregation
The curves show the effect of ADP (1 µm) only and fibrinogen (0.5 g/l) only on
platelet aggregation, in comparison with a combination of ADP (1 µm) together
with fibrinogen (0.5 g/l). Then the effect of tirofiban (250 ng/ml) on this
combination of ADP plus fibrinogen. Results are expressed as % median free
platelet count (n=7).
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Table 5.5 The Effect of Tirofiban on 5HT-induced Platelet Aggregation over Time 
 
 
Time (min) 
 
Saline   vs   5HT 
 
5HT   vs  Tirof + 5HT 
 
 
1 
 
 
3 
 
 
5 
 
 
10 
 
 
15 
 
 
20 
 
96 ± 5    vs    82 ± 7 
P = 0.002 
 
92 ± 5    vs    75 ± 9 
P = 0.004 
 
87 ± 8    vs    71 ± 10 
P = 0.014 
 
80 ± 13   vs   66 ± 11 
P = 0.04 
 
71 ± 13   vs   63 ± 12 
P= NS (0.18) 
 
64 ± 20   vs   60 ± 12 
P= NS (0.56) 
 
 
82 ± 7  vs  85 ± 10 
P= NS (0.64) 
 
75 ± 9  vs  85 ± 7 
P= 0.02 
 
71 ± 10  vs  86 ± 8 
P= 0.01 
 
66 ± 11  vs  86 ± 10 
P= 0.02 
 
63 ± 12  vs  87 ± 9 
P = 0.006 
 
60 ± 12  vs  86 ± 8 
P= 0.005 
 
Results show the effect of 5HT (5 µM)-induced platelet aggregation compared with saline, 
and the effect of tirofiban (500 ng/ml) on 5HT (5 µM)-induced platelet aggregation over 
time.  Results are expressed as mean and ± standard deviation and compare percentage free 
platelet count. 7 healthy volunteers were evaluated. 
 
Notes: serotonin = 5HT; tirof = tirofiban; NS = not significant 
 
 
 
 
 
 
 
 174 
 
5.4.2 Median Platelet Volume Measurement 
There was the expected significant increase in MPV (fl) when ADP-induced PSC 
was compared with saline control (mean and ± SD: 5.79 ± 0.55 vs 6.09 ± 0.55, P = 0.0001, n 
= 7). Tirofiban (50 – 500 ng/ml) had no significant inhibitory effect on this increase in PSC 
(6.09 ± 0.55 vs 6.12 ± 0.55, P = NS, n = 7).  
The effect of tirofiban on 5HT-induced PSC followed the same trend as above. Thus, 
5HT (6.12 ± 0.49 fl) vs saline control (5.79 ± 0.57 fl) demonstrated a significant increase in 
MPV (P = 0.0004, n = 7). However, tirofiban (50 – 500 ng/ml) did not show any inhibitory 
effect on this response (6.12 ± 0.49 vs 6.14 ± 0.50, P = NS, n = 7).  
The effect of fib (0.5 – 2 g/l) on MPV at various time points (between 1 min and 20 
min) was also evaluated. However, there was no apparent change in MPV (n = 7) when 
compared with saline controls (a representative result from 1 subject is shown below). Thus, 
MPV at the given time points are illustrated for saline control e.g. 1 min, 6.18 fl; 3 min 6.12 
fl; 5 min, 6.18 fl; 10 min, 6.06 fl; 15 min, 6.06 fl and 20 min 6.06 fl. Also the MPV are 
shown for fib (2 g/l) at the same time points 1min, 6.12 fl; 3 min 6.12 fl; 5 min, 5.99 fl; 10 
min, 5.93 fl; 15 min, 6.12 fl and 20 min 6.12 fl. Also, there was no additive MPV effect 
when fib (0.5 – 1.5 g/l) was used in combination with 5HT (0.25 µM) or ADP (0.2 µM) 
(results not shown). 
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5.4 DISCUSSION 
 
PSC is an early phase of platelet activation that precedes platelet aggregation. The 
technique used in this work to assess PSC is highly sensitive (resolution 0.07 fl) (Jagroop et 
al., 1996; Jagroop et al., 2000c; Jagroop et al., 2000a; see Appendix A: PSC reference list 
with IA Jagroop) as compared with others who assessed platelet volume with less sensitive 
methods (Maurer-Spurej et al., 2001; Wilde et al., 2000). This is why we used our high-
resolution technique of measuring MPV to observe if fib can affect PSC. In this study, fib 
(0.5 – 2 g/l) had no effect on PSC at various time points (between 1 and 20 min) which was 
in agreement with the findings of others (Negrescu et al., 1995). 
 Also, ADP and 5HT-induced PSC, was not inhibited by tirofiban (using a range of 
doses 50 – 500 ng/ml) a potent and specific GPIIb/IIIa receptor antagonist. This work 
therefore, suggests that fib has no effect on PSC and also that tirofiban does not inhibit PSC. 
In support of our findings, another study demonstrated that when platelets were pre-treated 
with EGTA or pre-incubated with RGDS (a fibrinogen receptor antagonist) to prevent the 
activation of the fibrinogen receptor (the integrin αIIbβ3), PSC induced by the peptide 
YFLLRNP still occurred (Negrescu et al., 1995). The technique they used to measure PSC 
in washed platelets was by recording the light transmission (Negrescu et al., 1995).  
In the work carried out here, the technique of measuring PSC is carried out using 
PRP, and its preparation may influence various aspects of platelet function (Storey et al., 
1998). The choice of anti-coagulant is also important. Citrate anti-coagulation was shown to 
demonstrate falsely high estimates of efficacy of eptifibatide due to the lowering of ionized 
calcium in vitro. Storey et al. also verified that eptifibatide was markedly more effective 
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both in whole blood and in PRP (P<0.0005), when citrate was used as an anti-coagulant 
rather than hirudin, an anti-coagulant that is a direct thrombin inhibitor and maintains 
physiological calcium ion levels (Storey  et al., 1998)   
Platelet agonists (like ADP and 5HT) may amplify platelet activation by binding to 
specific platelet membrane receptors and signalling the conformational change of 
GPIIb/IIIa, which then becomes an active receptor for fib initiating aggregation. It would 
therefore be an advantage to inhibit the effect of fib binding to the GPIIb/IIIa receptor, using 
a specific antagonist like tirofiban.  
This GPIIb/IIIa receptor antagonist reduced the risk of ischaemic complications in 
patients with unstable angina/non-Q-wave MI in patients undergoing PCI against a 
background of heparin and aspirin (Song et al., 2007). With this in mind, we observed the 
effect of tirofiban on fib-induced platelet aggregation. On its own fib showed significant 
platelet aggregation compared with the saline control. Increased circulating levels of fib, is 
an emerging predictor of vascular events. Fib levels are raised in patients with vascular 
disease (Corrado et al., 2010; Stefanadi et al., 2010; Kakafika et al., 2007; Paraskevas et al., 
2007). Fib also plays an important role in platelet aggregation by linking activated platelets 
(Jennings et al., 2009). It is therefore advantageous to inhibit fib-induced platelet 
aggregation. 
GPIIb/IIIa receptor antagonists are very potent inhibitors due to the critical role fib 
binding plays in platelet aggregation (Huang et al., 2004). When administered intra-
venously these drugs are effective as adjuvant therapy in PCI and in ACS (1994; 1997a; 
1997b no authors listed). The approval of tirofiban covers conservative treatment of MI and 
 
 
 
 
 
 
 177 
unstable angina, as well as PCI intervention (Bukow et al, 2006). Tirofiban has been shown 
to safe and effective in patients with acute coronary syndrome. Although, tirofiban when 
compared with abciximab demonstrates similar efficacy, its clinical use has not been as 
widespread as initially forecasted (De et al., 2011;Saucedo, 2010;Valgimigli et al., 2010).  
In this study, it was shown that tirofiban significantly decreased the aggregating 
effect of fib. However, it should be noted that GPIIb/IIIa antagonists are qualitatively 
different from classical anti-platelet agents, such as aspirin or clopidogrel. They do not 
inhibit platelet activation (i.e. intra-platelet signal generation or conduction) but primarily 
act outside the platelet by competing with ligand binding that is essential for platelet 
bridging and aggregate formation.  
The concentration of tirofiban used to achieve complete inhibition of fib was 500 
ng/ml. Mukherjee et al. (Mukherjee et al., 2007) stated that a lower dose of tirofiban (10 
µg/kg bolus followed by 0.15 µg/kg/min infusion was inferior to the standard dose of 
abciximab in patients with PCI. This was possibly due to insufficient platelet inhibition by 
this low dose. Thus, when a high-bolus dose of tirofiban 25 µg/kg bolus was administered 
followed by the standard infusion, tirofiban was as effective as abciximab with comparable 
safety (Mukherjee et al., 2007). Storey et al. also showed that higher concentrations (100-
1500 nmol/L) of GPIIb/IIa antagonists (eptifibatide, M0852 and GR144053) were required 
to inhibit platelet aggregation in whole blood compared with PRP turbidimetry (Storey et 
al., 1998). That is to say that a 3-fold higher concentration of eptifibatide was required to 
inhibit ADP-induced microaggregate formation (aggregation in whole blood or PRP) than 
was required to inhibit macroaggregate formation (PRP turbidimetry) (Storey et al., 1998).  
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This may explain why in my preliminary experiments with agonists-induced 
aggregation, lower doses (50 ng/ml) of tirofiban, only partially inhibited platelet 
aggregation. Thus, it was decided that higher concentrations (250-500 ng/ml) of tirofiban 
should be used. However, tirofiban at this lower concentration (50 ng/ml) did significantly 
inhibit SPA (table 5.1 & figure 5.1).  At the higher concentrations of tirofiban (250-500 
ng/ml) we observed complete inhibition of ADP as well as 5HT-induced platelet 
aggregation, to a level even better than the saline baseline value (table 5.3 and 5.5). In 
addition, tirofiban was effective in inhibiting platelet aggregation induced with a 
combination of agonists (ADP plus fib, table 5.4).  
Despite being as potent as their intra-venous counterparts, the oral GPIIb/IIIa 
inhibitors showed no benefit or even increased mortality in clinical trials. Furthermore, most 
GPIIb/IIIa antagonists have the ability to exert partial agonism. In the presence of high drug 
levels, this is not a problem, however the low trough levels with oral inhibitors can lead to 
increased platelet aggregation. There are a number of possible reasons for their failure, 
including low bioavailability that led to a large peak-trough difference (Cox, 2004). This 
rational supports the need to achieve higher circulating levels of GPIIb/IIIa. Furthermore, in 
a clinical setting, despite the administration of GPIIb/IIIa inhibitor the platelets may be 
‘primed’ (since PSC can occur). Therefore, inhibiting PSC (e.g. by administering aspirin, 
clopidogrel or both drugs together with a GPIIb/IIIa inhibitor) may be relevant. In this 
context, we previously evaluated the effect of ASA (75 mg/day), clopidogrel (75 mg/day) 
and both anti-platelet drugs on platelet function in patients with PAD. There was a 
significant decrease on ADP-induced aggregation after clopidogrel but not after taking ASA. 
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Dual therapy significantly decreased SPA, which was not significantly altered by either 
monotherapy. The same phenomenon was observed with 5HT-induced aggregation 
(Jagroop et al., 2004). 
The risk/benefit ratio of GPIIb/IIIa antagonists may be due to its differential effects 
on microaggregation and macroaggregation. It appears that it may be easier to inhibit the 
formation of larger aggregates of platelets (macroaggregates) than to prevent pairing of 
platelets and formation of smaller aggregates (micro-aggregates) (Storey et al., 1998). The 
hypothesis is that different GPIIb/IIIa antagonists will have different ratios of affinities for 
the resting receptor and the activated receptor. Also, adhesive proteins (other than fib) may 
play an important role in macroaggregation and finally a variable inhibition of the release 
reaction by GPIIb/IIIa antagonists as a result of outside-in signaling may have a greater 
effect on in vitro macroaggregation. Moreover, the differences in the outcome of studies 
looking at the effect of GPIIb/IIIa antagonists on the incidence of death and MI, may relate 
to the levels of these drugs on inhibition of microaggregation (Storey et al., 1998). 
In these studies, whole blood platelet aggregation was used, as it offers rapid results 
without imposing too many changes on the platelet population. Others have assessed platelet 
aggregation using PRP. There is however, some controversy as to whether PRP should be 
platelet count adjusted using PPP or if it is better to use native PRP. Moreover, the 
adjustment of PRP using PPP may falsify results. PPP is prepared by vigorous centrifugation 
where physiological agonists are released from platelets (remaining after removal of the 
PRP) activated by the high shear stress. Furthermore, even the ‘slower’ centrifugation for 
PRP preparation can activate platelets. Thus, adjusting PRP with this PPP may affect platelet 
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aggregation measurements. In contrast, Mani H et al. have demonstrated that there were no 
significant differences in the maximum platelet aggregation response when using either 
native PRP or adjusted PRP from healthy subjects and patients on anti-platelet treatment 
(Mani et al., 2005). In fact, the variation in the results was much larger when adjusted PRP 
was used. Moreover, in another study (Linnemann et al., 2008) where healthy subjects were 
compared with patients on anti-platelet therapy, the variability of aggregation in adjusted 
PRP in the subgroup of healthy subjects ranged from 9.2 - 95.3% (5th to 95th percentile). 
This is relative to 77.6 - 95.5% in the non-adjusted PRP when determining aggregation to 
arachidonic acid 0.5 mg/ml.  Thus, the time consuming process of PRP adjustment may not 
be necessary for platelet aggregation measurements.  
From this study, it is concluded that tirofiban significantly inhibited agonists (ADP, 
5HT)-induced platelet aggregation. This GPIIb/IIIa receptor antagonist is effective in 
inhibiting SPA as well as platelet aggregation induced by a combination of agonists (fib and 
ADP). That is to say, that tirofiban appears to be non-specific as it was effective in 
inhibiting aggregation (a later phase of platelet activation) induced by not only fib but also 
other agonists used alone or even in combination. In addition, it was effective in reducing 
even a very high concentration of fib (8 g/l, results not shown). We have also shown that 
tirofiban does not have an effect on PSC an early phase of platelet activation. (Jagroop et 
al., 2008).  
It is possible that in a clinical setting, despite the administration of a GPIIb/IIIa 
inhibitor the platelets may be ‘primed’ (at PSC) therefore maintaining a high degree of 
inhibition of the later stages of platelet activation may be very relevant. Further studies are 
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needed to reconfirm the findings, where fib does not affect PSC, and that in this model 
tirofiban does not inhibit agonist-induced PSC. It is difficult to say exactly what the clinical 
relevance of this is.  
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CHAPTER 6 
 
 
 
A New Rapid Method to Measure Human 
Platelet Cholesterol: A Pilot Study 
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6.1 (i) AIMS, BACKGROUND AND HYPOTHESIS 
Aims: The aim of this study was to develop a rapid, safe, reproducible and simple method to 
measure platelet cholesterol (PC). I also aimed to determine if PC correlated with circulating 
lipid levels. 
Background: Platelet hyperactivity has been linked to increased PC. The rational is that a 
rise in PC may cause increased platelet responses since cholesterol affects platelet 
membrane fluidity. Increased PC may also modulate the conformational state of platelet 
receptors, thereby indirectly affecting the effectiveness of antiplatelet drugs. Moreover, PC 
can be used as a marker of ‘tissue’ cholesterol. It is however, impractical to measure ‘tissue’ 
cholesterol, but, platelets are easily accessible. So far, the methods used to assess PC were 
too cumbersome. They involved a complex extraction process with the use of toxic and 
potentially harmful chemicals and an overnight incubation, making it time consuming and 
thus not suitable for serial measurements. Using the more complex method to measure PC, 
others have shown that lovastatin decreased plasma and PC levels and normalised elevated 
platelet fluidity and aggregation in hypercholesterolaemic patients. Thus, the development 
of a simpler and rapid method to measure PC would make studies like this easier to perform. 
It would be of interest to see if PC is affected before and after treatment with statins in 
hypercholesterolaemic patients, using my new method to assess PC.  
Hypothesis: The hypothesis is that using a rapid PC method we will be able to evaluate 
platelet receptor function (e.g. P2Y1, P2Y12 and GPIIb/IIIa) before and after treatment with 
statins. We will then be able to relate these findings to PC levels.  
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6.1 (ii) INTRODUCTION 
Platelets have been implicated in the pathogenesis of cardiovascular disorders, 
including unstable angina, stroke, myocardial infarction and sudden cardiac death 
(Alexander et al., 2010; Garg et al., 2010; Sakhuja et al., 2010). We suggest that platelet 
cholesterol (PC) may be another indicator of “tissue” cholesterol status in patients with 
vascular disease. However, the methods available so far to measure PC, involve a complex 
extraction process and are time consuming and therefore not suitable for multiple 
measurements. There are also safety issues since this process involves the use of flammable 
and potentially harmful chemicals (like chloroform and methanol) (Biro et al., 2005; Bligh 
et al., 1959; Garcia-Guerra et al., 1998). For example, a procedure for the isolation of 
glycoproteins from human platelet plasma membrane involves the differential extraction of 
platelet membranes using Triton-X, SDS solubilizaton of the 4% Triton-X supernatant, 
zonal centrifugation in a sucrose density gradient, and finally the preparative high-
performance size exclusion chromatography. It should also be noted that Triton-X is 
damaging as well as dangerous to the environment. Moreover, Triton-X may contain 
dioxane which is a probable carcinogen, toxic and harmful by inhalation (Biro et al., 2005; 
Bligh et al., 1959; Garcia-Guerra et al., 1998).  Ethylene oxide may also be present in 
Triton-X, this too is a carcinogen, mutagen and reproductive hazard. Even moderate levels 
(</> 0.1%) may rapidly be fatal if inhaled (Bligh et al., 1959; Poss et al., 2003).  Therefore, 
developing a simpler and safer method to measure PC is important, especially if large 
numbers of samples need to be analyzed.  
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In the present study, it was investigated if there a correlation between PC and 
circulating low density lipoprotein cholesterol (LDL-C) levels exists. LDL-C affects the 
function of blood cells, which play an important role in atherosclerosis and its complications 
(Steinbrecher et al., 1990). For example, LDL-C may influence the aggregation of isolated 
platelets (Freire de et al., 2007; Naseem et al., 1997; Vlasova, 2000). Platelets possess 
receptors for plasma lipoproteins (oxidised and native LDL-C) (Bochkov et al., 1995; 
Pedreno et al., 1994) and the binding of LDL-C to these receptors induces a cascade of 
intra-cellular biochemical reactions resulting in platelet activation (Block et al., 
1988;Bruckdorfer, 1989). Moreover, the lipid composition of platelets membranes is known 
to affect platelet activity (Kitagawa et al., 1985). It has been shown that an excess in PC 
results in platelet hyperactivity, and that there is a correlation with increased levels of PC 
and a decrease in plasma membrane fluidity (Padmavathi et al., 2010; Shattil et al., 1976).  
The aim of the study in this chapter, was to develop a simplified method to measure 
PC and assess if  there is a correlation between PC and LDL-C, high-density lipoprotein 
(HDL-C), LDL-C/HDL-C ratio, triglycerides (TG), non-HDL-C (TC minus HDL-C) and 
serum total cholesterol TC. 
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6.2 METHODS  
 
6.2.1 Selection of Subjects and Collection of Blood 
The main study population consisted of 47 healthy subjects (23 male; 24 female; 
mean age 37 ± 9 years). No drugs affecting platelet function were taken in the 8 days 
preceding blood sampling. All subjects participated after giving their informed consent. The 
study was approved by the University College London Ethics Committee. Whole blood was 
drawn by venepuncture after an overnight fast. Blood was obtained from an antecubital vein 
using a 21G needle with minimum stasis (as described in Chap 2). 
 
6.2.2 Serum Lipid Analysis 
For the determination of serum lipid analysis, 5 ml blood was collected in a serum 
gel tube, allowed to clot and then centrifuged (2,000 x g, 15 min at 40C) collecting the 
supernatant for analysis of serum TC, LDL-C, TG and HDL-C using a ‘Roche Modular P’ 
system and the associated kits (Roche Diagnostics, Indianapolis, USA). All our lipid assays 
participate in The United Kingdom National External Quality Assessment Service (UK 
NEQAS) which provides a comprehensive worldwide service that enables laboratories to 
fulfil quality goals.  UK NEQAS comprises a network of schemes operating from a number 
of centers based at major hospitals, research institutions and universities throughout the UK.  
The services cover qualitative and interpretative investigations in clinical chemistry along 
with a variety of other disciplines.  
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6.2.2.1 Serum HDL-C Measurement  
In this study, an automated method for the direct determination of serum HDL-C 
based on polyethylene glycol (PEG)-modified enzymes and dextran sulphate, was used. 
When cholesterol esterase and cholesterol oxidase enzymes were modified by PEG, they 
showed selective catalytic activities towards lipoprotein fractions, with the activity 
increasing in the order: LDL-C < very low density lipoprotein cholesterol = chylomicrons < 
HDL-C (Friedewald et al., 1972).  
In the presence of Mg2+ ions, dextran sulphate selectively formed water soluble 
complexes with LDL-C, VLDL and chylomicrons which were resistant to PEG-modified 
enzymes. The cholesterol concentration of HDL-C was determined enzymatically by 
cholesterol esterase and cholesterol oxidase coupled with PEG to the amino groups. 
Cholesterol esters were broken down quantitatively into free cholesterol and fatty acids by 
cholesterol esterase. In the presence of oxygen, cholesterol was oxidized to Δ4-cholestenone 
and hydrogen peroxide. With the presence of peroxidase, the hydrogen peroxide generated 
reacted with 4-amino-anti-pyrine and HSDA (sodium N-(2-hydroxy-3-sulfopropyl)-3,-5-
dimethoxyaniline and formed a purple-blue dye. The colour intensity of this dye was 
directly proportional to the cholesterol concentration and was measured photometrically 
(Roche Modular analyzer). 
 
6.2.2.2 Serum TG Measurement 
TG was determined by a method based on using a lipoprotein lipase from 
microorganisms for the rapid and complete hydrolysis of triglycerides to glycerol, followed 
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by oxidation to dihydroxyacetone phosphate and hydrogen peroxide. The hydrogen peroxide 
produced then reacted with 4-aminophenazone and 4-chlorophenol under the catalytic action 
of peroxidase and formed a red dyestuff. The colour intensity of the red dyestuff formed was 
directionally proportional to the triglyceride concentration and was measured 
photometrically (Roche Modular analyzer). 
 
6.2.2.3 TC Measurement  
The method to measure serum TC was based on the determination of Δ4-
cholestenone after enzymatic cleavage of the ester by cholesterol esterase, conversion of 
cholesterol oxidase, and subsequent measurement by the Trinder reaction of the hydrogen 
peroxide formed. Optimisation of the ester cleavage (>99.5%), allowed standardisation with 
primary and secondary standards and a direct comparison with reference methods. 
Cholesterol was determined enzymatically using cholesterol esterase and cholesterol 
oxidase. Cholesterol esters were cleaved by the action of cholesterol esterase to yield free 
cholesterol and fatty acids. Cholesterol was converted by oxygen by cholesterol oxidase to 
cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide created formed a red 
dyestuff by reacting with 4-aminophenazone and phenol under the catalytic action of 
peroxidase. The colour intensity was directionally proportional to the concentration of 
cholesterol and was determined photometrically (Roche Modular analyzer) (test range 0.08 
to 20.7 mmol/l).  
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6.2.2.4 Serum LDL-C Measurement 
LDL-C was estimated by the Friedewald equation (Friedewald et al., 1972): 
LDL-C =   TC – HDL-C – TG (mmol/l)/2.2 
 
This equation (Friedewald et al., 1972) is not valid at TG concentrations (>4.5 
mmol/l) or non-fasting samples containing chylomicrons.  
 
6.2.3 Blood Collection and Platelet Preparation for PC Measurement 
A further 9 ml of blood was also collected in polystyrene tubes containing 3.8% tri-
sodium citrate (9 parts blood to 1 part citrate) for the analysis of PC. This citrated sample 
was gently inverted to allow mixing without disrupting the platelets. It was then centrifuged 
at x150 g for 15 min (IEC Centra-7R refrigerated centrifuge; International equipment 
company, USA) to prepare platelet rich plasma (PRP). PRP was separated using a plastic 
Pasteur pipette to gently aspirate the top layer avoiding the ‘buffycoat’ and the red cells (see  
chapter 2, general methods). The PRP volume (ml) and count (109/L) was measured (Coulter 
Counter Act diff) and recorded as this result was needed for the final calculation of the PC. 
The PRP was placed into ‘conical bottomed’ plastic tubes and again centrifuged at 300 g for 
30 min at 40C. The platelet poor plasma (PPP) was poured off leaving a platelet pellet which 
was resuspended in 1 ml saline and then transferred to an Eppendorf tube.  
Platelet membrane disruption was achieved in 2 steps. Firstly, the 1 ml saline 
solution containing the platelet pellet was put through 2 freeze (at -200C) and thaw (room 
temperature) cycles. Then it was re-suspended using a whirlimixer. The Eppendorf tube 
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containing the ‘re-suspended pellet’ was then kept on crushed ice (to prevent the sample 
from heating up) and sonicated for 3 cycles, each for 10 sec, at 30 amplitude microns using a 
probe Sonicator (M.S.E. Soniprep, Crawly, UK). This was based on previous experiments 
where platelet membrane disruption was achieved to allow 5HT release (Fawcett  and 
Jagroop et al., 1998; Frampton and Jagroop et al., 2006). It was important to resuspend the 
pellet in the smallest possible volume of saline that would allow a sonication process, but 
will also be concentrated enough to allow platelet cholesterol measurement. During this 
sonication process care was taken to prevent ‘froth’ formation but to still obtain a ‘clear 
pellet solution’ (Fawcett and Jagroop et al., 1998; Frampton and Jagroop et al., 2006) that 
could be used for the analysis PC. 
 
6.2.3.1 PC Measurement 
Platelet cholesterol (PC) measurement was based on an enzymatic colorimetric test. 
The clear pellet solution (as prepared above) was added to a solution ‘R1’ (CHOL, 
cholesterol CHOD-PAP; Roche Diagnostics, Indianapolis, IN, USA). Cholesterol was 
determined enzymatically using cholesterol esterase and cholesterol oxidase. Cholesterol 
esters were cleaved by the action of cholesterol esterase to yield free cholesterol and fatty 
acids. Cholesterol was converted by cholesterol oxidase to cholest-4-en-3-one and hydrogen 
peroxide. The hydrogen peroxide created formed a red dyestuff by reacting with 4-
aminophenazone and phenol under the catalytic action of peroxidase. The color intensity 
was directly proportional to the concentration of cholesterol and was determined 
photometrically (Roche Modular P system). 
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6.2.4 Repeatability 
To determine the repeatability (i.e. corresponding to within-run precision) of this PC 
method, 3 healthy subjects were selected (2 males, 1 female). Blood was collected and 
prepared for PC measurement (as described below). 20 successive PC measurements were 
carried out under the same conditions on the same day.  
 
6.2.5 Reproducibility 
To determine the closeness of agreement between results of measurements 
performed under changed conditions, in this case, time (i.e. corresponding to between-run 
precision), 2 subjects were selected (1 male and 1 female). Blood was collected and 
prepared for PC measurement on 8 different days over a period of 2 months.   
 
6.2.6 Statistical Analysis  
Results are expressed as mean and ± SD. Correlations were assessed using non-
parametric tests (Spearman, correlation coefficient). Significance was considered as P<0.05 
(two-tailed). 
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 6.3 RESULTS 
 
6.3.1 Repeatability of PC method 
The within-run precision of PC carried out on 3 subjects (20 times each) showed a 
mean coefficient of variation (CV) of 4.8% (4.2, 4.6 and 5.5%, respectively, for each 
subject). 
 
6.3.2 Reproducibility of PC method 
The between-run precision of PC was carried out on 2 subjects and assessed on 8 
different days over 2 months. For subject 1, the PC method measured a CV of 8.9 % with a 
mean of 426 ± 38 µmol/1012 platelets. The CV of LDL-C was 7.5% with a mean of 3.5 ± 0.3 
mmol/l. For subject 2, the PC method showed a CV of 8.1% with a mean of 371 ± 30 
µmol/1012 platelets. For the LDL-C the CV was 5.6% with a mean of 3.6 ± 0.2 mmol/l.  
 
6.3.3 The Reportable Range PC Method  
The range observed with our PC method was between 173 – 830 µmol/1012 platelets. 
 
6.3.4 Study Population Selection 
The study population (n = 47) was split into 2 groups: Group 1: LDL-C < 2.6 mmol/l 
(n = 22) and Group 2: LDL-C > 2.6 mmol/l (n = 25). These LDL-C limits are those 
recommended by the National Cholesterol Education Program (NCEP) Adult Treatment 
Panel III (ATP III) (Grundy et al., 2004;Smith, Jr. et al., 2006)  
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Table 6.1 The Lipid Profiles of all Subjects, Categorized into 2 Groups 
 
  
LDL-C < 2.6 (mmol/l) 
(Group 1, n=22) 
 
Mean ± SD 
 
LDL-C > 2.6 (mmol/l) 
(Group 2, n=25) 
 
Mean ± SD  
 
 
LDL-C 
 
 
1.93 ± 0.36 
 
3.61 ± 0.73 
 
HDL-C 
 
 
1.64 ± 0.45 
 
1.33 ± 0.49 
 
LDL-C/HDL-C 
 
 
1.24 ± 0.54 
 
2.89 ± 1.29 
 
TG 
 
 
1.18 ± 0.77 
 
1.44 ± 0.67 
 
non-HDL-C 
 
 
2.51 ± 0.48 
 
4.32 ± 0.85 
 
TC 
 
 
4.15 ± 0.48 
 
5.65 ± 0.81 
 
Results are expressed as mean ± SD for LDL-C (mmol/l); HDL-C (mmol/l); LDL-C/HDL-C 
ratio; TG (mmol/l); non-HDL-C (mmol/l) and TC (mmol/l). Subjects with LDL-C <2.6 
mmol/l (Group 1, n = 22; 6 male; 16 female; mean age 34 years) as well as subjects with 
LDL-C > 2.6 mmol/l (Group 2, n=25; 17 male; 8 female; mean age 39 years) are listed. 
 
LDL-C = low density lipoprotein cholesterol (mmol/l) 
HDL-C = high density lipoprotein (mmol/l)  
TG = triglycerides (mmol/l) 
TC = total cholesterol (mmol/l) 
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6.3.4.1 Group 1 (LDL-C < 2.6 mmol/l)  
In Group 1 (LDL-C < 2.6 mmol/l, n = 22, 6 male, 16 female, mean age 34 years) the 
mean PC was 412 ± 147 µmol/1012 platelets with a median and of 388 (173 – 830 µmol/1012 
platelets). There was no significant correlation between PC and LDL-C (1.93 ± 0.36 
mmol/l), HDL-C (1.64 ± 0.45 mmol/l), LDL-C/HDL-C (1.24 ± 0.54 mmol/l), TG (1.18 ± 
0.77 mmol/l), non-HDL-C (2.51 ± 0.48 mmol/l) or TC (4.15 ± 0.48 mmol/l). The mean 
value for lipid variables were: LDL-C 1.93 ± 0.36, HDL-C 1.64 ± 0.45, LDL-C/HDL-C 1.24 
± 0.54, TG 1.18 ± 0.77, non-HDL-C 2.51 ± 0.48 and TC 4.15 ± 0.48 mmol/l. 
 
6.3.4.2. Group 2 (LDL-C > 2.6 mmol/l)  
In group 2, (LDL-C > 2.6 mmol/l, n = 25, 17 male, 8 female, mean age 39 years) the 
mean PC was 377 ± 120 µmol/1012 platelets. There was a positive correlation (rs = 0.45, P = 
0.02) between PC and LDL-C. There was also a positive correlation between PC and LDL-
C/HDL-C (rs = 0.45; P = 0.02), PC and TG (rs = 0.43, P = 0.03) and PC and non-HDL-C (rs 
= 0.53, P = 0.007). There was no significant correlation between PC and HDL-C (rs = -0.31) 
or between PC and TC (rs = 0.34). These results are illustrated in figures 6.1-6.4). The mean 
value for lipid variables were: LDL-C 3.61 ± 0.73, HDL-C 1.33 ± 0.49, LDL-C/HDL-C 2.89 
± 1.29, TG 1.44 ± 0.67, non-HDL-C 4.32 ± 0.85 and TC 5.65 ± 0.81 mmol/l. 
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Table 6.2 Statistical Analysis for Subjects with LDL-C > 2.6 mmol/l 
 Spearman  rs P  
 
PC 
vs 
LDL-C 
 
0.45 
 
0.02 
PC 
vs 
LDL-C/HDL-C  
 
0.45 
 
 0.02 
PC 
vs 
TG 
 
0.43 
 
 0.03 
PC 
vs 
non-HDL-C 
 
0.53 
 
 
0.007 
PC 
vs 
HDL-C  
 
-0.31 
 
NS (0.13) 
 
PC 
vs 
TC  
 
0.34 
 
NS (0.09) 
 
 
Results show statistical analysis (non-parametric correlation, Spearman, two-tailed) for 
subjects with LDL-C > 2.6 mmol/l (n=25). Correlations were carried out for PC (µmol/1012 
platelets) with LDL-C (mmol/l); LDL-C/HDL-C ratio; TG (mmol/l); non-HDL-C (mmol/l) 
and with HDL-C (mmol/l) and TC (mmol/l). 
 
Platelet cholesterol (PC, µmol/1012 platelets)  
LDL-C = low density lipoprotein cholesterol (mmol/l) 
HDL-C = high density lipoprotein (mmol/l)  
TG = triglycerides (mmol/l) 
TC = total cholesterol (mmol/l) 
ns = non significant 
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Figure 6.1 The relationship between PC and LDL-C
The curve shows the relationship between platelet cholesterol (PC,
µmol/1012 platelets) and low density lipoprotein cholesterol (LDL-C,
mmol/l). Spearman correlation coefficient = 0.45; P = 0.02; n = 25.
The  dashed lines represent 95% Confidence Intervals (CI).
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Figure 6.2 The relationship between PC and
               LDL-C/HDL-C ratio
The curve shows the relationship between platelet cholesterol (PC,
µmol/1012 platelets) and low density lipoprotein cholesterol/high
density lipoprotein cholesterol ratio (LDL-C/HDL-C). Spearman
correlation coefficient = 0.45; P = 0.02; n = 25. The dashed lines
represent 95% Confidence Intervals (CI).
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Figure 6.3 The relationship betwen PC (µmol/1012 platelets)
    and TG (mmol/l)
The curve shows the relationship between platelet cholesterol (PC,
µmol/1012 platelets) and Triglycerides (TG, mmol/l). Spearman
correlation coefficient = 0.43; P = 0.03; n = 25. The dashed lines
represent 95% Confidence Intervals (CI).
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Figure 6.4 Relationship between PC (µmol/1012 platelets) and
non-HDL-C (mmol/l)
The curve shows the relationship between platelet cholesterol (PC
µmol/1012 platelets) and non-high density lipoprotein cholesterol
(non-HDL-C, mmol/l). Spearman correlation coefficient = 0.53; P
= 0.007; n=25. The dashed lines represent 95% Confidence
Intervals (CI).
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Figure.6.5: Pre- and Post-drug treatment of PC and LDL-C.
The graphs show pre- and post-drug treatment (thyroid hormone therapy) of platelet
cholesterol (PC, µmol/1012 platelets) and low-density-lipoprotein-cholesterol
(LDL-C,mmol/l) in a hypothroid subject. PC was decreased by 34.2% (720 to
474mmol/1012 platelets) and LDL-C was decreased by 68.9% (5.4 to 2.9 mmol/l)
after six months of drug therapy.
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6.3.5 Pre- and Post-thyroid Hormone Replacement Treatment  
  The results of the lipid profile 1 subject we tested indicated that he was hypothyroid. 
His pre-treatment LDL-C, non-HDL-C and PC were 5.4 mmol/l, 6.1 mmol/l and 720 
µmol/1012 platelets, respectively. Subsequently, he was treated with thyroid hormone 
replacement and became euthyroid. The corresponding post-treatment values (6 months) 
were LDL-C 2.9 mmol/l, non-HDL-C 1.9 mmol/l, and PC 474 µmol/1012 platelets, 
respectively (see figure 6.5). 
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DISCUSSION  
In this work, a simplified and less time-consuming method for the measurement of 
PC was developed. This method is more suited to multiple measurements, since it does not 
involve complicated extraction stages, as was previously used in other techniques (Day et 
al., 1997;Padmavathi et al., 2010; Vevera et al., 2005). The PC levels we obtained using our 
technique were in agreement with those reported by others (Blache et al., 1995; Chetty et 
al., 1992; Hochgraf et al., 1994; Rabini et al., 1995; Sato et al., 1990). However, this 
method needs to be further assessed with a larger number of samples. In addition, it was 
observed, that it is limited by not being sensitive at lower LDL-C levels (i.e. <2.6 mmol/l). It 
is proposed that this method is evaluated in patients before and after treatment with statins.  
This work suggest, that PC could be used as a marker to assess “tissue” cholesterol 
status of patients with vascular disease. These patients tend to be on cholesterol lowering 
drugs (e.g. statins) that may have an effect on PC. Using an extraction method, Day et al 
demonstrated that cell membrane cholesterol significantly decreased (4.19 to 3.52 fmol/cell) 
after treating 12 hypercholesterolaemic patients for 6 weeks with simvastatin (20 mg/day) 
(Day et al., 1997). Moreover, a significant decrease in serum cholesterol (6.57 ± 1.26  
mmol/l to 5.10 ± 0.42 mmol/l, P<0.0001) and a non-significant decrease (0.755 ± 0.115 to 
0.688 ± 0.098, P = 0.17) in the ratio of cholesterol/total phospholipids (CH/PL) were found 
after 2 months of simvastatin (20 mg/day) therapy with 17 hypercholesterolemic patients 
(Vevera et al., 2005).   
 
 
 
 
 
 
 202 
Although statins are not considered as anti-thrombotic drugs, they exert other 
beneficial effects along with improving the lipid profile. These ‘pleiotropic’ actions include 
improved endothelial function, reduced oxidative stress and less platelet adhesion (Ludman 
et al., 2009). This may be a reason for the improvement in cardiovascular risk seen in 
clinical trials is incompletely explained by cholesterol lowering alone. Therefore it has been 
suggested, that the benefit from lipid lowering drugs may also involve non-lipid 
mechanisms. For example, beneficial effects on the arterial wall, improved endothelial 
function, and a positive effect on blood rheology and thrombogenesis (Milionis et al., 2003; 
Saw et al.,  2009).  
It is well documented that increased platelet activity is associated with 
hyperlipidemia (Chetty et al., 1992; Labios et al., 2005). However, few studies have 
addressed platelet activation and hypercholesterolemia and the potential effect of lipid 
lowering drugs on platelet activity. One group studied the effect of atorvastatin (20 mg/day) 
on platelet activation in hypercholesterolemic patients and found that after treatment, 
platelet function was normalized and there was a reduced GPIIb/IIIa response to ADP 
(Labios et al., 2005). These findings are in agreement with others who showed that platelets 
from hyperlipidaemic patients are hypersensitive to aggregation, with greater thromboxane 
B2 (TXB2; the spontaneous breakdown product of TXA2) production and 5HT release 
induced by thrombin when compared with platelets from normolipidemic controls (Chetty et 
al., 1992).  
These findings show that this PC method is reproducible and that PC levels were 
significantly correlated with serum LDL-C in subjects whose LDL-C was > 2.6 mmol/l. 
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Furthermore, significant correlations were also found for LDL-C/HDL-C ratio, TG, and 
non-HDL-C. It is of interest that the strongest correlation was with non-HDL-C, which in 
some circumstances is superior to LDL-C in predicting cardiovascular risk (Hoenig, 2008). 
These findings are in agreement with others who demonstrated a significantly higher platelet 
cholesterol ester in hyperlipidaemic patients (with LDL-C 5.72 ± 1.16) (Chetty et al., 1992). 
Their results also extended other findings where the levels of cholesterol and total 
phospholipids in type II hypercholesterolemia were 80% and 60% higher, respectively in 
platelet membranes of hypercholesterolemic subjects compared with their control group 
(Mosconi et al., 1988).  
We suggest that the increase in PC content may be sufficient to cause the increase 
platelet responses observed by others (Chetty et al., 1992), since cholesterol affects platelet 
membrane fluidity (Shattil et al., 1978). Membrane lipid fluidity is a measure of the 
dynamic state of the membrane and is a an important determinant of cell function 
(Shinitzky, 1984;Spector et al., 1985). Moreover, lovastatin decreases plasma and PC levels 
and normalises elevated platelet fluidity and aggregation in hypercholesterolemic patients. 
Also, platelets from hypercholesterolemic patients had a higher molar ratio of cholesterol to 
phospholipids (Hochgraf et al., 1994). This corroborates with the findings of others who 
also demonstrated similar increased molar ratio of cholesterol to phospholipids in 
hypercholesterolemic patients (Shattil et al., 1975; Shattil et al., 1976).  
In this study, the method of measuring PC has a disadvantage of not being sensitive 
if subjects have a lower circulating level of LDL-C (mean ± SD 1.93 ± 0.36 mmol/l). 
However, these levels of LDL-C are unlikely to require lipid lowering treatment. This 
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method also needs to be evaluated in larger numbers of subjects/patients before and after the 
use of lipid lowering drugs (e.g. statins).  
It is of interest that during our study one subject was found to be hypothyroid. 
Subsequently, he was treated with thyroid hormone replacement and became euthyroid. His 
pre-treatment LDL-C, non-HDL-C and PC were 5.4 mmol/l, 6.1 mmol/l and 720 µmol/1012 
platelets, respectively. Corresponding post-treatment values (6 months) were 2.9 mmol/l, 1.9 
mmol/l, and 474 µmol/1012 platelets, respectively. Thus, there was a decrease by 46.3% in 
LDL-C, 68.9% in non-HDL-C and 34.2% in PC (see figurer 6.5). 
In conclusion, this new technique of measuring PC has the advantage over 
previously used methods in that it is reproducible, rapid, safe and simple. Thus, it may be 
useful for multiple sampling when investigating changes in PC in hypercholesterolaemic 
patients. Whether any difference in PC represents changes in other tissues remains to be 
established.  
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CHAPTER 7 
 
General Discussion and  
Suggestions for Future Work 
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GENERAL DISCUSSION 
 
Others have previously shown that clopidogrel inhibits platelet aggregation, but the 
work presented in this thesis is the first report showing that this anti-platelet agent also 
affects platelet shape change (PSC), an early phase of platelet activation. Clopidogrel 
administration in patients with peripheral arterial disease (PAD) inhibited ADP-induced 
PSC. This finding might be expected since clopidogrel acts on the platelet ADP receptor 
(P2Y12). In addition, the fact that clopidogrel, also inhibited 5HT -induced PSC is 
interesting. Furthermore, there was a more significant inhibition of ADP- and 5HT-induced 
PSC with clopidogrel than with aspirin. It is unclear as to why PSC was induced by non-
ADP (i.e. 5HT) agonist was inhibited by clopidogrel. This effect may be attributed to a 
general decrease in platelet activity (‘resting state’). Others have also shown inhibition of 
platelet responses to non-ADP agonists (e.g. 5HT) after administering clopidogrel to dogs 
(Yao et al., 1992). These effects of clopidogrel on early stages of platelet activation may 
partly account for its efficacy in preventing thrombosis.   
With the use of a high-resolution channelyzer, it was possible to obtain an IC50 for 
the P2Y1 receptor antagonist (MRS 2179) since we could achieve up to 100% inhibition of 
PSC. Thus, using this technique, there is the potential to determine the potency of other 
purinoceptor inhibitors. Others showed that the P2Y1 receptor is essential for platelet 
aggregation, but an IC50 has not been previously derived for a P2Y1 receptor-blocker using 
PSC in human platelets. In contrast to the P2Y1 receptor, the P2Y12 receptor antagonist used 
provided only reversible and sub-maximal inhibition of PSC. Thus, we support others 
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(Gachet, 2001a; Gachet, 2005; Lubbe et al., 2002) who had suggested that antagonists to the 
P2Y1 receptor may become useful anti-platelet drugs. It is not possible to evaluate the IC50 
of clopidogrel in vitro because this is a pro-drug that has to be metabolized by the liver to 
produce an active a P2Y12 receptor antagonist.  
Tirofiban, added in vitro, had no inhibitory effect on either ADP- or 5HT-induced 
PSC. We experimented with ‘low to high’ (50-500 ng/ml) doses of tirofiban to ensure that 
there was no inhibitory effect. The fact that tirofiban, a potent and specific GPIIb/IIIa 
receptor antagonist, had no effect on PSC might be relevant. The inhibition of PSC may be 
important in vitro. In contrast, we found that clopidogrel demonstrated inhibitory action on 
both phases of platelet activation, PSC and aggregation. This effect was enhanced when 
clopidogrel and aspirin were administered together. This may explain why the clopidogrel 
plus aspirin combination appears to be a successful anti-platelet drug combination in 
patients with acute coronary syndromes (ACS) (Bowry et al., 2008; Patel et al., 2009; 
Squizzato et al., 2011)  
Tirofiban inhibited fibrinogen-induced platelet aggregation and raised circulating 
levels of fibrinogen are an emerging predictor of vascular events (Jagroop et al., 2002b; 
Kakafika et al., 2007; Mikhailidis et al., 1998a). Additionally, fibrinogen plays an important 
role in platelet aggregation by linking activated platelets (Jagroop et al., 2002b; Kakafika et 
al., 2007; Mikhailidis et al., 1998a). However, although it is advantageous that tirofiban was 
able to reduce fibrinogen-induced platelet aggregation, it may still be a disadvantage that 
this drug does not inhibit PSC. This may limit the clinical effectiveness of GPIIb/IIIa 
receptor antagonists.  
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 The findings described in Chapter 3 support the literature where clopidogrel was 
superior to aspirin in patients with PAD in terms of reducing vascular events (1996 no 
authors listed). However, clopidogrel does have several limitations, including variable 
absorption, drug-drug interactions and genetic factors that lead to reduced generation of the 
active metabolite, and a delayed onset of action (Paikin et al., 2010). 
 The search for ADP receptor inhibitors has yielded novel ADP (P2Y12 receptor) 
antagonists such as prasugrel, ticagrelor, cangrelor and elinogrel that are in current use or in 
various phases of clinical development (Mousa et al., 2010). Moreover, it has already been 
shown that these ADP (P2Y12 receptor) antagonists have advantages over clopidogrel 
ranging from faster onset of action, to greater and less variable inhibition of platelet function 
(Paikin et al., 2010). However, clinical studies that are still in progress focus on this new 
generation of ADP receptor antagonists (parsuragrel, cangrelor and ticagrelor) as successors 
of clopidogrel after coronary interventions (Hall et al., 2011; Kossler et al., 2009).  
 Prasugrel (CS-747; LY-640315) is an example of a novel third-generation oral 
theinopyridine, that is a specific, irreversible antagonist of the platelet ADP (P2Y12) receptor 
(Fletcher et al., 2010; Hall et al., 2011; Tagarakis, 2010). Pre-clinical and early phase 
clinical studies have shown prasugrel to be characterised by more potent anti-platelet effects, 
lower inter-individual variability in platelet response, and faster onset of activity as 
compared to clopidogrel (Fletcher et al., 2010; Laizure et al., 2010; Small et al., 2010). 
Ticagrelor has also been shown to be superior to clopidogrel in patients with ACS 
(Wallentin et al., 2009). Further research is needed to improve anti-platelet therapy with the 
aim of finding agents with favourable clinical outcome and lower bleeding risk.  
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 This thesis also presents a new method to determine platelet cholesterol (PC) which 
allows a relatively rapid throughput of samples. This method was demonstrated to be 
reliable, reproducible quick and easy. Thus, it may be possible to assess PC in patients 
before and after treatment with a statin. Furthermore, PC may be a surrogate marker of 
tissue cholesterol. Thus, for the first time, it would be possible to assess a ‘large’ population 
for an indirect measure of ‘tissue’ cholesterol. For example, it will now be possible to asses 
PC in different populations like post-menopausal women (before and after hormone 
replacement therapy), the obese (before and after dieting) and diabetic patients (possibly in 
relation to glycaemic control). Smoking can affect high density lipoprotein cholesterol 
(HDL-C) and triglyceride (TG) levels (Chelland et al., 2008). In turn, PC was significantly 
correlated with low density lipoprotein cholesterol (LDL-C) / HDL-C ratio as well as non-
HDL-C cholesterol. Therefore, it may be possible to detect changes in PC after smoking 
cessation or when comparing smokers with non-smokers. Some of the factors considered 
above (e.g. diabetes, smoking and obesity) are predictors of vascular disease.  
 It would therefore, be of interest to investigate their effect on PC. It will also be 
possible to investigate the relationship between PC and indices of platelet activation 
(including PSC). This may be relevant because a raised PC has been linked with activated 
platelets (Chetty et al., 1992; Labios et al., 2005).  
 The work presented in this thesis may provide a better understanding of 
platelet function and how to assess it. Furthermore, potential therapeutic targets are 
discussed. 
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Suggestions for Future Work 
 
 The channelyzer method used for assessing platelet shape change (PSC) in this thesis 
has the advantage that it is reproducible and suited for dose and time response studies. In 
work done previous to this thesis, PSC has been documented in several situations of 
potential clinical relevance. However, the disadvantage using a Coulter ZM34 counter 
coupled to a C-256 channelyzer to assess PSC is that this equipment includes mercury. 
According to the Committee For Occupational Safety And Health (COSH) Hospital 
Guidance book, mercury is considered to be a toxic hazard. In order to remedy the problem 
of using equipment that contains mercury, we phased out the ZM34, C-256 channelyzer, and 
upgraded to a Multisizer 3 (Beckman Coulter). The multisizer 3 also has the advantage that 
it occupies less bench space than the channelyzer. The channelyzer method to asses PSC 
comprised of 3 linked machines (the Coulter ZM34 counter coupled to a C-256 channelyzer 
with the sampling stand in the middle, see figure 2.1). In contrast, the Multisizer 3 is just one 
machine that can be connected to a computer (see figure 7.1 below).   
 The Multisizer 3 is a flexible, multi-channel analyzer employing the electrical 
impedance method together with the state-of-the art digital pulse processing technology. It 
provides both platelet (or other particle) sizing and counting within an overall size range of 
0.4 to 1200 µm. With the use of the very latest in digital pulse measurement technique, 
results may be stored either in memory, or on a disc for recall and processing on any 
computer or microprocessor that is compatible with the Beckman Coulter Multisizer 3 
software on Microsoft Windows. One of the important factors for us is that in comparison 
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with the Coulter ZM-34 (C-256 Channelzyer), the Multisizer 3 uses a unique, mercury-free 
system to draw suspensions through the aperture at a steady rate. This technology allows for 
the first time, the results of an analysis to be re-assessed (e.g. up to a 100-fold increased 
resolution), eliminating the need to re-run the samples. A higher number of channels provide 
more detail about the size of the particle. Data can be displayed graphically as number, 
volume, mass and surface area size distribution plots, or as tables of values versus size.    
 
 
Figure 7.1 Photograph of the Multisizer 3 (Beckman Coulter) 
  
 In this thesis, with the use of the channelyzer method to assess PSC, we established 
that both ADP receptors P2Y1 and P2Y12 were involved in the PCS phenomenon in human 
platelets. To our knowledge, we were the first to show an IC50 for the P2Y1 receptor-blocker 
using the human PSC phenomenon. Antagonists to these ADP receptors may become useful 
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anti-platelet agents. The search for more improved ADP-receptor inhibitors other than 
clopidogrel, has yielded novel ADP (P2Y12 receptor) antagonists such as prasugrel, 
ticagrelor, cangrelor and elinogrel. Since we have already done some investigations with 
clopidogrel, it would be of interest for us to investigate the risk -benefit profiles of these 
other ADP-receptor inhibitors.  
 There is conflicting evidence as to whether the P2X1 receptor is involved in PSC. We 
were unable to find an effect of the P2X1 receptor on PSC. This may be related to the fact 
that this receptor is involved with very rapid actions (1-2 s) and that it also becomes quickly 
desensitized. In the channelyzer method of assessing PSC, our sampling times are limited by 
the capacity of the operator. However, with the new Multisizer 3, it may be possible to 
observe these rapid changes in PSC since the method is computerised hence, it is likely to 
pre-set any time response. Therefore, we propose to use the new Multisizer 3 method, to 
investigate if the P2X1 receptor is also involved in the PSC phenomenon.  
 We studied the effect of tirofiban, a GPIIb/IIIa receptor antagonist on fibrinogen- 
and agonist- induced aggregation and PSC. With the methodology used in this study it 
would be of interest to assess the effect of other intra-venous agents directed against the 
GPIIb/IIIa receptors, namely abciximab, eptifibatide, and a non-peptide mimetic, lamifiban. 
We found that tirofiban does not appear to have an effect at the earlier stage of platelet 
activation, PSC. We would like to confirm this with our latest methodology of assessing 
PSC, the Multisizer 3, which has the capacity to increase the resolution of an analysis by up 
to a 100-fold.  
 
 
 
 
 
 
 213 
 There have been studies comparing dual with triple therapy based on iv GPIIb/IIIa 
inhibitors (Moser et al., 2003), aspirin, clopidogrel and/or cilostazol for preventing vascular 
events. Triple anti-platelet therapy was more effective than aspirin-based dual therapy on 
reducing vascular events in patients with acute coronary syndrome (STEMI and NSTEMI). 
However, insufficient data exists for patients with PAD on these drug regimes. With the 
technology used in this thesis, we have already investigated one GPIIb/IIIa receptor 
antagonist, tirofiban, on healthy volunteers, and in another study we observed the effect of 
clopidogrel (monotherapy and in combination with aspirin) on PAD patients. Thus, in future 
work, it may be possible for us to compare the effect of dual and even triple therapy on PAD 
patients since the ‘set up’ is already in place.  
 One of the methods developed in this thesis was for the measurement of PC. Our 
method proved to be simpler and less time-consuming than other methods previously used. 
This method should be further evaluated with a larger number of samples. In addition, we 
plan to assess this new method of measuring PC in hyperlipidaemic   patients pre- and post-
treatment with statins. It would also be of interest to use our PSC and platelet aggregation 
techniques concomitantly with our PC method to investigate platelets from hyperlipidaemic 
patients. These patients tend to demonstrate a significantly higher PC and also show that 
their platelets are hypersensitive to aggregation and therefore possibly shape change (an 
earlier phase of platelet activation).  
 In summary, in this thesis we have demonstrated a range of techniques that can used 
to assess platelet activation receptor type and release. This can be extended by future work 
in a clinical setting when assessing drug therapy. 
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APPENDIX D:  
Chemicals, Buffers & Solutions, Instruments and Apparatus 
 
I Chemicals 
 
Amersham International Plc, Aylesbury, UK 
5-Hydroxy [side chain-2-14C] tryptamine creatinine sulphate 
 
AstraZeneca R&D, Charnwood, UK 
AR-C69931MX 
 
BDH ltd. Dagenham, UK 
Acetone 
Acetic anhydride 
Aspirin (acetylsalicylic acid; ASA) 
Hydrochloric acid (HCL) 
Perchloric acid 
Potassium phosphate, mono-basic 
Sodium chloride 
Sodium bicarbonate 
di-sodium hydrogen orthophosphate, dehydrate 
sodium hydroxide 
tri-sodium citrate di-hydrate 
trichloroacetic acid (TCA) 
 
Coulter Electronics Ltd, Luton, UK 
Standard latex particles for calibration (9fl volume) 
Isoton II (a balanced electrolyte solution for blood cell counting and sizing containing: 
sodium sulphate 9.7 g/L; sodium chloride 4 g/L; dimethylolurea 1 g/L’ procaine 
hydrochloride 0.1 g/L 
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Immunotech- Beckman Coulter, High Wycombe, Bucks, UK 
5-HT Enzyme immunoassay kit 
 
Lipha Pharmaceuticals Ltd., West Drayton, UK 
Naftidrofuryl oxalate 
 
Merk Sharp and Dohme, Hertfordshire, UK 
Tirofiban (kindly donated) 
 
Molecular Probes, Eugene Oregon, USA 
TNP-ATP 
 
R&D Systems Europe, Oxon, UK 
Human soluble sP-selectin quanti-tative sandwich immunoassay 
Human platelet-derived growth-factor-AB (PDGF-AB) quanti-tative sandwich 
immunoassay 
 
Sanofi-Synthelabo, Paris France 
Plavix (clopidogrel) 
 
Sigma Chemicals Company Ltd., Poole, UK 
Alpha,beta-methylene ATP (αβ-meATP) 
N-acetylserotonin 
Acetone (HPLC grade) 
Adenosine diphosphate (ADP) 
Arachidonic  acid (sodium salt) 
Calcium ionophore (A231187; CaI) 
Citric acid 
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Cysteine hydrochloride 
Dibutyryl  cAMP (sodium salt) 
Disodium EDTA 
Fibrinogen type 1 (from human plasma, aprox. 60% protein. More than 90% of protein 
clottable and containing aprox. 15% sodium citrate and aprox. 25% sodium chloride) 
Formaldehyde (37% aqueous; w/v) 
Glutaraldehyde (25% aqueous; w/v) 
Hydrogen peroxide (30% aqueous; w/v) 
Human thrombin 
Indomethacin 
Noradrenaline bitartrate 
Serotonin creatinine sulphate  
tetramethylsaline 
U46619 (endoperoxide/thromboxane A2 mimetic) 
 
Tocris Cookson Ltd, Bristol, UK 
MRS 2179 
 
 
II  Buffers and Solutions 
 
Citrate anti-coagulant solution 
 Tri-sodium citrate 3.8% w/v 
 
Citrate-ASA anti-coagulant solution 
 Tri-sodium-citrate (3.8%) 
 ASA (10 mmol/L) 
 
EDTA anti-coagulant solution 
di-sodium EDTA (50 mmol/L) 
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Glutaraldehyde fixative solution 
glutaraldehyde (4% w/v) 
saline (150 mmol/L) 
Phosphate buffer to dissolve drugs 
di-sodium hydrogen orthophosphate 
dehydrate (116 mmol/L) 
potassium phosphate monobasic (20 mmol/L), pH 7.4 
 
Saline 
sodium chloride (150 mmol/L)  
 
5HT assay buffer (Gow et al., 1988) 
citric acid (0.1 mmol/L) 
sodium hydroxide (0.3 mol/L) 
EDTA (1 mmol/L) 
gelatin (1 g/L), pH 6.2 
 
*All buffers and solutions were made up with double distilled water. 
 
 
 
 
 
III Instruments and Apparatus 
 
Balance: Sartorius research balance, Sartorius Instruments ltd, Gillingen, Germany 
C-256 channelyzer: Coulter Electronics Ltd, Luton, UK 
Centrifuges: Eppendorf mocro-centrifuge (5414), Anderman Ltd, UK; ICE CENTRA-7R, 
International Equipment Company, USA 
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Chronolog dual-channel optical aggregometer 540: Coulter Electronics Ltd, Luton, UK 
Coulter particle counter ZM (with a 70 µm diameter sampling tube orifice): Coulter 
Electronics Ltd, Luton, UK 
Coulter counter (MD18): Coulter Electronics Ltd, Luton, UK 
Coulter ACT Diff Analyzer:  Coulter Electronics Ltd, Luton, UK 
Graph Pad Prism Version 4: Graph Pad Software, Inc; San Diego CA 
Microplate reader: model MCC/340, ICN Flow, High Wycombe UK 
Microplate shaker: Titertek, ICN Flow, High Wycombe UK 
Microplate washer: Titertek, ICN Flow, High Wycombe UK 
Needles: G19-21 (butterfly), Abbot Ireland, Rep. of Ireland 
pH meter: Corning 140, Corning Science Products, Halstead, UK 
Pipettes: Gilson pipetman and Eppendorf Repetitive pipette, Anachem, Luton, UK 
Sonicator: M.S.E Soniprep, Crawley, UK 
Syringes: 10 ml Sherwood Medical, Ballymoney, UK 
Water Bath: Shaking water bath, Grant Instruments Ltd, Cambridge, UK 
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